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Abstract
Arthritic diseases, a group of degenerative joint diseases, cause pain, disability
and the loss of independence. Research over the last 30 years has improved our
understanding of these conditions. We now know that these conditions are patho-
logical in nature, and are mediated by cytokines, cell signalling proteins. We still
have much to learn about disease initiation, control and progression if we wish to
develop reliable and eﬀective disease-modifying treatments.
In this thesis we use mathematical modelling to extend our understanding of
arthritic disease. We focus our attention on two arthritic diseases, rheumatoid
arthritis (RA), predominantly initiated in the synovium of joints, and osteoarthri-
tis (OA), predominantly initiated in the cartilage of joints.
We develop an ODE model of cytokine dynamics in the synovium and show that it
contains some features associated with RA. We ﬁnd that increases in cytokine pro-
duction rates over time can lead to initiation of RA, including periods of relapsing-
remitting disease. We ﬁnd that dose timing and interval as well as dose size are
all important to treatment outcome.
We develop two models of cytokine dynamics in cartilage and use these to analyse
OA initiation and progression. The ﬁrst model is an ODE model, expanding on the
synovium model, and the second model is a spatial Cellular Potts model. We use
these to consider pathways that could lead to the development of OA, and show
that combined treatment strategies are more eﬀective than single target therapies
in treating OA. We also show that diﬀusion in cartilage plays an important role
in OA.
We look brieﬂy at the downstream signalling pathways of cytokines, which are also
not fully understood. Here we focus on the binding of a family of transcription
factors (STAT proteins) to DNA. We ﬁnd that multiple high aﬃnity binding sites
are not a requirement for cooperative binding of STAT proteins.
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Chapter 1
Introduction
1.1 Motivation
The focus of this thesis is to study the dynamics of cytokines, particularly in
arthritic disease. Cytokines are cell signalling molecules present in joint tissue,
and have been implicated in initiation and progression of arthritic diseases such
as rheumatoid arthritis (RA) and osteoarthritis (OA). We aim to model the key
interactions that lead to arthritic disease and ﬁnd suitable strategies for phar-
macological interventions.In particular we focus on two types of arthritic joint
disease, RA and OA. In the case of RA, drug therapies targeting key cytokines
have been successful in treating, although not curing the condition. However,
there are no similar therapies available for OA. The World Health Organisation
estimates that there 9.6% of men and 18% of women over 60 have symptomatic
OA [129]. Whilst literature suggests that up to 80% of those over 75 have radio-
graphic evidence (where joint damage is seen on x-ray images) of OA, although
they may be asymptomatic [7]. As life expectancy increases the burden of OA on
both individuals and healthcare systems will likely increase.
Research into therapeutic interventions for OA has been largely unsuccessful.
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Whilst experimental research has provided some promising potential targets for
OA treatments, only a small number have made it to clinical trial stage, the re-
sults of which have been disappointing. This highlights the need for a better
understanding of the key mediators in OA, and importantly, how these interact
with each other. Mathematical modelling is a useful tool in human disease and
is particularly useful in understanding the dynamics of interacting species. We
ﬁrst consider RA, where although disease modifying treatments exist, optimum
treatment strategies are based mainly on clinician experience and the dynamics
leading to disease remission in some individuals are still largely unknown. We
hope to gain a better understanding of why remission is achievable only in some
cases, and give insight into optimum dose sizing and timing. We will then move
on to investigate OA, for which we know much less. Our aim in this thesis is to
produce a feasible model of the dynamics of key mediators of OA which can then
inform future experimental and clinical research into OA treatments. This may
highlight possible targets that would otherwise have been dismissed or suggest
that some current targets of research are unlikely to be successful.
1.2 Joint Biology
Joints are structures in the body where two or more bones meet. Articular (freely
moving) joints, those aﬀected by RA and OA are mainly weight-bearing joints
whose function is to provide movement. Examples of these joints include the knee
and hip joints. The joint is made up of three primary components, all relevant to
OA. These are cartilage, bone and the synovium (Figure 1.1).
Articular cartilage lines the articular joints and has the dual function of providing
a smooth surface for movement and absorbing stress [53]. These functions are
essential for maintaining joint integrity, and cartilage damage can lead to long
term mobility issues.
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Figure 1.1: Diagram of an articular joint showing the bone, cartilage and joint
capsule, taken from Textbook of Anatomy [30]
Cartilage tissue is avascular and aneural, comprised mainly of an extracellular
matrix (ECM) of collagen and proteoglycans (Figure 1.2). The ECM is sparsely
populated with chondrocytes, the only cell type. These are responsible for main-
taining cartilage homeostasis by degradation, synthesis and remodelling of the
ECM [86]. ECM synthesis and remodelling takes place on long time scales. ECM
structure varies through the tissue and can be divided into four zones: superﬁcial,
intermediate, deep and calciﬁed [7]. Collagen ﬁbres, predominantly type II colla-
gen, constitute up to 30% of the ECM [27]. The ﬁbers form cross-links resulting in
a mesh of collagen that imparts tensile strength to the ECM [117]. Proteoglycans,
constituting up to 10% [27], are hydrophillic in nature and give elasticity to the
ECM. The shape of cartilage is restored after deformation as water molecules are
pulled back into the tissue by proteoglycans [3].
Chondrocytes derive from the mesenchymal stem cell line but specialisation makes
them unique from all other cell types [97]. They are present in greatest numbers
3
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Figure 1.2: Schematic of cartilage tissue showing an ECM densely ﬁlled with
collagen ﬁbres and sparsely populated with chondrocytes (blue dots)
through childhood and adolescence then cell numbers start to decline when matu-
rity is reached at around 30 years of age [3]. Since there is little proliferation after
maturity chondrocytes have a long lifespan of decades. Chondrocytes enable the
cartilage to cope with the everyday wear and tear of a mechanically loaded tissue.
They respond both to mechanical changes in their environment and to chemical
signals from the surrounding tissue, by remodelling the ECM [55]. They do this
by producing a wide range of cytokines which have both autocrine (acting on the
cell that produced them) and paracrine (acting on other cells) eﬀects locally. De-
spite this chondrocytes are poor at repairing tissue from major injury or trauma
since they are unable to adequately compensate tissue loss and replace the intri-
cate network of cross-links in the cartilage. To help protect chondrocytes from
the eﬀect of excessive mechanical loading they are encapsulated within ﬂuid-ﬁlled
sacs called chondrons [109].
The synovium consists of the synovial membrane and the synovial ﬂuid within
the membrane. The synovial membrane is important to the correct functioning of
articular joints and is implicated in the pathobiology of articular disease [50]. It
provides a capsule for the synovial ﬂuid, which cushions the joint against stress
and provides a medium for chemical transport and immune cells; it provides a bar-
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rier to control which molecules and cells are able to move through the joint space;
and synoviocytes within the membrane play a crucial role in the biochemistry of
the joint by synthesis of enzymes, growth factors and cytokines. Synoviocytes are
the cells that make up the synovial membrane. Rather than there just being one
cell type present, as in cartilage, synoviocytes come in two forms, types A and B.
Type A cells are macrophages and as such are involved in the immune response of
the synovial membrane [65]. They have a key role in synovial inﬂammation (syn-
ovitis), since as well as their phagocytic function they produce pro-inﬂammatory
cytokines such as IL-1 [17]. Type B cells are ﬁbroblasts whose main function is the
secretion of components of synovial ﬂuid [65]. They produce hyaluronic acid which
is a major constituent of synovial ﬂuid and the main source of lubrication, whose
concentration is known to be depleted in arthritic joints [119]. Synovial ﬁbrob-
lasts have also been shown to produce matrix metalloproteinases (MMPs) which
are tissue degrading enzymes, pro-inﬂammatory and anti-inﬂammatory cytokines
when aggravated by microparticles [37], such as those present in synovitis.
Subchondral bone is the bone located immediately under the articular cartilage
and provides a surface for the cartilage to anchor to. It undergoes continual repair
and remodelling and releases growth factors and cytokines, some of which may
move into the cartilage [86].
In addition to the cells already discussed, that are native to the tissues of the joint,
some other cell types migrate to the tissue in the presence of inﬂammation and
disease. T cells are a class of lymphocyte, a type of white blood cell, responsible for
the cell mediated immune response which is part of the adaptive immune system
[67]. T cells have been shown to be present in the synovial ﬂuid of osteoarthritic
joints, suggesting that at least part of the OA inﬂammatory response is T cell
mediated [98]. T cell involvement has also been shown for related conditions
such as rheumatoid arthritis [87] and juvenile idiopathic arthritis [33], however
unlike OA these are both classed as autoimmune conditions (conditions where the
5
Chapter 1: Introduction
immune system attacks its own cells). B cells are part of the humoral immune
system, another part of the adaptive immune response and their main function
is to secrete antibodies [67]. These cells have been found to be activated in the
synovium of osteoarthritic patients [111].
1.3 Cytokine Signalling
Cytokines are cell signalling proteins that act by binding to receptors on the
cell surface. This initiates a chain of events that leads to transcription factors
within the nucleus binding to promoter regions of DNA. This in turn leads to
the gene expression, which involves the transcribing of the DNA and eventually
the translation of this transcribed DNA (RNA) to proteins. The exact process of
signal transduction varies between cell types and diﬀerent cytokines and there is
still much to be discovered about the control of these processes. However, there
are two common pathways that are initiated by cytokine signalling and that are
reasonably well understood. These are the Janus kinase / Signal Transducer and
Activator of Transcription (JAK/STAT) and the Nuclear Factor - κB (NF-κB)
signalling cascades.
The JAK/STAT kinase signalling cascade is one of the simplest pathways since
STAT proteins are uniquely able to move from the cytokine receptor through the
nucleus to bind to DNA as a transcription factor with no other molecules involved
[31] (Figure 1.3). Upon activation of the receptor a JAK kinase protein phos-
phorylates the tyrosine residues (tyrosine containing monomers) on the receptor.
This allows the receptor, in turn, to phosphorylate a STAT monomer [104]. Phos-
phorylated STAT monomers dimerise and enter the nucleus, where they bind to
the DNA at high aﬃnity sites, initiating gene transcription. This sequence of
events leading to DNA binding is shown in Figure 1.3. There are 7 types of STAT
and although they are similar, there are some physical and functional diﬀerences
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Figure 1.3: Schematic showing the JAK/STAT signalling pathway. Upon binding
of a cytokine to the receptor, the STAT monomer is phosphorylated, which allows
it to polymerise and move into the nucleus.
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which allows for binding and activation of diﬀerent gene sequences [63]. Binding of
STAT proteins to DNA is not fully understood, with some members of the STAT
family requiring polymerisation to remain bound to DNA and others able to bind
as dimers. These issues are areas of ongoing research, see Chapter 5.
Figure 1.4: Schematic showing the NF-κB signalling pathway. The binding of a
cytokine to the receptor sets oﬀ a chain of events leading to the NF-κB complex
binding to DNA.
NF-κB signalling is one of the best characterised signalling pathways. Its widespread
involvement in inﬂammatory, immune, neurological and oncogenesis processes
means it is implicated in a wide variety of diseases. NF-κB consists of a fam-
ily of eight closely related transcription factors [102]. When inactive they exist
mainly in the cytoplasm bound to IκB molecules. Upon activation of the relevant
cytokine receptor IκB molecules are phosphorylated by receptor-associated IκB ki-
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nases, which causes them to release the NF-κB complex. This complex then moves
into the nucleus where it binds to DNA, often in conjunction with co-activators
(see Figure 1.4). NF-κB is involved in many of the signalling cascades relevant to
OA cartilage, including IL-1 and TNF-α signalling [13]. Its potential as a target
for OA treatments has been researched but it is crucial for many normal biological
functions so inhibition-type treatments are impractical [113].
1.4 Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is an autoimmune disease predominantly aﬀecting the
joints. The condition causes chronic inﬂammation of the synovium due to raised
cytokine levels, this leads to joint degradation and eventual destruction of the joint
[26]. Symptoms of RA include pain, stiﬀness, immobility and inﬂammation. Addi-
tionally, individuals with RA may suﬀer from systemic symptoms such as fatigue
and weight loss [61]. As a result of high circulating levels of pro-inﬂammatory
cytokines, there is also a higher risk of developing cardiovascular diseases such
as ischemic heart disease, as a result of systemic inﬂammation aﬀecting coronary
arteries [56]. RA patients are also at higher risk of developing some cancers and
lung problems [18, 54, 92].
Causes of RA are still being investigated, however it has been established that
in active RA the telomeres within some types of T cells are excessively short-
ened [24]. Telomeres are regions at the ends of chromosomes that are shortened
over an individuals life span as part the normal chromosome replication process,
protecting genes within the chromosome from degradation [57]. Excessive or pre-
mature shortening of the telomeres can lead to defects and is associated with a
range of diseases [23]. It is thought that in RA this shortening leads to a loss
of T cell homoeostasis and the loss of the ability to control pro-inﬂammatory
cytokine production [72, 89]. Excessive cytokine production lies at the heart of
9
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RA. The pro-inﬂammatory cytokines TNF-α, IL-1 and IL-6 are found in raised
levels in the synovium, having been released by B cells and T cells in the joint
[90]. Anti-inﬂammatory cytokine levels, such as IL-10 and IL-4, are also raised in
response but are unable to halt the pro-inﬂammatory cytokine production. For
many individuals symptoms of RA are cyclic, and ﬂare ups may be linked to high
pro-inﬂammatory cytokine levels.
Treatments for RA include both pain relieving drugs and disease modifying drugs.
In terms of pain relief, the range of options is the same as that for OA (see
Section 1.5). Several types of disease modifying drugs are available for RA. The
most widely prescribed drugs are anti-rheumatic drugs such as Methotrexate and
Sulfasalazine, which are immunosuppressants. These drugs suppress the immune
system, throughout the body, allowing them to be used for a range of immune
and autoimmune conditions. This general action however, does mean that there
can be serious side eﬀects associated with their use [61]. For individuals where
anti-rheumatic drugs are not eﬀective biologic therapy may be used, such as anti-
cytokine therapy. These drugs work by suppressing the action of one of the key
cytokines active in RA. The ﬁrst licensed and most widely used drugs are anti-
TNF-α drugs such as Inﬂiximab and Etanercept [43]. Other biologics include
Tocilizumab, an IL-6 inhibitor and Rituzimab, a B cell inhibitor. All the biologic
therapies are relatively new drugs, having been available for only the last 15 years,
which means long term side eﬀects are not yet fully explored. For this reason, as
well as cost, biologic drugs are not currently used as a ﬁrst-line treatment.
1.5 Osteoarthritis
Osteoarthritis (OA) is a disorder of the synovial joints characterised by a loss
of cartilage, inﬂammation and changes to the subchondral bone [82]. Clinical
symptoms of the disease include inﬂammation, pain, stiﬀness in aﬀected joints,
10
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and instability of the joints. The joints in an individual are not typically aﬀected
homogenously, particularly if injury or repetitive strain has been a contributing
factor [7]. Studies of the epidemiology of OA show it is more prevalent in aged
individuals and more likely to aﬀect women than men [32]. Other risk factors
include obesity, genetic factors, particularly mutations of the Col2A gene, which
aﬀects collagen production, and a history of joint injury or excessive mechanical
strain as seen in certain manual occupations as well as professional sportsmen [7].
OA is a disease of the whole joint and changes associated with disease onset
and progression are seen in the cartilage, subchondral bone and synovium [46].
Changes in the cartilage are most pronounced and are thought to be most impor-
tant in terms of progression and loss of joint function [16]. However the cause of
disease onset is as yet unclear and may not be cartilage based. In some animal
models subchondral bone changes have been shown to precede cartilage damage
[74], whilst in other work increased numbers of pro-inﬂammatory cytokine recep-
tors have been found in OA chondrocytes [15]. One popular viewpoint is that OA
is not a disease with a single cause but rather a set of initial abnormalities that
lead to a single progression pathway [45]. Another viewpoint is that OA is a repair
mechanism for a variety of problems in the joint and with increasing age the repair
mechanism itself develops faults leading to clinically diagnosed OA. More research
is needed into the initiation and early stages of OA as it is likely that this is the
point where treatment would be most eﬀective as has been found in RA [96]. The
biological changes in OA are described below and summarised in Table 1.1.
In osteoarthritic cartilage the normal homeostatic balance between ECM synthe-
sis and degradation fails and both processes accelerate [115]. The changes that
characterise early OA are diﬀerent to those that characterise late OA. In early OA
there is an increased rate of cell proliferation, stimulated by cytokines, and char-
acteristic chondrocyte clustering is seen [50]. Synthesis of the ECM is increased,
either as the result of higher levels of anabolic cytokines (cytokines mediating
11
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ECM synthesis) or greater sensitivity to anabolic cytokines, both of which have
been observed [15]. However, despite the increased synthesis the ﬁbrils laid down
are disorganised and lacking the cross linkage needed to give strength. Cartilage
breakdown is also accelerated through raised pro-inﬂammatory cytokine levels,
which results in additional MMPs [86]. The degradation of the ECM includes
ﬁbronectin breakdown and waste ﬁbronectin fragments act as an irritant stimu-
lating further pro-inﬂammatory cytokine response [85].
As OA progresses, raised levels of TNF-α lead to increased levels of chondrocyte
apoptosis, although this has only a small eﬀect on the cartilage [115]. In later OA
however, there is a signiﬁcant decrease in matrix synthesis and increased rates of
degradation, some of which may be due to the reduction in chondrocytes. Inﬂam-
mation is often present in late osteoarthritis and evidence suggests that as well as
being an undesirable clinical symptom, inﬂammation leads to further breakdown
of the cartilage and a loss of function, probably due to additional inﬂammatory
cytokines [17]. Ultimately the ECM degradation processes begin to dominate the
ECM synthesis and the cartilage is thinned and damaged. Without cartilage the
bone endings rub together, causing pain, immobility and inappropriate mechani-
cal loading. Another change in late OA is the development of osteophytes, bony
spurs growing on the bone endings of OA joints, due to subchondral bone dam-
age. These are formed at the growth plate between the cartilage and subchondral
bone through ossiﬁcation of cartilage and bone remodelling. It is likely that this
process is mediated by anabolic cytokines since these are found in high levels
in osteophytes in experimental models [14]. Often, osteophytes do not have any
symptoms and may be an attempt to distribute loads more eﬀectively, but they
may cause pain and loss of mobility if they are in particularly sensitive areas, e.g.
close to nerve endings [20].
As previously discussed matrix degradation is a major reason for progression of OA
and is the main cause of joint instability and inﬂammation. It is now generally
12
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accepted that cytokines play a major role in the pathways leading to excessive
degradation as well as a role in the eﬀorts to limit or repair the damage [116].
Type II collagen is broken down by MMP-1 (Collagenase-1), MMP-8 and MMP-
13 and synthesis of these MMPs is increased in OA by raised levels of IL-1 and
TNF-α [126]. IL-1 and TNF-α bind to diﬀerent receptors on the cell but both
initiate similar responses once bound which involves activation of several types
of kinases, including NF-kB kinase, leading to activation of transcription factors
for the MMPs [126]. Oﬀsetting some of this activity IL-1Ra will also bind to the
IL-1 receptors but will not activate these pathways. Synthesis of proteoglycans,
another major component of the ECM is also inhibited by a pro-inﬂammatory cy-
tokine mediated pathway. Chondrocytes are induced to produce nitric oxide (NO)
by IL-1 and studies have shown that NO inhibits the synthesis of proteoglycans
within articular cartilage [121]. To a lesser degree TNF-α and IL-6 also reduce
proteoglycan synthesis, although in the case of the latter only in the presence of
soluble IL-6 receptor α.
OA bone shows increased remodelling near the joint which leads to greater den-
sity [75], which is associated with protection from osteoporosis. Mineralisation is
not increased so overall the bone contains less minerals and is more brittle [75].
This means that bone is more susceptible to damage on loading and more likely
to transfer inappropriate loads to the cartilage leading to damage. It has been
suggested that the increased bone density can be an initiating factor in OA [75].
In early OA bone resorption by osteoclasts is increased and lesions appear in the
bone. The number and size of these lesions increase as the disease progresses
and can be used as a measure of disease severity, since they are easily viewed by
MRI. In later OA additional bone is laid down by osteoblasts, and it has been
suggested that this is an attempt at widening the joint surface to distribute the
load [46]. Subchondral bone is known to express increased levels of growth factors
including insulin-like growth factor I (IGF-1) and TGF-β. These growth factors
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stimulate proliferation and diﬀerentiation of osteocytes as well as increased bone
matrix synthesis [74]. It is likely that these factors also pass directly across the
damaged growth plate in OA, to the cartilage, where they exert similar eﬀects on
the chondrocytes [46]. In late OA the synovium starts to show changes associated
with chronic inﬂammation.
Treatment for OA is aimed at relieving symptoms such as pain, inﬂammation and
stiﬀness rather than reducing or repairing the damage caused by OA. In part this
may be due to the historical diﬃculties in diﬀerentiating OA from general joint
pain at an early enough stage, meaning that patients present with considerable
damage to both the cartilage and subchondral bone. However, another major
reason for the lack of preventative treatments is the poor understanding of the
mediators of matrix degradation.
A range of pain relief drugs are oﬀered to individuals with OA, the most basic
of which are simple systemic analgesics such as paracetamol for moderate pain
or stronger opioids for more intense pain. More sophisticated treatments involve
reducing the inﬂammation, which increases mobility and reduces pain, typically via
Non Steroidal Anti Inﬂammatory Drugs (NSAIDs), such as ibuprofen or diclofenac
[70]. Alternatively COX-2 inhibitors, such as celecoxib, may be used if NSAIDs
are unsuitable [32]. In severe cases, steroid treatment may be used at the site of
the inﬂammation in the form of corticosteroid injections [100].
As OA progresses conventional drugs may be inadequate to alleviate the symp-
toms suﬃciently so in these cases surgery may be used. Surgical options include
keyhole surgery to clean out the joint and reduce inﬂammation, partial removal
of subchondral bone (in knee joints) and joint replacement surgery [84]. In ex-
treme cases a procedure called arthrodesis may be oﬀered, which involves fusing
the joint into a permanent position to increase stability [84]. Options such as
these highlight the need for research into eﬀective treatment in early OA to slow
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progression of the disease. Other complementary treatments for osteoarthritis
may be recommended alongside those mentioned above. These include treatments
to slow disease progression and increase mobility such as low impact exercise or
physiotherapy [32]. Another treatment used is Transcutaneous Electrical Nerve
Stimulation (TENS) therapy, which uses electrical impulses to block pain related
nerve signals [100]. However, although widely used evidence for the eﬀectiveness
of this treatment is lacking [91].
Treatments being researched for OA tend to fall into three categories: drugs aimed
at reducing the symptoms and progression of OA, tissue engineering to help repair
damage to the joints and gene therapy. Cytokines are involved in both inﬂam-
mation and matrix degradation in OA, meaning that they are relevant both to
disease progression and the clinical symptoms of OA. This makes them a good
target for possible treatment strategies. Many cytokines have been implicated
in OA but those thought to be of particular relevance are the pro-inﬂammatory
cytokines, IL-1 and TNF-α, and the anti-inﬂammatory cytokines, IL-4, IL-10 and
IL-1Ra. All of these have been shown to be present at higher than normal levels
in OA. Since so many growth factors, cytokines and hormones are involved in OA
pathways there are many potential targets for treatment, however the complex-
ity means that blocking one pathway will be unlikely to halt progression of the
disease altogether. It addition to this, speciﬁcity and side eﬀects make ﬁnding
suitable treatments diﬃcult. One treatment possibility is anti TNF-α treatment,
which inhibits the action of TNF-α thereby reducing the matrix degradation and
inﬂammation associated with OA. Anti TNF-α treatment was ﬁrst developed for
the treatment of rheumatoid arthritis, where inﬂammation plays a greater role.
Experimental studies showed blocking the action of TNF-α reduced inﬂammation
and clinical trials showed that this treatment was beneﬁcial in RA suﬀerers [2].
TNF-α has been shown to be important in the inﬂammatory response and ECM
degradation in OA so may prove to be a good therapeutic target. One anti TNF-α
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drug is currently undergoing clinical trials as a treatment for OA, but no results
have been reported [12]. Several other targets are in various stages of clinical trials.
These include drugs to target Nerve Growth Factor in order to reduce pain; MMP
inhibitors to reduce matrix degradation; and IL-1 inhibitors including IL-1Ra in-
jections [12]. One of the IL-1 inhibitors recently tested for OA was Anakinra [25],
this drug is clinically eﬀective in the treatment of RA (although not recommended
for treatment due to poor cost eﬀectiveness) however clinical trials found is was
not eﬀective as a treatment for OA.
Gene therapy has two potential uses in OA, ﬁrstly if used early enough it may
prevent the progression of the disease, secondly it may be used in the repair of
damaged tissue [41]. The ﬁrst of these cases includes injecting vectors carrying
genes into the synovium or articular cartilage. This method has had some success
in experimental models, particularly using genes coding for IL-1Ra, known to be
eﬀective at inhibiting the eﬀects of IL-1 [41]. Several of these treatments have
made it to the clinical trials stage, however these are still in the early stages so
although safety has been established, eﬀectiveness has still to be determined. The
use of gene therapy to initiate cartilage repair in partial thickness lesions, as seen
in OA, has also been successfully demonstrated in animal models, see Gelse et al.
[47] and Goomer et al. [51].
In order for cytokine related drug treatments to be used in OA, we need a clear
understanding of typical cytokine levels and a link between this and disease pro-
gression. Levels of cytokines are diﬃcult to measure and vary greatly in OA
between diﬀerent individuals. This may be the result of diﬀerent stages of disease
progression, diﬀering levels of inﬂammation or the complex interactions of diﬀer-
ent cytokines. There is also some evidence that genetic factors are important.
However generally, there is a consensus that the levels of the major cytokines in-
volved in OA are high compared with those of normal subjects [50, 116]. The
classiﬁcation of normal and osteoarthritic subjects is diﬃcult due to the nature
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of OA. There is no one marker that indicates the presence of OA and symptoms
vary both between individuals and within diﬀerent joints of a single individual.
An additional complication is that OA is highly prevalent in the elderly, who are
most at risk of the disease, so ﬁnding comparable healthy non arthritic subjects is
diﬃcult. It has been suggested that OA aﬀects as, many as 80% of those over 75
years of age [7]. Despite these diﬃculties some studies have found that cytokine
levels are raised in OA, Moos et al. [94] found the levels of IL-1, TNF-α, IL-4,
IL-6 and IL-10 were all raised compared to the level in normal cartilage tissue,
which was negligible. In a study by Goekoop et al. [48] subjects were taken from
volunteers of a cohort study of people born in the city of Leiden, The Netherlands,
rather than being taken from patients presenting with a illness as is more usual.
The subjects had blood samples taken at the age of 85, and a measure of ex vivo
cytokine levels was taken. Five years later the subjects completed a medical ques-
tionnaire to determine the presence or absence of OA. Sixteen of the 82 subjects
that were available for both parts of the study were considered to be free of OA (no
OA in the hips, knees or hands) and the study reported lower levels of IL-1b, IL-6
and IL-1Ra. Levels of IL-10 and TNF-α were not signiﬁcantly diﬀerent. Levels of
TNF-α are not elevated in many of the studies conducted, one reason for this may
be that TNF-α is implicated only in the most severe, late stage OA [86], so raised
levels would not be seen in most subjects with OA. Another reason may be that
rather than the TNF-α levels becoming raised, the cells themselves may become
more sensitive to this cytokine, this has been suggested by Arntz et al. [8].
We have a good understanding of the biochemical processes in the cartilage, and
which processes are implicated in OA. However, there is no clear understanding of
what the initiating events that cause OA are, or how the process may be halted.
Additionally, research in this area is challenging for many reasons. Cytokines
are short lived and act locally, hence making them diﬃcult to detect in easily
obtainable samples (e.g. blood serum, urine). Symptoms of OA in humans do
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not generally occur until late in the disease process, making research into early
OA limited. Finally, OA is a truly multi-scale disease with joint mechanics as
well as biochemical processes both being important factors. This means that
experimental cell based research cannot be easily extrapolated in vivo. Similarly,
joint mechanics in animal models are signiﬁcantly diﬀerent to human. All these
factors make this area an ideal candidate for mathematical modelling.
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1.6 Previous modelling work
1.6.1 Articular Cartilage and Subchondral Bone
The modelling of normal cartilage and bone has been relatively widely researched
in order to give an insight into what happens when these normal processes start
to malfunction. These models are often of the mechanics of the tissue rather than
the biochemical properties which may provide insight into some of the stimulus
or responses resulting from the biochemical changes during osteoarthritis. Several
authors have developed models of chondrocytes surrounded by ECM and these
may be particularly relevant as OA progresses and symptoms of OA such as apop-
tosis and depleted collagen and proteoglycan content become more profound. For
example, Wu et al. [130] proposed a model of cartilage containing chondrocytes
surrounded by ECM. These were considered to have diﬀerent material properties
as suggested by experimental results and showed how the tissue would deform in
space and time under mechanical loading. The authors did not explore how this
might change under degenerative conditions such as OA but did suggest that the
model could be used to look at degeneration and remodelling.
A paper by Trewenack [125] presented a continuum model of a single chondrocyte
producing an extracellular matrix. This model diﬀered from previous studies in
two main aspects, ﬁrstly it looked at a single chondrocyte in isolation, rather
than looking at cartilage as a tissue and secondly it considered two methods of
movement of matrix components, diﬀusion and advection. Generally diﬀusion is
considered to be the only signiﬁcant method of movement. In this article the
authors investigated the model in relation to the development of tissue engineered
cartilage, however it may have some relevance to the attempts at cartilage repair
during early OA, and the movement of cytokines through the ECM.
A model of fracture healing in bone by Bailón-Plaza et al. [9] may be relevant
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to our work. This model simulates cell migration, proliferation, ECM remodelling
and growth factor levels. The model used PDEs and ODEs to successfully demon-
strate the regulatory mechanisms of the fracture healing process which requires
migration and diﬀerentiation of mesenchymal stem cells followed by cartilage for-
mation and ossiﬁcation. The model neglects many of the growth factors and cells
involved in the process and concentrates on only two growth factors and three cells
types, which the authors considered to be most important, however the results are
still comparable to experimental results. Whilst the tissue and processes here are
diﬀerent to osteoarthritis in articular cartilage (the involvement of the vasculature
for example), the paper shows how models of the regulatory molecules and cells
can be used to simulate structural changes in the tissue.
More recent modelling include attempts to model synthetic or repaired cartilage,
such as a model by Lutianov et al, which used PDEs to model the cartilage
response to cell regeneration therapy [83], or a model by Catt et al [22], simulating
cartilage growth on a scaﬀold.
1.6.2 Arthritic Diseases
There is very little published work modelling arthritic conditions and those that
are available generally consider the mechanical aspects for the conditions rather
than the biochemistry mediating these events. In an early model of RA by Wit-
ten [128] the author presents a second order logistic growth model of articular
erosion in RA. The model shows how the cartilage might erode over time based
on reported erosion at presentation of an individual, however the model does not
consider the processes behind the erosion and so is of little use in investigating
how the disease progresses. Similarly, Pollatschek and Nadir [107] present a high
level ODE model of the deterioration of certain components in OA, such as pro-
teoglycan content, shock absorbance and microfractures. Whilst the model serves
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to demonstrate that OA can be modelled mathematically, the components iden-
tiﬁed are the observable clinical symptoms of OA rather than underlying factors
and processes such as cytokine mediation. Whilst models of OA and RA are not
common, some of the typical processes of these diseases are more widely mod-
elled, albeit for diﬀerent applications. For example, angiogenesis present in RA
has been modelled in relation to tumour growth (see [88], [106] and [69]), and
bone remodelling as seen in osteophyte formation has also been modelled [123].
Inﬂammation is now thought to be involved in osteoarthritis as well as RA and
models of inﬂammation are discussed below.
1.6.3 Inﬂammation
Models of inﬂammatory responses may be the most relevant models to look to
when building models of cytokine interactions in osteoarthritis, since inﬂamma-
tion is increasingly seen as an important part of OA [17], and even some non-
inﬂammatory events in OA are mediated by the same cytokines. Inﬂammation
may be classiﬁed as either an acute or chronic response, both of which may be
present in OA [19].
A model of acute systemic inﬂammation as a result of pathogen infection was
presented by Kumar et al. [73]. The model identiﬁed ﬁve possible outcomes de-
pendent on parameters: healthy response, non-infectious inﬂammation, infectious
inﬂammation, recurrent inﬂammation and immuno-deﬁcient response. It seems
likely, given reported clinical symptoms that some of these responses would be
present in OA, particularly healthy response and recurrent inﬂammation, although
the stimulus of inﬂammatory response would not be pathogen related and the in-
ﬂammation in OA is not systemic but is restricted to particular joints within an
individual. A general model of inﬂammation was proposed by Herald [60], which
showed conditions under which an inﬂammatory response would become chronic
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in the absence of ongoing infection. The model showed that if the macrophages are
particularly sensitive to pro-inﬂammatory cytokines, or if anti-inﬂammatory cy-
tokine levels are low, then even small inﬂammatory responses to infection become
chronic rather than being resolved.
1.6.4 Cytokines
There has been very little published work modelling cytokines either as part of
a biological process or alone, however two key models may be relevant to OA
modelling. One model uses a set of six continuous diﬀerential equations to describe
the behaviour of IL-1 and IL-10 with TNF-α in monocytes as an external stimulus
for IL-1 [118]. The model showed diﬀerent types of behaviour dependent upon the
parameter values including uncontrolled production of IL-1, stable equilibria and
stable limit cycles. The authors were able to link the model results to observed
behaviour in RA and Septic Shock, and it is likely that with some modiﬁcation,
some parts of this model could be incorporated into a model of synovitis in OA.
This may be complicated however by the involvement of chondrocytes as well as
macrophages.
A related model by Jit [68] looked in more depth at the pro-inﬂammatory TNF-
α and in particular, modelled the eﬀects of anti TNF-α drugs in the inﬂamed
synovial joint. The study considered the issue of why anti TNF-α drugs worked
well in the treatment of RA but were not eﬀective in Systemic Inﬂammatory
Response Syndrome (SIRS), another TNF-α mediated condition. From the model
results the authors suggested that cytokine levels in RA were usually in equilibrium
and anti TNF-α treatment forced a shift from a disease equilibrium to a healthy
equilibrium. However, they suggested that SIRS was a non-equilibrium condition
and as such was not able to be moved to a healthy equilibrium state, further they
suggested that the drugs may interfere with the body's natural attempts at repair.
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1.7 Thesis Outline
In the rest of this thesis we develop several models relevant to cytokine dynamics
in arthritic disease. In Chapter 2 we develop a two-variable model of pro- and
anti-inﬂammatory cytokine dynamics in the synovium. We use bifurcation anal-
ysis to explore the parameter space and ﬁnd monostable, bistable and oscillatory
behaviours. We consider how changes in cytokine production rates could lead to
RA and demonstrate that this model displays features present in RA initiation
and progression. We model anti-cytokine treatment and consider the importance
of dose size, interval and timing to treatment outcome.
In Chapter 3 we extend the previous model to include MMPs and ﬁbronectin
fragments, making it relevant to cartilage cytokine dynamics. We use one- and
two-parameter bifurcation analysis to explore the transitions between behaviour
types. We replace constant parameters with time dependent functions to explore
possible pathways to OA initiation. We consider the eﬀectiveness of diﬀerent
treatment strategies, and combine treatments to ﬁnd the best treatment outcome.
We consider the spatial aspects of cartilage cytokine dynamics in Chapter 4 by
developing a model of OA cartilage using a Cellular Potts model. We consider
two main tissue types, chondrocytes and ECM, surrounded by synovial ﬂuid and
bone. We investigate how the spatial separation of chondrocytes changes the
dynamics that we see in Chapter 3. Diﬀusion coeﬃcients are not readily available
for cytokines, MMPs and Fn-fs in cartilage so we consider the eﬀect that diﬀering
diﬀusion rates may have on the model.
In Chapter 5 we consider some of the downstream signalling dynamics that we
have so far neglected, but which could aﬀect cytokine signalling. In particular we
focus on the JAK/STAT pathway and focus our analysis on the binding of Stat
proteins to DNA. Given that Stat1 in known to require cooperative binding to
remain bound to DNA, we investigate whether there is a requirement for multiple
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high aﬃnity binding sites. We also consider how Stat3, another member of the
Stat family of proteins, interacts with Stat1 when competing for binding sites.
Finally in Chapter 6 we summarise the results we have found in this work and
consider how this could be developed in future work.
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Pro- and anti-inﬂammatory cytokine
model for rheumatoid arthritis
2.1 Introduction
Rheumatoid arthritis (RA) is a chronic inﬂammatory joint disease which aﬀects
around 1% of the adult population [128]. The condition is three times more likely
to aﬀect women (likely due to changes in hormone levels with age) than men and
disease onset generally occurs over the age of 40, although it occurs much earlier
in a small number of individuals [64].
The disease is characterised by chronic inﬂammation of the synovial lining of
joints (synovitis) with consequent destruction of cartilage and bone [26]. Cells in
inﬂammatory synovitis produce high levels of numerous cytokines which act locally
to produce the characteristic joint pain, swelling and stiﬀness, and systemically
to produce a range of eﬀects including the production of acute phase proteins by
the liver, part of the systemic immune response [64]. In addition to being easily
measurable markers of inﬂammation, these proteins contribute to some of the
long term systemic eﬀects of RA including the two-fold increase in cardiovascular
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mortality [34], as a result of exacerbated tissue injury during myocardial infarction
[105]. It is thought that cytokine interactions play a crucial role in the development
of RA and can modulate the severity and duration of the associated inﬂammation
[52].
A range of cytokines have been identiﬁed in the synovium and each one has a
unique but overlapping set of functions. They can be classiﬁed into pro-inﬂammatory
and anti-inﬂammatory groups according to the primary function of the cytokine in
the synovium. Two of the most important pro-inﬂammatory cytokines in rheuma-
toid arthritis are interleukin-1 (IL-1) and tumour necrosis factor-α (TNF-α) [26].
Examples of anti-inﬂammatory cytokines found in the synovium include IL-1 re-
ceptor antagonist (IL-1Ra) and Interleukin-10 (IL-10) [36]. Based on this we
think it is useful to model this system using the classiﬁcation of pro- and anti-
inﬂammatory cytokine groups. To date, there has been no RA-speciﬁc modelling
that considers the dynamics of both pro- and anti-inﬂammatory cytokines. By
modelling these two groups we can look at the involvement of cytokines in RA
onset and treatment, which has not been considered previously.
The redundancy and dual role of many cytokines suggests that a functional rather
than chemical classiﬁcation may prove particularly useful. We therefore aim to
represent the complex cytokine network in the synovium by a simple two variable
model. This will allow us to assess whether changes in the parameters governing
these two groups and their interactions can lead to the features seen in RA. In
addition to looking at the development and progression of RA we would like to
consider the eﬀect of anti-cytokine treatment of RA and consider which properties
of treatment lead to a beneﬁcial response.
In the following section we look at the model development and justify the terms
within the model. We also non-dimensionalise the model and give a biological
interpretation of each of the parameters. In Section 2.3 we analyse the model,
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beginning with consideration of the nullclines and steady states of the system. We
then look at bifurcations as we vary the pro-inﬂammatory cytokine production
parameter, which allows us to classify the diﬀerent types of behaviour in the
system. Lastly we look at bifurcations in two parameter space and consider how
these change for diﬀerent values of the other parameters. In Section 2.4 we consider
the possibility of time dependent changes in patient-speciﬁc parameters leading to
the onset of RA. In Section 2.5 we consider the eﬀect of treatment involving doses
of anti-inﬂammatory cytokines. We look at diﬀerent dose levels and regimes and
how these aﬀect the behaviour of the model. Finally in Section 2.6, we consider
possible clinical implications of the model as well as its limitations.
2.2 An activator-inhibitor model for cytokine in-
teractions
The synovium consists of a variety of cells including ﬁbroblasts, macrophages and
T cells and each individual cell has a diﬀerent response pattern [4], as discussed
Chapter 1. We neglect this variability in cell behaviour and the synovium is
modelled as a spatially uniform collection of homogeneous, generic cells. We fo-
cus on the cells' production of pro-inﬂammatory and anti-inﬂammatory cytokine
molecules and neglect other functions such as cytotoxic mechanisms or prolifera-
tion. The binding of pro-inﬂammatory cytokine molecules to membrane-bound
receptors induces production of both pro-inﬂammatory and anti-inﬂammatory
cytokines whilst the binding of anti-inﬂammatory molecules causes a downreg-
ulation in production of pro-inﬂammatory molecules. This has been demon-
strated by Brennan et al. [21] who showed that TNF-α has both an autocrine
and paracrine pro-inﬂammatory function, and upregulates itself as well as other
pro-inﬂammatory cytokines (particularly IL-1). TNF-α is also known to upreg-
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ulate the production of IL-10 which functions to downregulate both TNF-α and
IL-1 [36].
We denote the concentration of pro-inﬂammatory cytokine molecules by p and the
concentration of anti-inﬂammatory cytokine molecules by a. The degradation of a
cytokine concentration is assumed to be linear, with rates dp and da. The general
form of the equations for the cytokine dynamics is then
dp
dt
= −dpp+ φ(p)θ(a) (2.2.1)
da
dt
= −daa+ ψ(p). (2.2.2)
The product φ(p)θ(a) models the combined eﬀect of pro-inﬂammatory and anti-
inﬂammatory stimuli on pro-inﬂammatory cytokine production, based on the as-
sumption that anti-inﬂammatory molecules work by inhibiting the synthesis of
pro-inﬂammatory cytokine molecules [103]. φ(p) and ψ(p) are increasing sat-
urating functions of p, so that they represent induced upregulation with some
maximum production rate. Similarly, θ(a) represents the downregulation of p in
response to an increase in a and with a decreasing eﬀect from some maximum at
a = 0. Examples of functions which have these properties are
φ(p) = c0 + c1
pm1
cm12 + p
m1
(2.2.3)
θ(a) = c3
cm24
cm24 + a
m2
(2.2.4)
ψ(p) = c5
pm3
cm36 + p
m3
. (2.2.5)
where c0, c1, c2, c3, c4, c5 and c6 are non-negative constant parameters. Since
pro-inﬂammatory production is stimulated by an external stimulus and is de-
tected in low levels in normal blood [124], a background production term c0 has
been included in φ(p), anti-inﬂammatory production is stimulated only by pro-
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inﬂammatory cytokine molecules so no background term is necessary. The coeﬃ-
cients m1, m2 and m3 will all be taken as 2 for the analysis of this system since
values greater than 2 show qualitatively similar behaviour and a value of 1 reduces
the range of behaviours, this is discussed further in Appendix A. Some sample
forms for these feedback functions are shown in Figure 2.1.
p
ψ(p)
φ(p)c
c
+c0 1
2
0
c c 6
c 5
a
θ(a)
c 3
c 4
Figure 2.1: Examples of qualitative forms for the production feedback functions
φ(p), θ(a) and ψ(p) (Equations 2.2.3, 2.2.4,and 2.2.5).
The model equations are nondimensionalised using
p = p∗c2, a = a∗c4 and t = t∗
1
da
;
With the asterisks dropped for notational simplicity and setting m1 = m2 = m3 =
2, equations (2.2.1) - (2.2.2), with the equations 2.2.3, 2.2.4, and 2.2.5, become
dp
dt
= −γpp+ 1
1 + a2
(
Pbp + Ppp
p2
1 + p2
)
(2.2.6)
da
dt
= −a+ App p
2
A2ph + p
2
, (2.2.7)
where
Pbp =
c0c3
c2da
, Ppp =
c1c3
c2da
, Aph =
c6
c2
, App =
c5
c4da
and γp =
dp
da
.
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Pbp is the dimensionless background production rate for pro-inﬂammatory cy-
tokine so that when a = p = 0, pro-inﬂammatory production occurs at a rate
Pbp. The parameter Ppp corresponds to the maximum rate of pro-inﬂammatory
cytokine production over and above the basal rate. Aph is the concentration of
pro-inﬂammatory cytokine at which anti-inﬂammatory production is half maxi-
mal. App corresponds to the maximum rate of production of anti-inﬂammatory
cytokine. γp is the ratio of the pro-inﬂammatory and anti-inﬂammatory decay
rates.
Throughout this work we explore the behaviour of the system by looking at dif-
ferent parameter values so it is useful to have some idea of the values that would
be reasonable. We can gain some insight into this by examining the deﬁnitions of
the parameters which are summarised for reference in Table 2.1.
Parameter Interpretation
Pbp Background pro-inﬂammatory production rate
Ppp Magnitude of additional pro-inﬂammatory cytokine pro-
duction
Aph Pro-inﬂammatory cytokine concentration at which anti-
inﬂammatory production is half maximal
App Magnitude of anti-inﬂammatory cytokine production
γp Relative rate of clearance of pro-inﬂammatory cytokine
to anti-inﬂammatory cytokine
Table 2.1: Summary of the dimensionless parameters in the cytokine dynamics
model (2.2.6)-(2.2.7)
If we assume that the cytokine degradation rates are similar then we would ex-
pect γp =
dp
da
to be close to 1. Aph is the ratio of the EC50 of anti-inﬂammatory
production to the EC50 of pro-inﬂammatory production, where EC50 is the con-
centration of the variable which induces a response halfway between the maximal
and minimal response. Since both c2 and c6 are both thresholds for p and are
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activated via the same receptors we would expect them have similar values, hence
we expect Aph to be of order 1.
We expect Ppp to be of the same order as the maximum anti-inﬂammatory cytokine
production rate, App. We consider a range of values for these parameters in the
bifurcation analysis that follows in Sections 2.3.2 and 2.3.3. In order to have an
eﬀective response to infection and injury, the background level of cytokines must
be much smaller than the event stimulated production, hence Pbp needs to be
small, and should be much smaller than Ppp.
In the following sections we will consider how the nullclines of the system can
intersect for diﬀerent parameter values, determining the number of steady states
in the system. We show how through bifurcation analysis how bistability and os-
cillatory behaviour can arise from this model and consider possible interpretations
of this behaviour in a biological context.
2.3 Model Analysis
2.3.1 Nullclines and Steady states
To analyse the steady states of this system we will consider the forms of the
nullclines, and consider only the positive quadrant. The nullclines of the system
(2.2.6), (2.2.7) respectively, are as follows:
a = Na(p) =
Appp
2
Aph + p2
a = Np(p) =
√
f(p)
where
f(p) =
p2(Pbp + Ppp) + Pbp
γpp(1 + p2)
− 1.
32
Chapter 2: Pro- and anti-inflammatory cytokine model for
rheumatoid arthritis
Figure 2.2 shows the ways that these nullclines may intersect and hence how the
steady states may arise. The diagrams suggest there is always at least one steady
state and for some parameter values three steady states exist: S0, S1 and S2.
Figure 2.2: Schematic showing the nullclines of the system (2.2.6), (2.2.7) and
the diﬀerent ways they may intersect. The dashed line represents the a nullcline
(da
dt
= 0) and the solid line represents the p nullcline (dp
dt
= 0).
We cannot ﬁnd the steady states of this system analytically but by looking at the
turning points of each nullcline we can identify how many possible steady states
there may be. Na(p) is simply an increasing Hill function and always goes through
the point (p, a) = (0, 0). The number of turning points of Np(p) cannot be found
analytically but since we need only consider real positive values of p and a, we
can see that the number of turning points of Np(p) will be equal to the number of
turning points in f(p).
Diﬀerentiating f(p) shows it has four possible turning points at,
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p =
√
2
2
√
(Pbp + Ppp)((Ppp − 2Pbp)±
√
P 2pp − 8PppPbp)
Pbp + Ppp
(2.3.1)
and
p = −
√
2
2
√
(Pbp + Ppp)((Ppp − 2Pbp)±
√
P 2pp − 8PppPbp)
Pbp + Ppp
. (2.3.2)
p will always be either negative or complex in Equation 2.3.2, leaving only two
relevant turning points. If Ppp < 8Pbp then both these points will be complex.
This means that Np(p) will be a monotonically decreasing function and can cross
Na(p) only once, giving a single steady state. Otherwise, f(p) and consequently
Np(p) must decrease to zero and then increase again from zero so can cross Na(p)
three times giving a maximum of three steady states. It is not possible to ﬁnd the
stability of the steady states analytically, but the Jacobian, A, shown below, does
give us some information regarding the stability,
A =
−γ + 2Ppp(1+a2) p(1+p2)2 −2a(1+a2)2
(
Pbp + Ppp
p2
1+p2
)
2App
A2php
(Aph
2+p2)2
−1
 (2.3.3)
Hence,
TrA =
2Ppp
(1 + a2)
p
(1 + p2)2
− γ − 1 (2.3.4)
detA = γ − 2Ppp
(1 + a2)
p
(1 + p2)2
+ 4App
a
1 + a2
(
Pbp + Ppp
p2
1 + p2
)(
A2php
(Aph
2 + p2)2
)
(2.3.5)
We can see that when p  1 and a  1 then TrA ≈ −γ − 1 and detA ≈ γ,
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so for a small p, S0 will be stable. At some point, for steady states at larger
values of p and a, the steady state loses stability. The limp→∞ TrA = −γ − 1 and
limp→∞ detA = γ; so, S2 is stable for large values of p. The exact thresholds for
the loss of stability depend on the both the variable and parameter values and
cannot be determined analytically; however, numerical simulation reveals that in
the parameter ranges we are interested in, S0 is always stable, S1 is always unstable
and S2 can be either stable or unstable.
There is one case in which a steady state and stability can be determined an-
alytically: when Pbp is zero. We can see from the nullclines that if Pbp is zero
(i.e. there is no background pro-inﬂammatory cytokine production) then there is
a steady state at (p,a)=(0,0). Examining the trace and determinant in this case
gives TrA = −γ − 1, which will always be negative and detA = γ, which will
always be positive, meaning that the steady state must be stable.
The case of two state states only occurs at bifurcations. For this reason, through-
out this chapter we will focus more on the one and three steady state cases.
2.3.2 One Parameter Bifurcation Diagrams
Of the ﬁve free parameters, the cytokine production rates (Ppp and App) are rates
that could change as part of the immune response and so, are likely to change
over time in response to injury, aging, or therapeutic intervention. If we assume
that the rate of clearance is determined by the size and structure of the cytokine
and by the chemical environment within the host, it is reasonable to assume the
decay rate parameter γp will remain constant in an individual (or vary over a
much longer timescale than that over which cytokine interactions occur). Simi-
larly, we assume that the background production rate and the anti-inﬂammatory
production threshold parameter, Pbp and Aph, are ﬁxed within an individual. To
demonstrate the types of behaviour that can arise from this model we consider
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bifurcation diagrams of variations in Ppp for a range of diﬀerent values of the other
parameters. The types of behaviour displayed are summarised in Table 2.2 and
discussed in detail below. All bifurcation plots and simulations in this chapter
were produced in XPPAUT [39] and MatCont [35].
Case Steady States Limit Cycles
Ai S0 - Stable 
Aii S2 - Stable 
Aiii S0 - Stable; S1 - Unstable; S2 - Unstable 
B S2 - Unstable L1 - Stable
Ci S0 - Stable; S1 - Unstable; S2 - Stable 
Cii S0 - Stable; S1 - Unstable; S2 - Stable L2 - Unstable
Di S0 - Stable; S1 - Unstable; S2 - Unstable L1 - Stable
Dii S0 - Stable; S1 - Unstable; S2 - Unstable L1 - Stable; L2 - Un-
stable
Table 2.2: Summary of the behaviour types in the cytokine dynamics model
(2.2.6)-(2.2.7). S denotes steady states and L denotes limit cycles
Monostable and Bistable Behaviour
In a simple case, illustrated in Figure 2.3, two fold bifurcations give rise to monos-
table and bistable behaviour. For suﬃciently small values of Ppp monostable be-
haviour is seen where trajectories undergo at most one peak in p before decaying
to the steady state S0 which has a low level of p (case Ai). The phase plane for
this case is shown in Figure 2.3b, and the nullclines correspond to Figure 2.2a.
This case could generally be considered as a healthy state since p is always low
and there are no oscillations.
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For intermediate values of Ppp, bistable behaviour is observed, with two stable
steady states and a single unstable steady state (case Ci), shown in Figure 2.3c.
In this case the stable manifold of S1 divides phase space into two regions, the
basins of attraction of the healthy state S0 and the disease state S2. The values of
Ppp and App determine the size of the region contained within the stable manifold.
Increasing App decreases the size of the region whereas increasing Ppp increases the
size of the region. This means that if anti-inﬂammatory production is increased
then the set of disease states is smaller and if the pro-inﬂammatory production
is increased the set of disease states is larger. One counter-intuitive observation
to be made from Figure 2.3c is that any state within the disease region could be
returned to the healthy state by a stimulus that increases the pro-inﬂammatory
concentration suﬃciently. This would cause a further increase in p triggering
an anti-inﬂammatory response which would raise both a and p before returning
both to lower levels at the healthy steady state. Similarly, but more intuitively,
a suﬃcient increase in the anti-inﬂammatory concentration can always return the
system to a state of health.
Finally, for suﬃciently large Ppp there is another monostable case (case Aii), in
which all trajectories in the phase plane undergo oscillations of decaying magni-
tude to S2 (Figure 2.3d). In this case, the value of p is generally relatively high,
indicative of a disease state. However, as App is increased the value of p at S2 de-
creases, and case Aii starts to behave like case Ai, making the distinction between
health and disease less clear. Changes in App are discussed further in Section 2.3.3.
Monostable and Bistable Behaviour with Oscillations
For larger values of App (∼ 3-fold increase compared to Fig 2.3a) the model also
displays oscillatory behaviour in addition to the behaviours described above (Fig-
ure 2.4). This more complex bifurcation diagram corresponds to two additional
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Figure 2.3: Monostable and Bistable behaviour in the model (2.2.6)-(2.2.7) for
the interaction between pro and anti-inﬂammatory cytokines (Pbp = 0.025, Aph =
0.5, App = 3.5 and γp = 1.25). (a) Bifurcation plot of p against Ppp. The solid
lines represent stable branches whilst the dashed lines represent unstable branches.
The vertical red dashed lines signify the thresholds between diﬀerent behaviour
types. (b) Phase plane plot of Case Ai, a single healthy steady state (Ppp = 5).
(c) Phase plane plot of Case Ci, two stable steady states (S0 and S2) and one
unstable steady state (S1) (Ppp = 8). (d) Phase plane plot of Case Aii, a single
unhealthy steady state with (Ppp = 17).
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types of phase-plane behaviour. The ﬁrst type, case Di, has a single stable steady
state (S0), two unstable steady states (S1 and S2), and a stable limit cycle around
S2 (Figure 2.4b). In this situation the limit cycle represents inﬂammation in the
system due to ﬂuctuating high levels of p (perhaps reﬂecting relapsing-remitting
disease, see [79]). This case is similar to Ci, with all states within the stable man-
ifold of S1, evolving to the disease limit cycle and all states outside evolving to
the healthy state.
The second new behaviour, case B, has only a single unstable steady state (S2)
surrounded by a stable limit cycle (Figure 2.4c). The limit cycle can be thought
of as a disease state due both to high levels of p and the oscillatory behaviour.
This is similar to case Aii, since all trajectories undergo decaying oscillations into
the disease limit cycle.
The bifurcation plot in Figure 2.4a shows that as Ppp is increased it goes through a
fold bifurcation, then a Hopf, followed by a second fold and ﬁnally a second Hopf.
For larger values of App (∼ 6-fold increase compared to Fig 2.3a) we encounter
both the folds before the Hopf bifurcations (Figure 2.5a), which means that we
lose Di behaviour. As App is increased further (∼ 10-fold increase compared to
Fig 2.3a) Ci behaviour is also lost (Figure 2.5b).
Monostable and Bistable Behaviour with Homoclinic Bifurcations
For a small range of parameters, there is a saddle node bifurcation that gives rise
to a stable limit cycle, L1, surrounded by an unstable limit cycle, L2 (Figure 2.6a).
There is also a homoclinic bifurcation where the unstable limit cycle, L2, collides
with the steady state S1, giving rise to additional behaviours. A monostable
region exists with a stable steady state, S0, and two unstable steady states, S1
and S2 (case Aiii). This case behaves similarly to Ai, except that within the stable
manifold trajectories will approach S0 in an oscillatory manner (Figure 2.6b). For
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Figure 2.4: Monostable and Bistable behaviour with oscillations in the model
(2.2.6)-(2.2.7) for the interaction between pro and anti-inﬂammatory cytokines
(Pbp = 0.025, Aph = 0.5, App = 9 and γp = 1.25). (a) Bifurcation plot of p against
Ppp. The solid lines represent stable branches whilst the dashed lines represent
unstable branches. The vertical red dashed lines signify the thresholds between
diﬀerent behaviour types. (b) Phase plane plot of Case Di, one stable steady state
(S0) two unstable steady states and a stable limit cycle around S2 (Ppp = 15).
(c) Phase plane plot of Case B, one unstable steady state (S2) surrounded by a
globally stable limit cycle (Ppp = 30). Cases Ai, Ci and Aii are shown in Figure
2.3.
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Figure 2.5: Bifurcation plots for diﬀerent values of App showing how cases Ci and
Di are lost compared with Figure 2.4a (Pbp = 0.025, Aph = 0.5 and γp = 1.25).
The solid lines represent stable branches whilst the dashed lines represent unstable
branches. The vertical red dashed lines signify the thresholds between diﬀerent
behaviour types. (a) App = 18, ﬁrst Hopf bifurcation moves to right of the second
fold and case Di is lost (b) App = 30, folds coalesce and all bistability is lost.
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a very narrow parameter range the system is bistable (Figure 2.6c) with one stable
steady state and one stable limit cycle, as well as two unstable steady states and
an unstable limit cycle (case Dii). The stable limit cycle, L1, with high pro-
inﬂammatory cytokine concentrations, represents a disease state and lies inside
the unstable cycle, L2. L2 deﬁnes the basin of attraction of the disease cycle and
the most suitable treatment strategy depends on the current stage in the cycle.
For example, if an individual has a high level of a and an intermediate level of p,
then to bring about a state of health, an increase in anti-inﬂammatory cytokine
would be more eﬀective than a decrease in pro-inﬂammatory cytokine of similar
magnitude.
Figure 2.6: Monostable and Bistable behaviour with homoclinic bifurcations in
the model (2.2.6)-(2.2.7) for the interaction between pro and anti-inﬂammatory
cytokines, showing the new behaviours Aiii and Dii. (a) Bifurcation plot of Ppp
against p. The solid lines represent stable branches whilst the dashed lines rep-
resent unstable branches. The vertical red dashed lines signify the thresholds
between diﬀerent behaviour types. (b) Phase plane plot of Case Aiii, a stable
steady state (S0) and two unstable steady states (Ppp = 15).(c) Phase plane plot
of Case Dii, a stable steady state (S0), two unstable steady states, a stable limit
cycle and an unstable limit cycle (Ppp = 18.73). Cases Ai, Ci and Di are shown in
Figure 2.4. (Pbp = 0, Aph = 0.5, App = 7 and γp = 1.25)
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Bistable behaviour with a homoclinic bifurcation
One ﬁnal type of behaviour (case Cii) can be seen for larger values of Aph (Figure
2.7). Here, an unstable limit cycle exists with two stable steady states (S0 and
S2) and one unstable steady state (S1). The limit cycle is the boundary of the
basin of attraction of S2. The unstable manifold of S1 divides the remaining region
into those states which evolve to health in an oscillatory fashion (those inside the
unstable manifold) and those which have at most one extremum (those outside
the unstable manifold). This state arises though a supercritical Hopf bifurcation,
where the branch of limit cycles turn and become unstable almost immediately
after the bifurcation.
So far we have considered only variations in the pro-inﬂammatory cytokine pro-
duction rate, Ppp. It is likely that the anti-inﬂammatory cytokine production rate,
App, is also important in determining disease activity since anti-inﬂammatory cy-
tokines will mitigate pro-inﬂammatory cytokine response. Hence, in the next
section we will look at Ppp-App parameter space for diﬀerent values of the other
three parameters.
2.3.3 Two Parameter Bifurcation Diagrams
It is useful to consider the two parameter bifurcation structure in Ppp-App param-
eter space. Figure 2.8 shows bifurcation diagrams for several diﬀerent values of
Pbp. It illustrates the curves of Hopf and fold bifurcation points and the types of
phase-plane behaviour that are observed in this space and demonstrates the eﬀect
that changes in Pbp have on the bifurcations. The ﬁgure also shows that where the
Hopf and fold bifurcations meet we have Bogdanov-Takens points. A Bogdanov-
Takens bifurcation is a bifurcation of codimension 2, i.e. it is only seen as we vary
two parameters, and occurs where there is a pair of zero eigenvalues. From this
point a homoclinic bifurcation emerges between the fold and Hopf bifurcations. In
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Figure 2.7: Bistable behaviour with a homoclinic bifurcation in the model (2.2.6)-
(2.2.7) for the interaction between pro and anti-inﬂammatory cytokines. (a) Bi-
furcation plot showing Ppp plotted against p. The inset shows how Case Cii
arises through a supercritical Hopf bifurcation where the branch of limit cy-
cles turns and becomes unstable almost immediately after bifurcation. The
solid lines represent stable branches whilst the dashed lines represent unstable
branches. The vertical red dashed lines signify the thresholds between diﬀer-
ent behaviour types. (b) Phase plane plot showing case Cii, two stable steady
states (S0 and S2), an unstable state(S1) and an unstable limit cycle around
S2 (Ppp = 7.75). Cases Ai, Aii, Aiii and Ci are shown in Figures 2.4 and 2.6.
(Pbp = 0.01, Aph = 1, App = 10 and γp = 1.25)
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the diagrams in this section the Hopf bifurcations are denoted H1 and H2, the fold
bifurcations are denoted F1 and F2 and the Bogdanov-Takens points are labelled
BT. The dotted line in Figure 2.8b corresponds to the one parameter bifurcation
diagram shown in Figure 2.4. It is now clear why increasing App results in the loss
of Di and Ci, since the overlap of the regions enclosed by the Hopf and fold bifur-
cations is decreased and then the folds are destroyed at the cusp. It is important
to make the distinction between a healthy state and a disease state since when
App is suﬃciently small there is a range of Ppp over which two observable stable
steady states can coexist. Where there are two stable steady states the relative
levels of p allow one to be designated as disease and the other as health, since
in any individual baseline levels of cytokines may vary. Where there is only one
stable state, designation of health or disease is more diﬃcult.
As Pbp is decreased, the fold and Hopf bifurcations connect at a Bogdanov-Takens
point, one of the Hopf bifurcations is lost and a homoclinic bifurcation emerges.
Additionally, the cusp where the fold bifurcations meet occurs at larger values of
both Ppp and App. The background production parameter Pbp does not signiﬁcantly
alter the position of the Hopf bifurcation H1. However, as Pbp is decreased H2
moves closer to F1, with H2 eventually being destroyed, leaving the system with
only one Hopf bifurcation, H1, which is then supercritical as before and can cause
the creation of a stable limit cycle.
Figure 2.8d shows the two parameter bifurcation diagram for Pbp = 0, where is no
background production, and here the steady state structure of the system changes.
When the system is at zero concentration no cytokine is produced and it remains
at this state, thus the healthy state S0 is ﬁxed at (p = 0, a = 0) and is stable.
The system still has an unstable state S1 and a state S2 which can be stable or
unstable. Since S2 occurs at a relatively high value of p, if S2 is stable it represents
a disease state and may lie an unstable limit cycle. S2 can also be unstable in
which case the system can only be in the healthy cytokine-free state unless S2 lies
45
Chapter 2: Pro- and anti-inflammatory cytokine model for
rheumatoid arthritis
Figure 2.8: Parameter space plots in Ppp-App (Aph = 0.5 and γp = 1.25) showing
the fold (F1 and F2) and Hopf (H1 and H2) bifurcations and types of phase space
for decreasing values of Pbp.(a) Cases Ai, Aii, B, Ci and Di are shown. (b) Cases
Ai, Aii, B, Ci and Di are shown. The red dashed line represents a slice through
the parameter space at App = 9, consistent with the bifurcation plot in Figure 2.4
(Pbp = 0.025). (c) Cases Ai, Aii, Aiii, B, Ci, Di and Dii are shown., (d) Cases Ai,
Aii, Aiii, Ci, Di and Dii are shown. The red dashed line represents a slice through
the parameter space at App = 7, consistent with the bifurcation plot in Figure 2.6
(Pbp = 0).
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within a stable limit cycle (with the system at either the healthy state or in a state
of periodically varying cytokine concentrations). When this is compared with the
behaviour when Pbp > 0 we see that cases Aii and B are no longer possible since
there is always a stable healthy state.
Variations in Aph and γp show similar eﬀects to variations in Pbp. Figure 2.9 shows
Ppp-App parameter space for a range of values of Aph. As Aph increases, the cusp at
which the fold bifurcations meet and are destroyed occurs for a higher value of the
anti-inﬂammatory production parameter App. The pro-inﬂammatory production
parameter Ppp at the cusp varies little with Aph. One consequence of this eﬀect
is that if the threshold Aph is large then the range of states which can exhibit
health and disease is increased. When Aph is small, most conditions lead a single
state with pro- and anti-inﬂammatory concentrations varying according to Ppp.
Figure 2.10 shows a two parameter bifurcation diagram for a large value of Aph
but a smaller value of Pbp. Here, all the possible behaviours are observed through
variations in Ppp and App.
Figure 2.11 shows Ppp-App parameter space diagrams for various values of γp and
demonstrates that as γp decreases the fold and Hopf bifurcations move apart.
This means that the parameter region over which there is bistability decreases
and the majority of parameter space leads to a single generic stable steady state
or a stable limit cycle. Biologically this implies that decreasing the clearance
of pro-inﬂammatory cytokine from the system, leads to disease, and reduces the
likelihood of curable disease. Conversely, increases to the rate of clearance could
oﬀer better treatment response rates.
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Figure 2.9: Figure showing the dependence on threshold parameter Aph of the
location of fold and Hopf bifurcations in Ppp-App parameter space for parameter
values (Pbp = 0.025, γp = 1.25).
Figure 2.10: Ppp-App parameter space showing all the behaviour types found in
the model. The red dashed line represents a slice through the parameter space at
App = 10, corresponding to the bifurcation plot in Figure 2.7 (Pbp = 0.01, Aph =
1 and γp = 1.25)
48
Chapter 2: Pro- and anti-inflammatory cytokine model for
rheumatoid arthritis
Figure 2.11: Diagrams showing the positions of the fold (F) and Hopf (H) bifur-
cations in Ppp-App parameter space for decreasing values of γp and the parameters
(Pbp = 0.025 and Aph = 0.5).
2.4 Time-Dependent Parameter Variations
Some cases of rheumatoid arthritis have a characteristic mode of onset in which an
initially healthy individual experiences ﬂaring and remitting inﬂammation (palin-
dromic RA) over a sustained length of time before eventually reaching a state of
persistent synovitis. The model given by equations (2.2.6)-(2.2.7) is capable of re-
producing some of the key features of this onset pattern by using a time-dependent
pro-inﬂammatory production parameter Ppp. It is likely that such ﬂuctuations in
Ppp occur in vivo due either to a spontaneous rise in pro-inﬂammatory cytokine
production in response to injury or infection or a gradual rise in production with
increasing age [29, 114]. To illustrate the potential of this approach we can con-
sider Ppp as an increasing, saturating function of time,
Ppp(t) = P
min
pp +
(Pmaxpp − Pminpp )t2
P Tpp
2 + t2
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so that Ppp(0) = Pminpp with Ppp increasing with time and limt→∞ Ppp(t) = P
max
pp .
The parameter P Tpp is the time at which the Ppp(t) is at half maximal. We take
Pminpp = 1, P
max
pp = 50 and Ppp
T = 15 with the remaining parameters given by
{γp = 1.25, Pbp = 0.025, Aph = 0.50}. Figure 2.12 shows how Ppp changes over
time.
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Figure 2.12: Plot of the time dependent pro-inﬂammatory cytokine production
parameter Ppp against time.
We run simulations for a set of constant values of App, equivalent to taking a
horizontal section through the parameter plane in Figure 2.8(b). It is immediately
obvious that App will be critical in determining the evolution pattern. To show this
eﬀect the simulation is run for the values App = {2, 7, 15} and the concentration
evolution in each case is shown in Figure 2.13.
These results show that in each case, when Ppp is suﬃciently large, the system
is forced to the disease state, S2, but signiﬁcant diﬀerences in the form of the
cytokine response are observed. For low App, as Ppp increases with time , the
state is forced to stable disease without any oscillations. For larger App, as Ppp
increases the state is still forced into stable disease but has an intermediate period
of oscillations. The length of time over which the system is in an oscillatory
state increases with App and for a large App the system is forced into sustained
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Figure 2.13: Plots of pro-inﬂammatory and anti-inﬂammatory cytokine concen-
trations for App = 2, 7 and 15. (Pbp = 0.025, Aph = 0.5, γp = 1.25,). In each case,
the system moves to a disease state over time as Ppp increases. As App gets larger,
the time the system is in an oscillatory state increases until, for some value of App,
the system moves onto a stable limit cycle. The parameter Ppp increases over time
and this is equivalent to taking a horizontal slice through the bifurcation diagram
in Figure 2.8(b).
oscillations. The highest values of App result in a disease state with lowest pro-
inﬂammatory concentration and highest anti-inﬂammatory concentration. These
concentration patterns emphasise the diﬀerences which can be attributed to an
individual's ability to produce anti-inﬂammatory cytokine. Those individuals with
a faster rate of anti-inﬂammatory cytokine production (large App) may be more
likely to see the remitting and relapsing pattern of disease onset.
The function used here for Ppp is representative of an age related increase in
Ppp over time. Responses due to infection may lead to an initial spike in pro-
inﬂammatory production rate (Ppp) followed by the gradual decline of the rate to
a new base line rate (Figure 2.14). In this case the system may settle either to
a state of health or disease, determined by the value of Ppp after infection. For
appropriate parameter values there can be a period of oscillations, which may
be representative of the mechanism by which some individuals go on to develop
sustained RA after a period of palindromic RA, whilst others move into remission.
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Figure 2.14: Plots of Ppp and pro-inﬂammatory cytokine concentrations against
time. The two plots in the upper panel show two forms of the Ppp function, in
both cases Ppp starts at 3 and spikes to 25 after t=5. They then settle to a new
value of Ppp, 16.5 in the ﬁrst column and 10 in the second. The plots in the lower
panel show how the concentration of pro-inﬂammatory cytokine varies over the
same time period. Both plots show decaying oscillations to a steady state, in the
ﬁrst column the steady state is a disease state and in the second it is healthy.
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2.5 Treatment Strategies
Some individuals with RA are treated with doses of pro-inﬂammatory cytokine
inhibitors, known as anti-cytokine therapy, either in the form of pro-inﬂammatory
cytokine receptor antagonists or antibodies targeting pro-inﬂammatory cytokines
[49]. Doses are given either by subcutaneous injection or intravenous infusion at
intervals ranging from weekly to four-weekly. Short term eﬀects of the reduction
of pro-inﬂammatory cytokine activity include reduction in joint swelling, pain
and stiﬀness and improvement in general well-being [80]. Long term eﬀects in-
clude reduction in the rate and severity of joint damage [44]. For simplicity, we
assume that each dose of pro-inﬂammatory cytokine inhibitors causes a propor-
tional decrease in pro-inﬂammatory cytokine level. We then use an instantaneous
decrease in pro-inﬂammatory cytokine concentration (p) in the model to mimic
these cytokine treatments. Some eﬀects similar to those reported during cytokine
treatment, such as a temporary reduction in disease activity or remission, are
exhibited by the model.
To see the importance of dose size and interval, parameters for which the system
displays type Ci behaviour (see Section 3.2.1) are taken so that the system can
show both healthy and disease stable steady states. We start the system at a
stable disease state (S2) and reduce the value of p by a ﬁxed amount at a speciﬁc
time point. An increase in dose magnitude is modelled by a larger reduction in the
level of p. If the system is at the disease state and a single dose of anti-cytokine
treatment is given then the response of the system depends entirely on the size of
that dose.
A reduction in pro-inﬂammatory concentration which is not suﬃcient to shift the
system to a state outside the basin of attraction of S2 can cause a temporary fall in
pro-inﬂammatory concentration followed by an overshoot and decaying oscillations
back to the disease state (Figure 2.15). A larger dose can be suﬃcient to trigger a
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Figure 2.15: Pro-inﬂammatory and anti-inﬂammatory cytokine concentration re-
sponse to a single infusion of anti-inﬂammatory cytokine at time t = 50 (dose of
magnitude 0.02 in the ﬁrst column and 0.04 in the second). The ﬁrst row shows
the time course for the change in Pro-inﬂammatory cytokine concentration, whilst
the second row shows the phase plane for the parameters used. The red curves on
the phase plane track the time evolution of p as seen on the time course. The time
courses of anti-inﬂammatory cytokine concentration are not shown for brevity, but
proﬁles look similar to pro-inﬂammatory cytokine concentration. The parameters
used are {Pbp = 0.025, Ppp = 15.5, Aph = 0.5, App = 18 and γp = 1.25}.
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monotonic decrease in p until the system settles at the healthy state. This is not a
feature that is normally seen in clinical practice which may suggest that either the
dose levels used do not move the system outside of the basin of attraction of S2,
or that disease relapses by a change in the parameters, moving the system from a
healthy steady state or that the patient in not curable.
The pattern of treatment is also pivotal to the results obtained. By administering
multiple treatments it may be possible to achieve results which are not seen for a
single dose, although the timing can be crucial. Using the same parameter values
as in Figure 2.15, taking a dose of magnitude 0.02 (which as a single dose did not
return the system to S0) and giving two doses at diﬀerent intervals, shows that
the response depends in a non-trivial way on timing (Figure 2.16).
A dose interval of 10 units drives the system to the stable healthy state, whilst
a 15 unit interval sees a return to stable disease after an initial response. Re-
markably, a longer interval can be beneﬁcial; for a 17 unit interval a healthy state
is achieved. This dependence on timing arises because in the 15 time unit dos-
ing interval protocol, the second dose is applied when the pro-inﬂammatory and
anti-inﬂammatory concentration have risen signiﬁcantly from their ﬁrst minimum,
meaning that the second dose is insuﬃcient to force the trajectory out of the stable
manifold (Figure 2.16). In the ﬁrst and third case, the second dose is administered
at a point where the pro-inﬂammatory concentration is low and so the dose pushes
the trajectory out of the basin of attraction of the disease state. The trajectory
must be suﬃciently close to the basin boundary (the manifold) at the time the
second dose is given.
So far, each of the doses provided has been able to shift the system to the healthy
state. Some doses, however, are not large enough to achieve this, regardless of
the number of doses unless the pattern of dose administration is changed. Using
the same parameters as before with a dose half the size of the previous dose size
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Figure 2.16: Time dependence of pro-inﬂammatory and anti-inﬂammatory cy-
tokine concentration for diﬀerent time separation between doses. All doses have a
magnitude of 0.02 and the parameters values are {Pbp = 0.025, Ppp = 15.5, Aph =
0.5, App = 18 and γp = 1.25}. The ﬁrst column shows the time courses of pro-
inﬂammatory concentration for two doses given 10, 15 and 17 time units apart.
The time courses of anti-inﬂammatory cytokine concentration are not shown for
brevity, but proﬁles look similar to pro-inﬂammatory cytokine concentration. The
second column shows phase plane diagrams of the simulations, with the red curves
showing the time evolution of p.
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(0.01) and applying it at time intervals of 5 units over a sustained period of time,
we obtain the pro-inﬂammatory concentration proﬁle shown in Figure 2.17a. This
treatment pattern brings about a temporary reduction in the concentration of
pro-inﬂammatory cytokine although there are oscillations in the level. When the
treatment ceases, the pro-inﬂammatory cytokine concentration returns to the pre-
treatment level. Only by reducing the time interval can this change be sustained
after treatment has ceased (Figure 2.17b). The reduction in time interval means
that the next dose is given before the system has moved fully back to disease,
hence increasing the eﬀective dose.
Figure 2.17: Pro-inﬂammatory cytokine proﬁles for the system with doses of anti-
inﬂammatory cytokine of magnitude 0.01 at (a)5 unit intervals between t = 25
and t = 75 and (b) 3 unit intervals between t = 25 and t = 75 and parameters
{Pbp = 0.025, Ppp = 15.5, Aph = 0.5, App = 18 and γp = 1.25}. There is a trade
oﬀ between dose size and interval. The dose interval needs to be reduced to give
a sustained response for smaller dose sizes.
2.6 Discussion
Cytokines are important mediators in RA. The success of clinical treatments based
on altering the synovial cytokine proﬁle suggests that the composition and inter-
actions of the cytokine network are key factors in at least the regulation, if not the
onset, of rheumatoid arthritis [44]. The model developed here is a two variable
activator-inhibitor system that simulates the dynamics of two classes of cytokines,
57
Chapter 2: Pro- and anti-inflammatory cytokine model for
rheumatoid arthritis
pro-inﬂammatory and anti-inﬂammatory. Five key dimensionless parameters have
been identiﬁed. We have shown that the model can have either one steady state
(S0 or S2) or three steady states (S0, S1 and S2). This leads to a range of phase
plane behaviours.
The model shows four types of monostable phase plane behaviour (Ai, Aii, Aiii
and B). These behaviours may be interpreted as a healthy response (Ai and Aiii)
due to a low level of p, a disease response due to a high level of p (B) or an un-
clear response of health/disease due to an intermediate range of p. In addition
to monostable behaviour, the model also shows four types of bistable phase plane
behaviour (Ci, Cii, Di and Dii). These have a stable healthy steady state and a
stable disease state which is either a ﬁxed point or a limit cycle. One point to note
is that if an individual has a high level of pro-inﬂammatory production, so that a
monostable disease state prevails, increasing the magnitude of anti-inﬂammatory
production, App, does not return the system to distinct health, but does reduce
the level of p at the ﬁxed point (see Figure 2.8b). In clinical practice, only cy-
tokine concentrations are changed rather than production rates, so increasing the
magnitude of anti inﬂammatory cytokine production would relate only to intrinsic
changes in parameters at present. However, this may be relevant for development
of gene therapy approaches.
Figure 2.13 shows that as the pro-inﬂammatory production parameter (Ppp) in-
creases over time the system moves from the healthy steady state to a disease
state. Here, the anti-inﬂammatory production parameter, App, determines the
pattern of disease onset. As App increases, the approach to the disease state
changes from a straightforward switch to an oscillatory approach. The size of App
determines the time taken for the oscillations to settle until, for some larger App,
we have sustained oscillations. These counter-intuitive features highlight the need
for a well-deﬁned measure of the link between the cytokine proﬁle and synovial
inﬂammation in the model, since lower cytokine levels may still result in a longer
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period of persistent disease. Figure 2.14 shows that temporary spikes in the pro-
inﬂammatory production parameter, which may represent a response to infection,
can also initiate disease onset. In this case, disease onset is determined by the
level of pro-inﬂammatory cytokine production after the initial spike as well as the
underlying individual's parameters.
Cytokine treatment simulations show the relevance of dose size to the eﬃcacy of
a particular treatment. Two doses were applied when the system was at rest at
the disease state (Figure 2.15). We demonstrated that the larger dose could move
the system to a state of health, whilst the smaller dose was insuﬃcient. Repeated
smaller doses could be used to move the system to health, but the dose interval
used here is crucial. The key factor in determining the dose interval is the point
in the oscillatory cycle at which the second or subsequent dose is administered
(Figure 2.16). Intuitively, the best time to apply the second dose is when the
pro-inﬂammatory concentration is at its lowest so that the cumulative eﬀect is as
large as possible. Mathematically, the best time to apply it is when the horizontal
separation in the (p, a) phase plane between the bounding curve of the basin of
attraction of S2 and the concentration trajectory is a minimum, since this gives
the best chance of leaving the basin of attraction of the disease state. These
conditions are not necessarily equivalent. If the side eﬀects of a high dose of a
drug are unacceptable then we have shown that it may be possible to apply a
course of smaller doses at targeted times to return the system to health. Clearly,
it may be possible to manipulate the treatment regime to include the smallest
possible dose over the fewest possible applications. The model has the surprising
property that an increase in the pro-inﬂammatory cytokine level can also bring
about remission, this has not been tested clinically but has interesting implications
for novel treatment strategies.
In parameter regimes where only the disease state exists, no treatment of the types
described here, no matter how large the dose, could ever achieve remission (i.e.
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a sustained state of health). Manipulation of the system parameters is the only
way this could be achieved. However, a dose of anti-cytokine therapy would move
an individual to a lower pro-inﬂammatory cytokine level temporarily followed by
a gradual return to the disease state. This is still a desirable outcome in clinical
practice and justiﬁes the use of anti-cytokine therapy, particularly when given as
a series of regular treatments, even where remission is impossible.
We believe that a healthy individual at low risk of developing RA will have param-
eters corresponding to a phase plane with a single, globally stable, steady state.
Individuals with very early RA or at risk of developing RA will have parameters
deﬁning a system with three steady states. These individuals may go on to oc-
cupy a steady disease state from which it is possible to return to a healthy state by
appropriate manipulation of pro- and anti-inﬂammatory cytokine levels. Corre-
spondingly, clinicians refer to a window of opportunity in treating early RA during
which remission is more likely than in later disease [99], implying time dependence
of the underlying parameters. In clinical practice, the closure of this window of
opportunity marks the transition from early to established disease. In this model,
it may mark the transition from a system with three steady states to one with
a single, steady, inescapable disease state characterised by high pro-inﬂammatory
cytokine levels, which occurs as Ppp changes. In established RA, remission rates
with anti-cytokine therapy are only around 20% [60], suggesting that the either
majority of patients with established RA are in this state or they are not being
treated optimally.
This model has produced many of the features observed in real cytokine systems,
but if the characteristics of this model are to be interpreted in a clinical context,
then it is necessary to link concentration of cytokines to a measurable disease in-
dicator. Ideally, we would like to link the model results to clinical data of cytokine
levels over time in individuals with early and late RA. Practical considerations,
including the short half life of cytokines and the diﬃculty of extracting synovial
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ﬂuid from the joint, mean this type of data is diﬃcult to obtain in humans. It
may be possible to collect similar data from animal models or alternatively we may
be able to use other types of clinical data. The inﬂammatory marker C-Reactive
Protein (CRP) is routinely used by clinicians as a measure of disease activity in
RA [101]. However, variation between individuals is large and the link between
cytokine level and CRP level or inﬂammation is as yet unclear. That said, in the
majority of cases we identify from our model, the interpretation is very clear. We
either have low levels of p indicating health or high levels of p indicating disease.
It is only when the levels are intermediate that we are unable to deﬁne a clear
threshold between health and disease. Whilst there is no precise link between
model variables and speciﬁc disease markers, the interactions in the model are
well-established and the predictions are robust to variations in parameter values
and functional forms. It would ultimately be desirable to have a model which
includes a number of speciﬁc cytokines and measurable disease markers to allow a
clear link between model behaviour and disease activity. This would give a better
idea of how cytokine levels inﬂuence disease manifestations and would provide a
clearer deﬁnition of health and disease.
The dynamics of pro- and anti-inﬂammatory cytokines are likely to be relevant in a
wider context than RA in the synovium. As discussed in Chapter 1, Osteoarthritis
involves the same cytokines, and hence similar dynamics are likely to exist. It is
likely that the RA model presented here could form a basis for examining the
cytokine dynamics within OA tissue and we will consider this further in Chapter
3. Additionally, other conditions, such as diabetes, sepsis, Alzheimer's disease and
lupus, are also known to have cytokine involvement and due to the generality of
this model it may be applicable in these wider contexts.
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The focus of the model developed in the previous chapter was to understand the
pro-inﬂammatory and anti-inﬂammatory cytokine interactions in the synovium.
The network of cytokine interactions in the joint is more complex than in the
synovium. In the cartilage, since the main role of the cytokines to control ECM
remodelling, it makes sense to extend the model to include the dynamics of MMPs,
the enzymes that break down ECM ﬁbres, and degraded ﬁbronectin fragments (Fn-
fs), a waste product which can stimulate cytokine production. A predominant
feature of OA is excessive breakdown of the ECM. Higher than normal levels of
Fn-fs have been found in osteoarthritic individuals and are thought to contribute
to the acceleration of the disease [86]. The model we have developed is based on
the simpliﬁed cytokine network schematised in Figure 3.1.
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Figure 3.1: A simpliﬁed network of cytokine interactions within articular cartilage.
Cytokines are classed as pro-inﬂammatory or anti-inﬂammatory. MMPs have a
direct role in the breakdown of the ECM leading to increased Fn-fs. Fibronectin
fragments are irritants to the cartilage and lead to increased cytokine production
as part of the inﬂammatory response.
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3.1 Model Rationale
In this paper we develop a four-variable model of cytokine interactions in the carti-
lage, as seen in OA. Our model variables are pro-inﬂammatory cytokines (p), anti-
inﬂammatory cytokines (a), MMPs (m) and Fn-fs (f). In order to keep the model
tractable, cytokines have been put into two functional groups, pro-inﬂammatory
and anti-inﬂammatory. This is the same grouping as we used in the cytokine-only
model of the synovium (Chapter 2). Pro-inﬂammatory cytokines are normally
present at low levels in the cartilage as they play a role in mediating the normal
turnover of the ECM [108], which involves remodelling the cartilage ECM at a very
slow rate to maintain tissue integrity. Production of pro-inﬂammatory cytokine
is up-regulated in response to trauma or infection, as part of the inﬂammatory
response and repair mechanism. This response is usually kept in homeostatic bal-
ance by anti-inﬂammatory cytokines, which act both to inhibit the synthesis of
pro-inﬂammatory cytokines and also to block pro-inﬂammatory cytokine receptors
[103]. To model these processes we assume that production of pro-inﬂammatory
cytokines, p, is dependent on itself, anti-inﬂammatory cytokines, a, and Fn-fs, f ,
dp
dt
=
(
pbp + ppp
p2
pph2 + p2
+ pfp
f 2
pfh2 + f 2
)(
pah
2
pah2 + a2
)
− dpp. (3.1.1)
We make the source term saturating since we assume there will be a maximal
production rate in the cell and therefore model functions of p, a and f as Hill
functions. We also assume that pro-inﬂammatory cytokines will degrade natu-
rally at rate dp. We have chosen all the Hill coeﬃcients to be 2. We choose
to make the stimulatory terms additive as we expect these two pathways to be
independent since they are biochemically distinct and activate diﬀerent cell re-
ceptors. This means that even if there is no cartilage degradation there may still
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be a large cytokine response due to an increase in p. This may be the case, for
example, if there is an inﬂammatory episode where there is no physical damage
to the cartilage. Since anti-inﬂammatory cytokines reduce production and ef-
fectiveness of pro-inﬂammatory cytokines regardless of the source we apply the
anti-inﬂammatory inhibition term to all the source terms.
The dynamics of the anti-inﬂammatory cytokines, a, includes source terms rep-
resenting the up-regulation of a, by both pro-inﬂammatory cytokines and Fn-fs,
and a natural degradation term,
da
dt
= app
p2
aph2 + p2
+ afp
f 2
afh2 + f 2
− daa. (3.1.2)
The source terms are saturating Hill functions of p and f .
MMPs mediate ECM degradation and the synthesis of MMPs is stimulated by
pro-inﬂammatory cytokines [126]. MMPs are also found at low levels in normal
cartilage so we assume some basal production. The dynamics of MMPs (m) are
therefore modelled as having source terms that account for basal production and
up-regulation by pro-inﬂammatory cytokines and a natural degradation term,
dm
dt
= mbp +mpp
p2
m2ph + p
2
− dmm. (3.1.3)
Fn-fs, produced as a result of ECM degradation, need to be explicitly included in
the model since they are involved in the stimulation of cytokine production, see
Figure 3.1. Since the ECM is degraded by MMPs the source term is a function of
m. Additionally, breakdown of the ECM may be caused by mechanical damage,
represented by the term fdam. We also include natural degradation, giving
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df
dt
= fmpm+ fdam − dff. (3.1.4)
3.2 Model Equations
We non-dimensionalise the model using the scalings:
p = pphp˜ a = paha˜ m =
pfhdam˜
fmp
f = pfhf˜ t =
t˜
da
where the tilde denotes dimensionless quantities. Dropping the tildes for conve-
nience, gives the dimensionless model:
dp
dt
=
(
Pbp + Ppp
p2
1 + p2
+ Pfp
f 2
1 + f 2
)(
1
1 + a2
)
− γpp (3.2.1)
da
dt
= App
p2
Aph
2 + p2
+ Afp
f 2
A2fh + f
2
− a (3.2.2)
dm
dt
= Mbp +Mpp
p2
Mph
2 + p2
− γmm (3.2.3)
df
dt
= m+ Fdam − γff (3.2.4)
where,
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Pbp =
pbp
pphda
, Ppp =
ppp
pphda
, Pfp =
pfp
pphda
, App =
app
pahda
,
Aph =
aph
pph
, Afp =
afp
aphda
, Afh =
afh
pfh
, Mbp =
mbpmpp
pfhda
2 ,
Mpp =
mppfmp
pfhda
2 , Mph =
mph
pph
, Fdam =
fdam
pfhda
, γp =
dp
da
,
γm =
dm
da
, γf =
df
da
.
The meaning of each of these new parameters is summarised in Table 3.1.
Table 3.1: The parameters in the system (3.2.1) - (3.2.4) and their interpretation
Parameter Description
Pbp Background pro-inﬂammatory production
Ppp Pro-inﬂammatory cytokine driven pro-inﬂammatory cytokine production
Pfp Fibronectin fragment driven pro-inﬂammatory cytokine production
App Pro-inﬂammatory cytokine driven anti-inﬂammatory cytokine production
Aph Pro-inﬂammatory cytokine concentration at which pro-inﬂammatory
cytokine driven anti-inﬂammatory cytokine production is half maximal
Afp Fibronectin fragment driven anti-inﬂammatory cytokine production
Afh Fibronectin fragment concentration at which Fn-fs driven
anti-inﬂammatory cytokine production is half maximal
Mbp Background MMP production
Mpp Pro-inﬂammatory cytokine driven MMP production
Mph Pro-inﬂammatory cytokine concentration at which MMP
production is half maximal
Fdam Mechanical damage parameter
γp Relative rate of clearance of pro-inﬂammatory cytokine
to anti-inﬂammatory cytokine
γm Relative rate of clearance of MMP to anti-inﬂammatory cytokine
γf Relative rate of clearance of Fn-fs to anti-inﬂammatory cytokine
3.3 Steady States
Insight into the nature of the steady states of this system can be gained from the
nullclines, hypersurfaces given by,
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p˙ = 0⇐⇒ a = Np(p, f) =
√
g(p, f), (3.3.1)
where
g(p, f) =
1
γpp
(
Pbp + Ppp
p2
1 + p2
+ Pfp
f 2
1 + f 2
)
− 1,
and
a˙ = 0⇐⇒ a = Na(p, f) = App p
2
A2ph + p
2
+ Afp
f 2
A2fh + f
2
, (3.3.2)
m˙ = 0⇐⇒ m = Nm(p) = Mbp
γm
+
Mpp
γm
p2
M2ph + p
2
, (3.3.3)
f˙ = 0⇐⇒ f = Nf (m) = m+ Fdam
γf
. (3.3.4)
The steady states of the model are the points where all the nullclines intersect.
We can locate these points by solving equations (3.3.1)-(3.3.4) simultaneously,
however this is analytically intractable. We can, however, substitute m = Nm
and f = Nf (Nm(p)) into Np and Na, reducing the problem to two simultaneous
equations,
a = Np(p,Nf (Nm(p))), a = Na(p,Nf (Nm(p))),
leading to,
a =
√
h(p), (3.3.5)
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where
h(p) =
1
γpp
Pbp + Ppp p2
1 + p2
+ Pfp
(
Fdamγm +Mbp +Mpp
p2
M2ph+p
2
)2
(γfγm)2 +
(
Fdamγm +Mbp +Mpp
p2
M2ph+p
2
)2
− 1,
and
a = App
p2
A2ph + p
2
+ Afp
(
Fdamγm +Mbp +Mpp
p2
M2ph+p
2
)2
(γfγm)2A2fh +
(
Fdamγm +Mbp +Mpp
p2
M2ph+p
2
)2 . (3.3.6)
The intersections of these two curves, equations (3.3.5) and (3.3.6), give the steady
states. Although analytical solutions are not tractable, the forms of the curves
tell us the possible number of steady states.
Equation (3.3.6) consists of two terms, the ﬁrst is a Hill function of p and the
second is a Hill function of p embedded within another Hill function. This allows
(3.3.6) to take two forms, either a sigmoidal shape, if Aph and Afh are close in
value (Figure 3.2a), or a double sigmoidal shape if Aph and Afh are suﬃciently
diﬀerent (Figure 3.2b).
Equation (3.3.5) involves the square root of the function h(p), and therefore only
exists when h(p) ≥ 0. As p → 0, h(p) → ∞. As p → ∞, h(p) → −1 and h(p) is
continuous. Hence, (3.3.5) always meets the p-axis for a large enough value of p.
If we consider h(p) as,
h(p) =
k(p)
γpp
− 1,
the function k(p), similar to eq. (3.3.6), can have either a sigmoidal or double
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sigmoidal shape. The double sigmoidal shape is possible when the terms involving
Ppp and Pfp are suﬃciently diﬀerent. This leads to several possible shapes for the
function h(p) and likewise a =
√
h(p). These are shown in Figures 3.2c-f.
The forms of equations (3.3.5) and (3.3.6) mean that they will always intersect at
least once, so the system will always have at least one steady state. It is clearly
possible for these curves to also intersect three times. We could conceivably have
up to nine intersections, but we have found a maximum of ﬁve (see Section 3.4.6)
with the Hill coeﬃcients of 2. Two or four steady states will only occur when the
curves meet tangentially. Since this only occurs at bifurcations we will focus on
cases with one, three or ﬁve steady states. In each case when the levels of p are
low we assume this would indicate a healthy steady state. We chose the value of
all the Hill coeﬃcients in the model to be 2, which determines the shapes of the
nullclines. With a coeﬃcient of 1 we would restrict the number of steady states
possible. Equation (3.3.6) increases monotonically and equation (3.3.5) decreases
monotonically, giving only one possible steady state. For Hill coeﬃcients greater
than 2 or mixed coeﬃcients, the nullclines take the same form as with coeﬃcients
of 2, although the parameter values diﬀer and the steeper gradients allow for the
possibility of additional steady states. For example we have been able to ﬁnd up
to seven steady states with mixed Hill coeﬃcients of 2 and 4. These additional
states occur in only small regions of parameter space. For this reason we consider
only the case where the Hill coeﬃcients are 2, and consider the implications of
higher coeﬃcients in the Discussion, as in our previous work, [10].
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Figure 3.2: Diagrams of the shapes that the p and a nullclines may take, with m =
Nm(p) and f = Nf (Nm(p)). The steady states of the system occur where these
equations intersect. The a nullcline is either sigmoidal (a) or double sigmoidal (b)
in shape. The p nullcline can take up to several forms that may meet the x-axis
zero (c) and (f), one (e) or two (d) times.
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3.4 Bifurcation Analysis
This model has a large number of parameters and it is not feasible to explore
the entire parameter space so we will limit our analysis of model behaviour to
a reference parameter set and look at one- and two-parameter variations around
that point, through bifurcation analysis. Additionally we will look at signiﬁcant
variations to that reference parameter set where the behaviour is of particular
interest either mathematically or biologically.
Due to the diﬃculties of obtaining measurements of cytokine rates and levels both
in vivo and in vitro, there is little reliable and reproducible data concerning the
parameters in the model. We therefore start with a simple set of parameters,
summarised in Table 3.2, avoiding unlikely scenarios. All the sensitivity param-
eters (Aph, Afh and Mph) are set to 1 so that they are of the same magnitude
as the thresholds of the other functions in the model. Similarly, the degradation
rates (γp, γm and γf ) are set to 1 to match the degradation rate of a. We set the
mechanical damage parameter initially to 0. We set all the cytokine and MMP
production parameters (Ppp, Pfp, App, Afp and Mpp) to 10, making them equal
avoids unnecessary bias in the networks, and this magnitude allows the nullclines
to intersect. We wish the background production parameters (Pbp and Mbp) to be
much smaller so we set these to 0.01. We believe we have a clear understanding
of the dynamics of the model as demonstrated below. Thus despite incomplete
knowledge about the parameters, we think that variations reasonably close to this
reference parameter set show the range of behaviours that the model can display.
With these parameters there are three steady states: S0, S1 and S2 (variable
values and eigenvalues shown in Table 3.3). The system is bistable with S0 likely
to indicate health due to low levels of p and f , which are very close to basal
production levels, and a limit cycle around S2 likely to indicate disease due to
high and ﬂuctuating levels of p and f .
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Parameter Value
Pbp 0.01
Ppp 10
Pfp 10
App 10
Aph 1
Afp 10
Afh 1
Mbp 0.01
Mpp 10
Mph 1
Fdam 0
γp 1
γm 1
γf 1
Table 3.2: Reference parameter set
S0 S1 S2
p 0.013 0.054 0.260
a 0.003 0.044 3.57
m 0.012 0.039 0.645
f 0.012 0.039 0.645
Eig(1) -0.497 0.454 0.015 + 0.780i
Eig(2) -1.00 -0.995 0.015 - 0.780i
Eig(3) -1.12 + 0.327i -1.20 + 0.728i -1.85 + 1.30i
Eig(4) -1.12 + 0.327i -1.20 - 0.728i -1.85 - 1.30i
Stability Stable Unstable Unstable (with stable limit cycle)
Table 3.3: Details of the steady states of the reference parameter set used for
bifurcation analysis of the dimensionless model (Eqn. 3.2.1-3.2.4). The position
of the steady states, eigenvalues and stability of steady state are shown.
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A sensitivity analysis of small parameter changes around the reference parameter
set gives some insight into the behaviour of the system. Figure 3.3 shows sensi-
tivity of the parameters to a ± 10% change as measured by three features: the
concentration of p at the steady state, the amplitude and the period of any limit
cycles. We use a one-at-a-time sensitivity analysis to measure the sensitivity gain
for each feature according to the sensitivity function,
Sφk =
δφ/φ
δk/k
, (3.4.1)
where φ is the feature being measured and k is the parameter being changed.
Parameters related to anti-inﬂammatory cytokine production and clearance rate
parameters are consistently the most sensitive when the system is at the disease
state. This suggests that if we alter these parameters from the reference parameter
set we may have signiﬁcantly diﬀerent bifurcation behaviour. We will consider this
later in the next section. When the system is at the healthy state it is additionally
sensitive to changes in Pbp and γp.
For this parameter set, due to γf being 1 and Fdam being zero, m and f are equal
at the steady states. Figure 3.4a shows simulated solution trajectories for various
sets of initial conditions for the reference parameter set as a three dimensional
projection in (p, a,m) space.
The ﬁgure shows that the basin of attraction of the disease state is very large
compared to that of the healthy state and that decaying oscillations into the
disease state have a large amplitude. This may translate clinically to slow onset of
OA with periods of ﬂare up followed by asymptomatic periods. However, we need
to view the basin of attraction in terms of realistic perturbations from the steady
state. Figure 3.4b shows perturbations within a small range of the healthy steady
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Figure 3.3: Diagrams of the sensitivity of the parameters as measured by the
values of p at the steady state, the period and amplitude of limit cycles. The x-
axis shows the relative sensitivity coeﬃcient as the parameters are varied by 10%
(blue circles) or -10% (red triangles). A value of 1 on the x-axis is representative of
a 10% change in the feature given a 10% change in the parameter. The diagrams
show that the parameters related to anti-inﬂammatory cytokine production are
particularly sensitive to small changes.
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(a) (b)
Figure 3.4: Projection of the phase space for the reference parameter set, speciﬁed
above, showing trajectories, for the cartilage model, for various regularly spaced
initial conditions in (p, a,m) space. (a) shows all three steady states whilst (b)
focuses on the behaviour around the healthy steady state. The black circles show
the position of unstable ﬁxed points and the red dot shows the stable ﬁxed point.
The trajectories either move to the stable ﬁxed point or the stable limit cycle
which surrounds an unstable ﬁxed point.The unstable steady state inﬂuences the
path taken by trajectories.
state. We can see from this that increases in the anti-inﬂammatory cytokine level
do not move the system to disease and, for this parameter set, up to a six fold
increase in either pro-inﬂammatory cytokine, MMP or Fn-fs is required. We can
also see that the unstable steady state inﬂuences the path taken by trajectories.
In some cases, this may lead to large ﬂuctuations, which we will discuss later.
Throughout this analysis we will be drawing comparisons with the cytokine-only
model from the previous chapter. We have redone bifurcation plots from the
previous chapter using the parameters we have chosen for this reference param-
eter set, Figure 3.5. Using parameter values Pbp=0.01, Ppp=10, App=10, Aph=1,
γp=1 to match the reference parameter set from this model, we have produced
single parameter bifurcation diagrams for each of the parameters. We use this for
comparison with the fuller model later in this section.
The bifurcation analysis of the full cartilage model reveals a wide range of be-
haviours as we vary the parameters away from the reference parameter set, these
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Figure 3.5: Bifurcation plots of the cytokine-only model using the reference pa-
rameter values used in this chapter showing the transitions from monostable to
bistable. Comparison with the cartilage model in this chapter gives insight into
the eﬀect of the ECM fragment driven feedback.
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Name No. of Stability of Steady States Limit Cycles Type
Steady States
Ai 1 SS0 - Monostable Health
Aii 1 SS0 - Monostable Disease
Aiii 1 SU0 L
S
1 Monostable
Bi 3 SS0 , S
U
1 , S
U
2 - Monostable Health
Bii 3 SU0 , S
U
1 , S
S
2 - Monostable Disease
Biii 3 SS0 , S
U
1 , S
S
2 - Bistable
Ci 3 SS0 , S
U
1 , S
U
2 L
S
1 Bistable
Cii 3 SU0 , S
U
1 , S
S
2 L
S
1 Bistable
Ciii 3 SS0 , S
U
1 , S
S
2 L
S
1 Bistable
Civ 3 SS0 , S
U
1 , S
S
2 L
U
1 , L
S
2 Bistable
Cv 3 SU0 , S
U
1 , S
U
2 L
S
1 Monostable Disease
Di 3 SS0 , S
U
1 , S
S
2 L
U
1 , L
S
2 Bistable
Dii 3 SS0 , S
U
1 , S
U
2 L
S
1 , L
U
2 Bistable
Diii 3 SU0 , S
U
1 , S
S
2 L
U
1 , L
S
2 Bistable
Ei 5 SS0 , S
U
1 , S
S
2 , - Tristable
SU3 , S
S
4
Eii 5 SS0 , S
U
1 , S
U
2 , - Bistable
SU3 , S
S
4
Fi 5 SS0 , S
U
1 , S
U
2 , L
S
1 Tristable
SU3 , S
S
4
Fii 5 SS0 , S
U
1 , S
S
2 , L
U
1 Tristable
SU3 , S
S
4
Table 3.4: Summary of the behaviours that arise for diﬀerent values of the pa-
rameters in system (3.2.1 - 3.2.4). The abbreviation S means Stable and U means
Unstable, indicating the stability of the steady state or limit cycle.
are summarised in Table 3.4. In the rest of this section we will look at single
parameter variations away from the reference parameter set for each parameter.
This may give insight into OA initiation and allow suitable treatment strategies
to be considered.
3.4.1 Changes in Pbp,Ppp and Pfp
The parameters Pbp, Ppp and Pfp govern the production of pro-inﬂammatory cy-
tokines. These cytokines are raised in OA and this has been implicated in disease
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progression [59]. The mechanism by which these raised levels occur is unclear but
could be the result of higher than normal production rates of pro-inﬂammatory
cytokines.
Figure 3.6: Bifurcation plots of the pro-inﬂammatory cytokine level (p) against
the pro-inﬂammatory cytokine production parameters (a) Pbp, (b) Ppp and (c)
Pfp. The dashed lines denote the transition between diﬀerent behaviours, which
are labelled.
In this four-variable model if any of these three parameters are suﬃciently high
bistability is lost through a fold bifurcation and there is a single steady state
(Fig 3.6). For intermediate Pbp and Ppp values loss of bistability is followed by a
single stable limit cycle (Figs 3.6a and b) representing an oscillatory state. Then
at higher levels of these parameters this is lost, via a Hopf bifurcation, leaving a
single stable steady state. For increases in Pfp, the Hopf bifurcation is encountered
before the fold bifurcation, giving rise to two stable steady states for some values
of Pfp. For low values of Pfp, we can have a single stable steady state representing
health. As the limit cycle collides with S1 at a homoclinic bifurcation it leaves
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only one stable and two unstable steady states. Examination of the phase space
suggests that, as for the reference parameter set, the basin of attraction of the
disease state is large in the bistable region and remains large even as we move
towards the homoclinic (Figure 3.7). Indeed, in the monostable health region,
trajectories undergo large ﬂuctuations in p before settling to the healthy state
(Figure 3.8). One interpretation of these large basins of attraction is that major
deviations from the state of health due to trauma or infection are likely to move
an individual to a state of disease, since the large basins for disease persist over
the range of small parameter variations, which we might expect to see in diﬀerent
individuals. Even in monostable health large deviations from the healthy state
could cause cartilage damage. This behaviour may be point to the reasons for OA
being so prevalent since the system trajectories deviate from the healthy steady
state for wide ranges of parameters and initial conditions.
From our reference parameter set, variations in either of the other two pro-
inﬂammatory cytokine production parameters (Pbp, Ppp) cannot lead to monos-
table health, although altering Ppp can change the stable disease state from a
limit cycle to a ﬁxed point. We do not know whether a ﬁxed disease state or a
oscillatory disease state is more damaging to the cartilage. An oscillatory state
may be considered to be less damaging since it results in periods of low damage
and possible repair. However, due to the poor repair capacity of cartilage it is
also possible that a stable steady disease state might be preferable to a limit cycle
disease state, since the large amplitude ﬂuctuations may result in more cartilage
damage at high points on the cycle and little repair at low points. The average
value of the limit cycle (the blue dashed line on Figure 3.6) may indicate how
damaging the limit cycle is compared to steady states.
Comparison of Figure 3.6a and b with Figure 3.5a and b (the cytokine-only model)
shows similar behaviour. One important diﬀerence is that both Pbp and Ppp in
Figure 3.6 show oscillatory behaviour whereas the disease states are ﬁxed points
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Figure 3.7: Projection of the phase space for the reference parameter set except
Pfp = 5, showing trajectories for various regularly spaced initial conditions in
p − a −m space. These parameters are close to a homoclinic orbit and the plot
shows that even here the basin of attraction of disease is large, compared to that
of the healthy steady state. The red dot denotes a stable ﬁxed point and the black
circle denote unstable ﬁxed points.
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Figure 3.8: Projection of the phase space for the reference parameter set with Pfp
changed to 3, showing trajectories for various regularly spaced initial conditions
in p− a−m space. There is only one stable steady state which is healthy but the
ﬂuctuations into the state are large. The red dot denotes a stable ﬁxed point and
the black circle denote unstable ﬁxed points.
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in the cytokine-only model. If a ﬁxed disease state is clinically preferable to an
oscillatory one the model suggests that inhibition of fragment-driven feedback
may be a justiﬁable treatment aim. This may be achieved by greater clearance of
ﬁbronectin fragments or lower MMP production, both of which have been explored
clinically, although without clear results. We consider these treatment options in
Section 3.8.
3.4.2 Changes in App and Afp
Anti-inﬂammatory cytokines reduce the production and activation of pro-inﬂammatory
cytokines and hence we expect that higher values of App and Afp, the anti-
inﬂammatory cytokine production parameters, would lead to health. Figure 3.9
shows that this is indeed the case with high levels of either parameter resulting in
the loss of the disease state. For App the disease state is lost through a fold bifur-
cation. Whereas for Afp, the disease state becomes unstable at a much lower level
and the disease limit cycle is lost through a homoclinic orbit. Decreasing App from
its reference value leads to an increase in the amplitude of the limit cycle of the
disease state (Fig 3.9a), which seems likely to have a detrimental aﬀect. A lower
level of Afp results in the disease limit cycle being replaced with a disease steady
state (Fig 3.9b). However, the average of the limit cycle decreases when Afp in-
creased so this will depend on the relationship between cytokine level and cartilage
destruction. These bifurcation plots suggest that increases to anti-inﬂammatory
cytokine production levels could be beneﬁcial and lead to reduced or even halted
cartilage degradation. As discussed previously, a shift from a disease limit cycle to
the disease steady state could be beneﬁcial. Hence decreases to anti-inﬂammatory
production, whilst not moving the system to health, may also be beneﬁcial.
Comparing this behaviour with the cytokine-only model (Fig 3.5c), the bistable
region occurs over a much wider range for this cartilage model. In some cases this
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Figure 3.9: Bifurcation plots of the pro-inﬂammatory cytokine level (p) against
anti-inﬂammatory cytokine production parameters (a) App and (b) Afp. The
dashed lines denote the transition between diﬀerent behaviours, which are labelled.
could mean that inhibition of fragment-driven feedback could move the system
from disease to health.
3.4.3 Changes in Mpp and Mbp
The parameters Mbp and Mpp determine the maximum rates of MMP production.
Since MMP levels are known to be raised in OA these parameters are of great
interest. Figure 3.10 shows that, for variations in these parameters about the
reference parameter set, there are no regions of monostable health. At high levels
of MMP production, with either high Mbp or Mpp, there is a region of monostable
disease with a stable steady state. In both cases, at production levels below the
reference parameter set, a fold bifurcation leads to bistability with the introduction
of stable and unstable steady states, providing the possibility of moving to a
healthy state. For Mpp, Figure 3.10b, within the bistable region there is a region
of oscillatory disease due to two Hopf points.
For this parameter set, for an individual in an oscillatory disease state, an increase
in Mpp production pushes the system to a steady disease state in p which is lower
than the average of the limit cycle in the oscillatory states. However, if the level is
too high, although the disease state may result in slower cartilage destruction, we
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Figure 3.10: Bifurcation plots of the pro-inﬂammatory cytokine level (p) against
the MMP production parameters Mbp and Mpp. The dashed lines denote the
transition between diﬀerent behaviours, which are labelled.
lose the possibility of moving to a healthy steady state. However, the level of f is
lower at smaller values of Mpp so the lower levels of p do not necessarily imply less
cartilage degradation. This counter-intuitive result arises as a result of a balance
in the positive and negative feedback pathways. Mpp is part of both pathways and
for the reference parameter set the negative feedback is dominant.
3.4.4 Changes in Aph, Afh and Mph
The parameters Aph and Afh are the concentrations of p and f at which the anti-
inﬂammatory cytokine production terms are half maximal. As such they represent
the sensitivity of the anti-inﬂammatory cytokine response to pro-inﬂammatory and
Fn-fs stimulation.
When either Aph or Afh is small, the anti-inﬂammatory cytokine response is max-
imal at low inputs, and we only have a low single steady state, indicative of health
(Figure 3.11). At higher values of either Aph or Afh, larger concentrations of p
or f are required for anti-inﬂammatory cytokine production, and there is a fold
bifurcation. For Aph this leads to bistability whereas for Afh the region immedi-
ately after the fold bifurcation is still monostable since both additional states are
unstable. This is due to the branch of a Hopf bifurcation at a higher value of Afh
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Figure 3.11: Bifurcation plots for the pro-inﬂammatory cytokine level (p) against
the parameters Aph, Afh andMph. The dashed lines denote the transition between
diﬀerent behaviours, which are labelled.
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colliding with the unstable branch. A Hopf bifurcation at higher values of Aph
leads to an oscillatory disease state.
The bifurcation plot of Aph is similar to that in the cytokine-only model (Fig 3.5d)
for low levels of Aph. Here however, there is oscillatory disease in addition to a
ﬁxed disease state.
Mph governs the sensitivity of MMP production in response to activation by pro-
inﬂammatory cytokine. When Mph is small there is a single stable steady state
with a high value of p indicative of disease (Figure 3.11). For higher values of
Mph we move to bistability through a fold bifurcation. The disease state is also
oscillatory for some values of Mph due to two Hopf bifurcations.
3.4.5 Changes in γp, γm and γf
Figure 3.12a shows that when the clearance of pro-inﬂammatory cytokines, γp, is
low the steady state is at a high level of p indicating disease. When γp is high
there is a stable steady state, at low p, indicating health for these parameters. This
implies that inactivation or rapid clearance of pro-inﬂammatory cytokines could
be eﬀective in halting the disease course of OA, and clinical trials investigating
this approach have had some measure of success. The bifurcation plot here is
relatively similar to the γp bifurcations on the cytokine only model (Fig 3.5e).
For the reference parameter set the bifurcation plots of γm (Fig 3.12b) and γf (Fig
3.12c) are qualitatively similar with monostable disease for low levels of γf and
γm and bistability for higher levels. The bistable region is divided into a region
with an oscillatory disease state and a region with a ﬁxed disease state. γf is the
degradation rate of ﬁbronectin fragments and principally represents removal from
the ECM via diﬀusion or advection. Diﬀusion rates are likely to be decreased by
the changes in the joint that are seen in OA, e.g. increased water content and im-
mobility, hence worsening OA progression. However, ECM fragment clearance can
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Figure 3.12: Bifurcation plots of the pro-inﬂammatory cytokine level (p) against
the natural degradation parameters γp, γm and γf . The dashed lines denote the
transition between diﬀerent behaviours, which are labelled.
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be increased by mechanical loading such as exercise. If the move from monostable
disease to bistability exists in vivo it suggests that increasing ECM fragment clear-
ance could be beneﬁcial, possibly improving the outcome of treatment to reduce
cytokine levels if the two treatments were used together, increasing the parameter
at the same time as reducing variable levels.
3.4.6 Additional behaviour seen in the model
So far we have looked only at variations in a single parameter from the reference
parameter set, which is a relatively restricted region. Explorations of other param-
eter sets reveal other features and bifurcation behaviour that we do not encounter
with the reference set. These include regions with ﬁve steady states, tristability
and isolas. We will now look at some of these in more detail and discuss the pos-
sible biological applications. Due to the large number of parameters involved we
will focus particularly on those that we believe are most likely signiﬁcant in the
development and progression of OA. Background levels of cytokines and MMPs
are unlikely to vary much as a result of disease, and although there may be sig-
niﬁcant variation between individuals we neglect changes in Pbp and Mbp in this
analysis. Similarly, degradation rates of cytokines and enzymes are unlikely to
vary signiﬁcantly so variation in γp and γm can be ignored. In contrast γf may be
aﬀected by joint and behavioural changes as discussed above. Aph, Afh and Mph
are half maximal rate parameters and are likely to be determined by the chemistry
of the molecules involved in the production of the cytokines and enzymes, hence
are unlikely to change much either over time or in response to disease. Fdam is
the mechanical damage parameter and we will look at the eﬀects of mechanical
damage later in this chapter. For the time being we shall set it to zero. This
means that we are left with 6 parameters that we would like to focus the analysis
on: Ppp, Pfp, App, Afp, Mpp and γf .
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Tristable parameter values
As discussed in Section 3.3 the system can have one, three or ﬁve steady states.
Single parameter variations from the reference set did not show any ﬁve-state
behaviour, however this can arise from variations in two parameters. Figure 3.13
shows that the ﬁve states emerge as a result of fold bifurcations as Afp and Aph
are varied. In the bottom left corner of the diagram, where the Hopf and fold
bifurcation meet there is a Bogdanov-Takens bifurcation point. From this point
the homoclinic bifurcation emerges between the fold and Hopf bifurcations.
Figure 3.13: Bifurcation plot of Afh against Afp, for the reference parameter set.
The diagram shows that if we reduce the value of both Afp and Afh from the
values of the reference set there is a region where there are ﬁve steady states as
a result of fold bifurcations (shown in blue). A homoclinic bifurcation is shown
in black, which arises as a result of a Bogdanov-Takens bifurcation (labelled BT).
Cusp points of the fold bifurcations are labelled CP. The Hopf bifurcation is shown
in green.
At Afp = 3.2 and Afh = 0.2 there are ﬁve steady states (Figure 3.14) with two
stable steady states and a stable limit cycle. As a result of the smaller value of
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Afp, the maximum rate of anti-inﬂammatory cytokine feedback is lower than that
of the reference parameter set. However a smaller Afh means the fragment-driven
anti-inﬂammatory cytokine production rate may be stronger when levels of f are
low. Tristability may be important for OA treatment, if realised biologically, since
a move from one disease state to a less destructive one could slow the disease course
where movement to the healthy state is not possible. This is discussed in Section
3.8. The phase space projection (Figure 3.14) for this alternative parameter set
shows that like the reference parameter set, the basin of attraction of the healthy
state is small, but the basin of attraction for the lower disease limit cycle is larger.
Figure 3.14: Projection of the phase space for a parameter set displaying trista-
bility. The lower healthy stable state has a small basin of attraction whereas the
disease steady state and disease limit cycle both have large basins of attraction.
The red dots denote stable steady states, whilst the black circles denote unstable
steady states. A stable limit cycle surrounds one of the unstable steady states.
The reference parameters have been used except Afp=3.2 and Afh=0.2.
Figure 3.15 shows bifurcation plots for single parameters variations of Ppp, Pfp,
App, Afp, Mpp and γf for this new parameter set. Comparing the plots in Figure
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3.15 to those of the reference parameter set, for Pbp we see a reduced range of
oscillatory behaviour and monostable disease occurs at lower values of Pbp. The
bifurcation plot of Ppp, Fig 3.15b, shows that a region of monostable health emerges
when Afp and Afh are lower, compared to the reference parameter set. As with
Pbp the range over which oscillatory disease occurs is much reduced. Pfp variation
(Fig 3.15) changes little from the bifurcations in the reference parameter set.
Bistability persists at high values of Mbp when Afp and Afh are lower (Fig 3.15d),
however the levels of p in both states are high and are likely to indicate diﬀering
intensities of disease rather than health and disease. The plot for Mpp (Fig 3.15e)
looks considerably diﬀerent to that of the reference parameter set, as additional
fold bifurcations in the upper branch cause the branch to fold back on itself.
Additionally the limit cycle branches from the two Hopf points now collide with
unstable branches at homoclinic bifurcation points rather than connecting. This
has a signiﬁcant eﬀect as there is now a region of monostable health between the
two regions rather than bistability. γF , (Figure 3.15f), like Mbp, has a new region
of monostable health between two disease states.
Excitability
For some parameter sets (e.g. the reference parameter set with γp increased to
2) the model displays excitable behaviour. This behaviour is most pronounced
where there is a single healthy steady state with unstable disease states. Here
perturbations from the steady state result in long trajectories around the unstable
states.
Figure 3.16 shows an example of this. Here, after a perturbation from the steady
state of p = 0.1, the system moves directly back to the steady state, but a larger
perturbation from the steady state (p = 0.4) has a long trajectory around both the
unstable states. Perturbations close to the unstable state spiral outwards before
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Figure 3.15: Bifurcation plots of the cartilage model in a parameter region with ﬁve
steady states. The subﬁgures show the pro-inﬂammatory cytokine level plotted
against for the parameters Ppp, Pfp, App, Afp, Mpp and γf and show regions of
monostability, bistability and tristability. The dashed lines denote the transition
between diﬀerent behaviours, which are labelled and described in Table 3.4. The
reference parameters have been used except Afp=3.2 and Afh=0.2.
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Figure 3.16: Plot of the (p, a,m) phase space showing excitable behaviour in the
system. The red dot denotes the stable steady state which is healthy, whilst the
black circles denote unstable steady states. Trajectories arising suﬃciently close
to the healthy state, quickly move into it. However, trajectories originating else-
where have much longer paths including oscillations. [Pbp=0.01, Ppp=10, Pfp=10,
App=10, Aph=1, Afp=10, Afh=1,Mbp=0.01,Mpp=1Mph=1, Fdam=0, γp=2, γm=1
and γf=1]
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moving back to health.
Biologically, this excitable behaviour may mean that a healthy individual who
sustains trauma to the cartilage may have a long recovery period and display
OA-like symptoms as the cytokine levels return to normal.
Mushrooms and Isolas
If we move far away from the parameter sets we have considered so far, we ﬁnd
further new bifurcation behaviours. Figure 3.17 shows a parameter set which
displays mushroom bifurcations, which are composed of four fold bifurcations.
Figure 3.17: Bifurcation plots of p against Mpp showing fold bifurcations forming
a mushroom. [Pbp=0.01, Ppp=24, Pfp=25, App=1.7, Aph=0.1, Afp=1.7, Afh=0.1,
Mbp=0.01, Mph=0.1, Fdam=0, γp=1.25, γm=1.25 and γf=1.25]
As we increase Ppp, two of the folds move together and the upper branch pinches
oﬀ leaving an isola (Figure 3.18). Isolas are closed loops of equilibrium points
and in this case contain both fold and Hopf bifurcations. This behaviour appears
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to be displayed over a small range of parameters, which may not be biologically
relevant.
Figure 3.18: Bifurcation plots of p against Mpp showing a fold bifurcations form-
ing an isola. [Pbp=0.01, Ppp=25, Pfp=25, App=1.7, Aph=0.1, Afp=1.7, Afh=0.1,
Mbp=0.01, Mph=0.1, Fdam=0, γp=1.25, γm=1.25 and γf=1.25]
However, if this behaviour does exist then it has interesting and counter-intuitive
implications for the disease course. For instance in Figure 3.17 we can see that
someone in a disease state at a low level of Mpp may be forced to a lower disease
state ifMpp increases during the progression of their disease, for example by having
Mpp between the upper two folds.
3.5 Two Parameter Variations
The previous section demonstrated how the behaviour of the model changes as we
vary one parameter at a time. It also showed that these behaviours are sensitive to
changes in the other parameter values and that varying two parameters could lead
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to additional steady states. To further explore the parameter space and better
understand how the diﬀerent behaviours are connected we will now expand the
bifurcation analysis in two parameters, to a wider group of parameters. Here we
focus on the six parameters that we consider to be the most relevant to disease pro-
gression and most likely to change over the disease course: Ppp, Pfp, App, Afp,Mpp
and γf .
3.5.1 Ppp variations
Two parameter bifurcation diagrams are shown in Figure 3.19 with the parameters
Pfp, App, Afp, Mpp and γf plotted against Ppp.
In the one parameter analysis Pfp had a value of 10 and as Ppp was increased the
system moved through four fold bifurcations moving from bistability at low Ppp to
monostable disease. At a higher level of Pfp (Figure 3.19a) the bistable region is
lost and we have monostable disease at a lower value of Ppp, as might be expected
since Ppp and Pfp both increase pro-inﬂammatory cytokine production. Both the
Hopf bifurcation and the homoclinic bifurcation are generated from a Bogdanov-
Takens point at a low value of both Ppp and Pfp. These change the nature of
monostable disease from ﬁxed to oscillatory. A Bogdanov-Takens bifurcation is
a bifurcation of codimension 2, i.e. it is only seen as we vary two parameters,
and occurs where there is a pair of zero eigenvalues. At this point the fold and
Hopf bifurcations collide. At parameter values close to this point the limit cycle
connects with one of the two steady states, resulting in the loss of the limit cycle
to a homoclinic orbit [66]. Often in the vicinity we also have a Generalised Hopf
(GH) point (or Bautin bifurcation) where the Hopf switches from subcritical to
supercritical. In this case the GH point is at a high level of Ppp, and results in a tiny
region of bistability with a stable ﬁxed point surrounded by both an unstable and
stable limit cycle. Since this region is so small and also relies on huge diﬀerences
97
Chapter 3: Mathematical modelling of cytokines, MMPs and ECM
fragments in osteoarthritic cartilage
Figure 3.19: Two parameter bifurcation diagrams showing Ppp against Pfp, App,
Afp, Mpp and γf . Fold bifurcations are shown as blue lines, Hopf bifurcations as
green lines and homoclinic bifurcations are shown in black. Areas of monostable
health, bistability and monostable disease are indicated . The reference parameter
set is used.
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in magnitude between Pfp and Ppp, it is unlikely to have biological signiﬁcance.
App is ﬁxed at 10 in the previous Ppp bifurcation analysis. At much higher levels
of App we have a region of monostable health emerging for low values of Ppp as a
result of a fold bifurcation. When App is large enough we also lose the oscillatory
disease behaviour which is replaced with monostable disease.
In contrast with App the bifurcation diagram of Afp against Ppp shows a large
region of bistability and only a small region of monostable disease (Figure 3.19c).
This may suggest that any changes to App are more likely to be damaging than
changes to Afp since they are more likely to move an individual to monostable
disease. As Afp increases a small region of monostable health emerges at small
values of Ppp.
When Mpp is very small two fold bifurcations move the system from monostable
health, through bistability to monostable disease as Ppp increases (Figure 3.19d).
For larger values of Mpp the region of health is lost and we have bistability and
monostable disease. The bifurcation plot is dominated by a Hopf bifurcation which
encloses a region where the disease state is oscillatory.
The two parameter bifurcation plot for γf against Ppp is relatively similar to that of
Mpp. Here, however the region of health for a low Ppp occurs when γf is relatively
large. Again, the closed Hopf bifurcation encloses the oscillatory region.
Generally, as Figure 3.19 shows, the behaviour of the system mostly displays
behaviour associated with monostable disease. When Ppp is low we generally
have bistability, with disease occurring at higher levels of Ppp. This behaviour
may indicate that this parameter is important in OA initiation and progression.
The behaviour suggests that increases in this parameter either though genetic,
biochemical or physical processes, regardless of the parameters of the rest of the
system, is likely lead to disease.
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3.5.2 Pfp variations
Figure 3.20 shows the changes in the behaviour of the system as we vary Pfp
alongside each of the other parameters (excepting Ppp which was discussed above).
Generally, regardless of the value of the other parameter varied, if Pfp is made
large enough the system moves to monostable disease. Compared to the Ppp
parameter variations above, the regions of monostable health and bistability are
much larger when we vary Pfp with other parameters. This suggests that the
system is better able to withstand variation in Pfp than Ppp before the system
is pushed to monostable disease, where treatment options are likely to be more
limited.
Figure 3.20: Two parameter bifurcation diagrams showing Pfp against App, Afp,
Mpp and γf . Fold bifurcations are shown as blue lines, Hopf bifurcations as green
lines and homoclinic bifurcations are shown in black. Areas of monostable health,
bistability and monostable disease are indicated. The reference parameter set is
used.
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3.5.3 App variations
Changes in the system behaviours as we vary App with the other parameters are
shown in Figure 3.21. In terms of the general behaviour as we change App with
the parameters Afp, Mpp and γf we have only bistable and monostable healthy
behaviour. However, in the case of Ppp and Pfp (Figs 3.19b and 3.20a) there is
monostable disease at low levels of App as the pro-inﬂammatory cytokines over-
whelm the anti-inﬂammatory cytokine response.
Figure 3.21: Two parameter bifurcation diagrams showing App against Afp, Mpp
and γf . Fold bifurcations are shown as blue lines and Hopf bifurcations as green
lines. Areas of monostable health, bistability and monostable disease are indicated.
The reference parameter set is used.
101
Chapter 3: Mathematical modelling of cytokines, MMPs and ECM
fragments in osteoarthritic cartilage
3.5.4 Afp variations
Figure 3.22 shows the bifurcation behaviour as we vary Mpp and γf with Afp. In
both diagrams there is a region of bistability for low Afp moving to monostable
health as Afp increases. For a high value of Mpp there is a region of monostable
disease regardless of the values of Afp. Similarly, we have a region of monostable
disease for low γf .
Figure 3.22: Two parameter bifurcation diagrams showing Afp against Mpp and
γf . Fold bifurcations are shown as blue lines, Hopf bifurcations as green lines and
homoclinic bifurcations are shown in black. Areas of monostable health, bistability
and monostable disease are indicated. The reference parameter set is used.
Generally, higher values of Afp lead to health as we would expect, both in these
plots and in the previous sections. However there is an exception to this for certain
values of Mpp, where increasing Afp moves the system from health to bistability.
3.5.5 Mpp variations
The bifurcation diagram of γf against Mpp is shown in Figure 3.23. The majority
of the plot is bistable with a small area of monostable disease at small values of
γf . There are no regions of monostable health for this parameter set, however, the
variations of Mpp with other parameters (Figures 3.19d, 3.20c, 3.21b and 3.22a)
do display monostable health.
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Figure 3.23: Two parameter bifurcation diagram showing Mpp against γf . Fold
bifurcation is shown as a blue line and Hopf bifurcations as green lines. Areas of
bistability and monostable disease are indicated. The reference parameter set is
used.
Generally speaking, in the two parameter variations we have analysed, increases in
Mpp are detrimental to individuals, moving the system from health to bistability
or from bistability to disease. However, the single parameter bifurcations showed
this was not always the case for other parameters sets. Since Mpp forms part of
both negative and positive feedback loops within the model, the eﬀect of increases
is dependent upon which type of feedback is dominating the system.
3.5.6 γf variations
Two parameter variations in γf have been presented in the previous ﬁve sections.
As in the case of Mpp, increases in γf can have both positive and negative eﬀects
in terms of moving the system from disease to health or vice versa.
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3.6 Mechanical Damage
In our model we represent mechanical damage to the cartilage by an increase in
Fdam, the rate at which ﬁbronectin fragments are produced. Mechanical damage
is considered to be a major risk factor in OA and the ﬁrst stage of repair after
mechanical damage to the cartilage is necrosis of the damaged tissue which leads
to increased concentrations of ﬁbronectin fragments. Thus, changes in the model
behaviour as Fdam increases could be indicative of the changes in OA. Figure
3.24a shows the bifurcation diagram for small changes in Fdam, with the reference
parameter set used for the other parameters. Since Fdam was zero in the reference
parameter set, there is bistability at Fdam = 0 as before. As Fdam increases a fold
bifurcation removes the lower two states leaving only monostable disease.
(a) (b)
Figure 3.24: Bifurcation plots of the parameter Fdam against p. The changes in
behaviour are indicated by dashed lines. a) shows small changes in Fdam close to
zero where there is bistability. b) shows changes in Fdam extending further from
zero. Here the level of p at the disease state decreases. The reference parameter
set is used
For this parameter set even small levels of damage lead to sustained disease, how-
ever, when we look at Fdam on a larger scale (Fig 3.24b) we see that if we increase
this parameter further the level of p at the disease state reduces. This feature is
counter intuitive and may be due to the simplifying assumptions within the model,
since large amounts of mechanical damage would most likely cause changes in joint
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loading also.
3.7 Biological Applications
In the previous sections we have considered how the behaviour of the system
depends on the parameter values. In clinical settings, we would generally be more
interested in how the key variables change over time, stimulated by either changes
in variable levels or parameter values. In this section we will examine time course
simulations and consider such biological applications.
The reference parameter set discussed previously shows bistability. An individual
at the healthy steady state will move to the disease state if an appropriate stimulus
is applied (Figure 3.25). In this case an increase in the pro-inﬂammatory cytokine
level to 0.05 at time 20 is not suﬃcient to move the system to disease, whilst a
stimulus of 0.06, does move the system into the basin of attraction of the disease
state.
Figure 3.25: Time course plot of cartilage model with a pro-inﬂammatory stimulus
at t = 20.(a) the pro-inﬂammatory level is increased to 0.05 and the system
recovers after a short time. (b) the pro-inﬂammatory level is increased to 0.06
leading to disease. The parameters used are that of the reference parameter set.
In addition to bistability, for other parameter values, there are also regions of
monostable health. As discussed earlier, the model displays regions of excitable
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behaviour which means that not all regions of monostable health behave in the
same way. Figure 3.26 shows two sets of time courses for parameters with only
one stable steady state. In the ﬁrst there are no other steady states and after a
trauma the system, modelled as an instantaneous increase in all four variables,
quickly moves back to the healthy state. In the second, there are two unstable
steady states and the system oscillates around these for a short period before
returning to health. In this case, the level of Fn-fs is raised, suggesting that the
cartilage is being damaged as the system oscillates before health is restored.
Figure 3.26: Time course plot of system with a stimulus [p = 0.5, a = 2, m = 0.5,
f = 0.5] at t = 20. In ﬁgure (a) the parameter γp is 3 indicating monostable health
with only one stable steady state. In ﬁgure (b) the parameter γp is 2 indicating
monostable health with one stable and two unstable steady states. (Pbp = 0.01,
Ppp = 10,Pfp = 10,App = 10, Aph = 1, Afp = 10, Afh = 1, Mbp = 0.01, Mpp = 10,
Mph = 1, Fdam = 0, γm = 1 and γm = 1)
3.7.1 Time dependent changes in feedback parameters
The previous sections have shown that a wide range of behaviours can be observed
in this system. We will now show that changes in the system parameters over
time could be biologically signiﬁcant and lead to the development of OA. In the
cytokine-only model (Chapter 2) we proposed that changes in key parameters
over time could lead to the onset of RA. In this model we similarly suggest that
changes in parameters could lead to OA in the cartilage. In RA it is thought
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that the parameter changes are the result of premature aging in T cells [72, 89],
whereas in OA much less is known about the reason for OA onset. It is likely that
the onset of OA varies between individuals, and possible reasons include changes
to chondrocytes, changes in chondrocyte numbers, and mechanical factors.
The network diagram (Figure 3.1) shows that there are four feedback pathways
in this system and we will investigate whether changes in any or all of these can
lead to disease.
Positive cytokine-driven feedback
The cytokine-driven positive feedback loop highlighted in Figure 3.27 has only one
parameter, Ppp.
Figure 3.27: Cytokine network diagram showing the positive cytokine driven feed-
back loop which has only one parameter.
Bifurcation analysis suggested that high values of Ppp correspond to a disease
state (Section 3.4.1). In the previous chapter we showed that increases in the
equivalent parameter (Ppp) over time may lead to RA in the synovium. In this
model increasing Ppp over time also leads to disease. We can simulate an increase
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in the pro-inﬂammatory-driven pro-inﬂammatory cytokine production rate over
time by making Ppp a function dependent on time, similar to the time varying
function in the two variable model. In this model we use the function,
Ppp = P
min
pp +
(Pmaxpp − Pminpp )t2
P Tpp
2 + t2
, (3.7.1)
and set the parameters as Pminpp = 1, P
max
pp = 26, and P
T
pp = 20. Figure 3.28 shows
the system initially has a healthy steady state, but as the value of Ppp increases
the system moves to an oscillatory disease state. This move corresponds to a fold
bifurcation as we increase Ppp, see Figure 3.6. Since we set the maximum value
of Ppp to 26 we do not encounter the Hopf bifurcation as Ppp changes. However,
if we allowed Ppp to increase past the Hopf bifurcation the system would move
from oscillatory disease to a stable steady disease state. Oscillatory behaviour of
OA is diﬃcult to conﬁrm clinically due to the lack of biomarkers for OA, however
some patients report intermittent pain or stiﬀness on early OA [58, 120]. Currently
diagnosis of OA relies on pain, as reported by patients, and radiographic evidence,
both of which are often not formally investigated until later in the disease course.
Positive fragment-driven feedback
The second positive feedback loop in the model is driven by MMP and ECM
fragment interactions and involves the parameters Pfp,Mpp andMph (Figure 3.29).
The latter two are also involved in negative feedback so we will consider these
separately further on, leaving only Pfp. We simulate a time dependent increase in
Pfp by,
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Figure 3.28: System variables plotted against time as the parameter Ppp increases
in a time dependent fashion. The system moves to a disease state as Ppp moves
through a fold bifurcation. The other parameters are the reference parameter set.
Figure 3.29: Cytokine network diagram from Fig 3.1, highlighting,the positive
ECM fragment driven feedback loop which has only three parameters: Pfp, Mpp
and Mph.
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Figure 3.30: System variables plotted against time as the parameter Pfp increases
in a time dependent fashion. The system moves to a disease state as Pfp moves
through a fold bifurcation. The other parameters are the reference parameter set.
Pfp = P
min
fp +
(Pmaxfp − Pminfp )t2
P Tfp
2
+ t2
, (3.7.2)
where Pminfp = 1, P
max
fp = 45, and P
T
fp = 20.
As in the case of Ppp, changes in Pfp move the system to a disease state (Figure
3.30) as time progresses, and this again corresponds to moving through a fold
bifurcation. The disease state in this case is not oscillatory. These diﬀerent disease
states and routes to progression may account for the variability seen in clinical
presentation and disease progression of OA.
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Negative cytokine-driven feedback
The negative cytokine driven feedback is controlled by two parameters App and
Aph (Figure 3.31), the ﬁrst governing the maximum rate of production and the
second controlling the sensitivity of the production rate to changes in p.
Figure 3.31: Cytokine network diagram highlighting the negative cytokine driven
feedback loop which has two parameters: App and Aph.
The bifurcation analysis suggested that decreases in the parameter App could lead
to disease since this would interfere with the systems ability to down-regulate
pro-inﬂammatory cytokines. We make App dependent on time with the function,
App = A
min
pp +
(Amaxpp − Aminpp )
ATpp
2 + t2
, (3.7.3)
where Aminpp = 1, A
max
pp = 5, and A
T
pp = 20, which decreases monotonically.
When we simulate the system with this time dependent anti-inﬂammatory pro-
duction rate we remain in a state of health, conﬁrming that decreases in App alone
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would not lead to OA as seen in the bifurcation analysis (Fig 3.9a). However, if
we add a trauma to the simulation , modelled as an instantaneous increase in pro-
inﬂammatory cytokine concentration as before, the system now moves to a state
of disease due to bistability in the system (Figure 3.32). The move to disease is
dependent on both the timing and the severity of the trauma.
Figure 3.32: Time series plot of three system variables (p, a and m) against time
as the parameter App decreases in a time dependent fashion (App proﬁle shown
in the lower right plot). A trauma is simulated at time = 40, modelled as an
instantaneous increase in the p by 0.1. The system moves to a oscillatory disease
state. The other parameters are the reference parameters.
Mathematically the trauma needs to take place once we have passed into the
bistable region and be large enough to push the system outside of the basin of
attraction of the healthy stable steady state. Intuitively, it seems to make sense
that a decrease in anti-inﬂammatory cytokine alone would not lead to disease
since the function of anti-inﬂammatory cytokines is to react to the presence of a
pro-inﬂammatory response.
The second parameter in this feedback loop, Aph controls the sensitivity of the
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feedback to changes in the level of pro-inﬂammatory cytokine. If this is not sensi-
tive enough then an inadequate anti-inﬂammatory cytokine response may lead to
OA. We simulate a time dependent increase in Aph using,
Aph = A
min
ph +
(Amaxph − Aminph )t2
ATph
2
+ t2
, (3.7.4)
where Aminph = 0.001, A
max
ph = 2, and A
T
ph = 20.
As in the App case, increasing the parameter alone is not suﬃcient to drive the
system to disease. However with an additional trauma the system moves to disease
as before (Figure 3.33).
Figure 3.33: System variables plotted against time as the parameter Aph increases
in a time dependent fashion. A trauma is simulated at time = 40, modelled as
an instantaneous increase in p by 0.1. The system moves to an oscillatory disease
state. The other parameters are the reference parameters.
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Negative fragment-driven feedback
The second negative feedback loop in this model is via MMP and Fn-fs production
and contains the parameters Afp, Afh, Mpp and Mph (Figure 3.34).
Figure 3.34: Cytokine network diagram highlighting the negative fragment driven
feedback loop which has four parameters: Afp, Afh, Mpp and Mph.
We will consider the latter two in the next section since these also have a role a
positive feedback loop. We use the functions,
Afp = A
min
fp +
(Amaxfp − Aminfp )
ATfp
2
+ t2
, (3.7.5)
and
Afh = A
min
fh +
(Amaxfh − Aminfh )t2
ATfh
2
+ t2
, (3.7.6)
where Aminfp = 1, A
max
fp = 5, A
min
fh = 0.001, A
max
fh = 2, and A
T
fp = A
T
fh = 20.
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As in the case of App and Aph, time dependent increases to Afp and Afh alone
do not move the system to disease. Instead as before an additional stimulus is
required. This time, however, as expected from the bifurcation plots in Figure
3.35, the disease state is ﬁxed rather than oscillatory.
Figure 3.35: System variables against time as the parameters (a)Afp and (b)Afh
increase in a time dependent fashion, given by equations 3.7.5 and 3.7.6. A trauma
is simulated at t = 40, modelled as an instantaneous increase in the p by 0.1 in both
cases. The systems move to a stable disease steady state. The other parameters
are from the reference parameter set.
MMP-driven feedback
The MMP production rate parametersMpp andMph, are involved in both positive
and negative feedback (Figure 3.36).
Hence, the eﬀect of time dependent changes in these parameters may be dependent
on the relative strengths of the positive and negative feedback loops. In the
parameter set we have been using in this section the feedback is relatively balanced
and we expect increases in Mpp and decreases in Mph to lead to disease. Using the
functions,
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Figure 3.36: Cytokine network diagram highlighting the negative and positive
feedback loops involving Mpp and Mph.
Mpp = M
min
pp +
(Mmaxpp −Mminpp )t2
MTpp
2 + t2
(3.7.7)
Mph = M
min
ph +
(Mmaxph −Mminph )
MTph
2
+ t2
, (3.7.8)
where Mminpp = 0,M
max
pp = 5,M
min
ph = 0.001,M
max
ph = 0.5, and M
T
pp = Mph = 20,
we can show that this is indeed the case. Figures 3.37 and 3.38 show simulations
using each of these functions and in both cases a disease state is reached.
In the case of Mph the disease state has a comparatively low level of p, but higher
levels of a, m and f . We can see from Figure 3.10 why this is the case since, by
the time we move past the fold the disease state is relatively low. If we introduce
a trauma, as we have done previously we force the system to move to the disease
state much sooner (Figure 3.39).
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Figure 3.37: System variables plotted against time as the parameterMpp increases
in a time dependent fashion. The system moves to a disease state as Mpp moves
through a fold bifurcation. The other parameters are from the reference parameter
set.
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Figure 3.38: System variables plotted against time as the parameterMph decreases
in a time dependent fashion. The system moves to a disease state as Mph moves
through a fold bifurcation. (The parameters are taken from the reference param-
eter set.)
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Figure 3.39: System variables plotted against time as the parameterMph decreases
in a time dependent fashion. A trauma is added at t = 20 resulting in a move to
the disease state. The other parameters are taken from the reference parameter
set.
119
Chapter 3: Mathematical modelling of cytokines, MMPs and ECM
fragments in osteoarthritic cartilage
3.7.2 Mechanical Damage
Mechanical damage is a large risk factor in OA but the response to mechanical
damage may diﬀer between individuals. We consider two diﬀerent scenarios in-
volving mechanical damage, ﬁrstly where the damage causes a previously healthy
individual, with parameters indicating monostable health, to move to a disease
state and secondly where an individual susceptible to developing OA, with pa-
rameters indicating bistability, is pushed into active disease due to damage. In
the ﬁrst case a change to the parameter values would be required, whereas the
second requires only a variable change.
In the ﬁrst case, as in the previous section we increase the level of the parameter
Fdam over time which may be representative of an individual who incurs a persis-
tent level of damage over time for example though occupational stresses, gradual
weight gain or high impact exercise. We model this increase as a function of time
as before with,
Fdam = F
min
dam +
(Fmaxdam − Fmindam)t2
F Tdam
2
+ t2
, (3.7.9)
where Fmindam = 0, F
max
dam = 0.5, and F
T
dam = 20.
In this case the system moves to disease as time increases (Figure 3.40) and the
system moves through a fold bifurcation.
In the second case we assume that individuals with high pro-inﬂammatory cy-
tokine production rates are likely to be more susceptible to the development of
OA and look at the eﬀect of mechanical damage to these individuals. We take
two parameter sets, the ﬁrst, termed Lower Risk, has low pro-inﬂammatory cy-
tokine production rates (Ppp = 5). The second, termed Higher Risk, has higher
pro-inﬂammatory cytokine production rates (Ppp = Pfp = 24); all other param-
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Figure 3.40: Plot of the system variables against time as the parameter Fdam
increases in a time dependent fashion, according to equation 3.7.9. The system
moves to a disease state as the value of p at the steady state increases. (Pbp = 0.01,
Ppp = 5, Pfp = 10, App = 5, Aph = 0.5, Afp = 5, Afh = 0.5,Mbp = 0.01,Mpp = 0.2,
Mph = 0.1, γp = 1.25, γm = 1.25 and γm = 2)
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eters are the same. For all the simulations we have used the initial conditions:
p = 0, a = 0,m = 0, f = 0, which are close to a healthy steady state in both
groups when Fdam = 0.
We simulate a short pulse of mechanical damage by an increase in Fdam, to 1, for
30 ≤ t ≤ 31, this emulating a short time period of high damage, representing an
injury, followed by a return to zero. Figure 3.41 shows that lower risk individuals
maintain a healthy steady state with the anti-inﬂammatory feedback mechanism
keeping the pro-inﬂammatory production low whereas in higher risk individuals
the system moves to a disease state (Figure 3.41).
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Figure 3.41: Time courses for two groups Lower Risk (Ppp = 5) and Higher Risk
(Ppp = 24) with diﬀerent pro-inﬂammatory production rates and a pulse of me-
chanical damage applied at time 30 (Fdam = 1). (Pbp = 0.01, App = 5, Aph = 0.5,
Afp = 5, Afh = 0.5, Mbp = 0.01, Mpp = 0.2, Mph = 0.1, γp = 1.25, γm = 1.25,
γf = 1.25).
3.8 Treatment Strategies
Clinical trials of disease modifying drugs for OA so far have not shown a slowing
down of disease progression, as measured by pain, inﬂammation and joint space, or
have had unexpected complications. Several treatment options have reached clin-
ical trials for OA and here we consider two of the main types that have been con-
sidered; anti-cytokine drugs and MMP inhibitors. Anti-cytokine therapy, licensed
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for use in RA, inhibits either the production or functioning of pro-inﬂammatory
cytokines, usually TNF-α. We model this treatment option as an instantaneous
reduction in the level of model variable p to a minimum of zero. Additionally we
consider an anti-cytokine therapy which increases the level of anti-inﬂammatory
cytokine. This type of treatment is licensed for RA but trials for OA have been
unsuccessful [25]. We model this treatment type as an instantaneous increase in
the level of the model variable a. We model MMP inhibitors as a reduction in the
level of m in the system. In addition to these threes types of therapies we also
consider the possibility of Fn-fs as a target for OA treatment and model this as
a reduction in the level of f . Here we consider how monostable disease, bistable
and tristable behaviours may respond to treatments.
3.8.1 Treatment for bistable cases
In the bistable case (as in the reference parameter set we consider here) it is
theoretically possible for an individual in the disease state to be moved to a state
of health, and this should be the aim for disease modifying treatment, to achieve
the best clinical outcome.
In this model, for the reference parameter set, we tried single doses of anti-cytokine
therapy, MMP inhibition or Fn-fs inhibition modelled as instantaneous reductions
in p, m or f respectively. In each case we modelled the largest possible dose by
reducing the level to zero, but none of these treatments moved the system to health
(Figure 3.42), since the system was not moved outside the basin of attraction of
disease.
This result is in line with data from clinical trials, of anti-cytokine and MMP
inhibition treatments, that have shown no long term beneﬁt in single dose therapy
[110]. However, we have found that a combined treatment strategy can bring the
system to a state of health. Over several simulations we reduced the magnitude
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Figure 3.42: Time course simulations of single treatments where the system dis-
plays bistable behaviour. At t = 0 the system is at the disease limit cycle. A
single dose of anti-cytokine (reduction in p), MMP inhibition (reduction in m) or
Fn-fs inhibition (reduction in f) treatment was simulated at t = 20. The dose size
given in each case was the maximum possible (i.e. an instantaneous decrease to
zero of each of the variables). None of these treatments are suﬃcient to move the
system to health. The reference parameter set was used for these simulations.
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of the doses used, until we found the smallest dose of each treatment that would
bring the system to health when combined, this is time-dependent. Figure 3.43
shows the system moving from disease to health with a combined dose of all three
treatments, with the smallest dose of each treatment. In this case the magnitudes
of the variable reductions are 0.2(p), 0.5(m) and 0.4(f).
Figure 3.43: Time course simulations of combined treatments where we have
bistable behaviour in the system. At t = 0 the system is at the disease limit
cycle. A single combined dose of anti-cytokine, MMP inhibition and Fn-fs inhibi-
tion treatment was simulated at t = 20 and t = 16. The dose size is the minimum
dose size (see text) that moves the system to health (0.2(p), 0.5(m) and 0.4(f)).
The reference parameter set was used for these simulations. The diagrams show
that dose timing as well as dose size is important
The timing of the dose is of crucial importance, particularly for this parameter set
since the disease state is oscillatory. If a dose is given at the wrong point in the
disease cycle then it may not be large enough to move out of the basin of attraction
of the disease state and may result in a period of increased amplitude oscillations
as it moves back to the disease state (Figure 3.43). This type of behaviour could
have large implications both for clinical trial results and treatment regimens for
drugs taken to market.
We ﬁnd that multiple doses of treatment given over time can also reduce the
system to health and allow smaller individual doses to be given. Figure 3.44
shows a series of six doses, given ten time units apart, which moves the system to
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health; the magnitude of each dose is 0.1(p), 0.2(m) and 0.1(f). Compared to the
single dose strategy this represents a large reduction in dosage at any particular
time. This may be beneﬁcial if there are side eﬀects associated with the drugs,
although overall, the dosage would be higher in this case. As with the single dose,
the timing and size of the dose is important as well as the total number of doses.
Figure 3.44: Time course simulations of multiple combined treatments where we
have bistable behaviour in the system. At t = 0 the system is at the disease
limit cycle. Six combined doses of anti-cytokine, MMP inhibition and ﬁbronectin
fragment inhibition treatment are simulated starting at t = 20, with a dose interval
of ten time units. This allows the magnitude of the dose to be reduced from the
single dose therapy. The dose magnitude for each of the six doses is 0.1(p), 0.2(m)
and 0.1(f). The reference parameter set was used for these simulations.
Anti-inﬂammatory cytokines are not currently used in anti-cytokine therapy as
they have shown poor responses in clinical trials. We found that a single dose
of anti-inﬂammatory cytokines was able to bring the system to a healthy state
from the disease state. Figure 3.45 shows a dose of 40 units given at time t = 20,
which moves the system to health, when given at t = 20. This dose is the lowest
that will bring the system to health. However, this dose is an order of magnitude
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greater that the anti-inﬂammatory cytokine level at the disease state, so may not
be clinically feasible.
Figure 3.45: Time course simulations of single doses of anti-inﬂammatory cy-
tokines where we have bistable behaviour in the system. At t = 0 the system
is at the disease limit cycle. A dose of 40 units of a is given at t = 20 bringing
the system to health. The reference parameter set (Table 3.2) was used for these
simulations.
Since the disease state in this case is oscillatory, timing of doses can have an eﬀect
on the magnitude of the dose needed. For example, in this case by changing the
timing of the dose to t = 26 we can reduce the dose required to 21 units, almost
half that needed at t = 20. The timing of the dose however is not trivial and the
optimal dose timing is not at the highest point of p of the limit cycle as might be
expected, but at the point where the system is closest to the basin of attraction
of the healthy state. This point may vary between individuals so individually
tailored treatment plans may be necessary for most eﬀective treatment.
We investigated application of multiple doses of anti-inﬂammatory cytokines in
order to further reduce the dose size necessary. By giving 3 doses at intervals of
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14 time units starting at t = 20 we were able to bring the system to health with a
dose size of 20, reduced from 40 in the single dose case at this time (Figure 3.46).
Again timing of the initial dose, the interval and number of intervals are of crucial
importance.
Figure 3.46: Time course simulations of multiple doses of anti-inﬂammatory cy-
tokines where we have bistable behaviour in the system . At t = 0 the system is
at the disease limit cycle. In the top row three doses of 20 units of a are given as
indicated by the black arrows. In the bottom row ﬁve doses of 10 units of a are
given as indicated by black arrows. Multiple doses reduces the size of dose need
to move the system to health but timing of the initial dose, dose interval and dose
size are all crucial in determining treatment outcome. The reference parameter
set (Table 3.2) was used for these simulations.
Finally for the bistable case we have considered how an increased rate of Fn-fs
clearance could aﬀect treatment options. Research has shown that clearance of
macromolecules such as Fn-fs is increased in the cartilage with cyclic loading [42],
so an increase in γf alongside reductions in p or m, may be representative of a
course of exercise or physiotherapy in combination with disease-modifying drugs.
Increasing the value of γf has a similar eﬀect to Fn-fs inhibition and simulations
show that if this is raised we no longer need to alter the amount of f to bring
the system to health (Fig 3.47). This may mean that combined anti-cytokine and
MMP inhibition therapy, alongside physical therapy, could be a viable treatment
option.
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Figure 3.47: Time course simulations of multiple combined treatments where the
system displays bistable behaviour. The ﬁrst row shows the system with the
reference parameter set, whilst the second row shows the same parameters except
that γf is increased by 15%. At t = 0 the system is at the disease limit cycle. Six
combined doses of only anti-cytokine and MMP inhibition treatment are simulated
starting at t = 20, with a dose interval of ten time units. The dose magnitude for
each of the six doses is 0.4(p) and 0.4(m).
3.8.2 Treatment for tristable cases
Where we have tristable behaviour we generally have two disease states and one
healthy state. Simulations of treatment options for this type of behaviour show
that if the system is at either one of the disease states it will act as in the bistable
case and can be moved to the healthy state, with a suﬃcient number of doses of
combined treatments. Additionally, if the system is at the higher disease state
it can be moved to the lower disease state with fewer doses of treatment than
are required to move the system to health. Figure 3.48 shows multiple doses of
combined treatments of anti-cytokine, MMP inhibition and Fn-fs clearance ther-
apies. Where two doses are given the system returns to the original disease state.
When four doses are given the system moves to a lower disease state, which in
this case is a limit cycle. Six doses are suﬃcient to move the system to a state of
health. Figure 3.49, shows a similar pattern of behaviour for anti-inﬂammatory
cytokine therapy. For this parameter set much lower doses of a bring about health
compared to the bistable case.
129
Chapter 3: Mathematical modelling of cytokines, MMPs and ECM
fragments in osteoarthritic cartilage
Figure 3.48: Time course simulations of multiple combined treatments where the
system displays tristable behaviour. The ﬁrst column shows two doses of treat-
ment, the second column four doses and the third column six doses. The doses
of anti-cytokine, MMP inhibition and ﬁbronectin fragment inhibition treatment
are simulated starting at t = 20, with a dose interval of ten time units. The dose
magnitude for each of the doses is the same as in the bistable case. The number
of doses determines which state the system is moved to.
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Figure 3.49: Time course simulations of multiple doses of anti-inﬂammatory cy-
tokine where we have tristable behaviour in the system. The ﬁrst column shows
one dose of treatment, the second column two doses and the third column three
doses. The doses of anti-inﬂammatory cytokine have a magnitude of 2.5 and are
simulated starting at t = 20, with a dose interval of ten time units. The number
of doses determines which state the system is moved to.
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3.8.3 Treatment for monostable cases
In cases of monostable disease a move to a healthy state is not possible without
parameter changes. However, disease control may still be possible with ongoing
doses of disease modifying drugs (Figure 3.50) which can reduce the cytokine and
ﬁbronectin levels to those comparable with a healthy state. In this case the dose
size required is much higher than that needed in the bistable case, to bring the
system to low cytokine levels.
Figure 3.50: Time course for the system showing monostable disease. Multiple
combined treatments are given ten time units apart starting at time 20. The
dose size for the treatments are 0.4(p), 1.2(m) and 1.1(f) representing a 98%(p),
82%(m) and 75%(f) reduction from the disease state. These lower the system
variables to a healthy level but cessation of treatment would cause the system to
move back to the disease state. Parameters used are the reference parameter set
as described in Section 3.4, except for Pfp=40.
There is a trade oﬀ between dose size and dose interval, with smaller intervals
allowing a decrease in the size of the dose. However, in clinical practice there
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would be both medical and practical considerations in reducing dose interval.
Repeated doses of anti-inﬂammatory cytokine can also reduce the cytokine and
ﬁbronectin levels. However, the dose size needs to be very high. For this parameter
set a dose size of 500 units, 62 times greater than the disease state is required. The
system is also very sensitive to dose size with some smaller dose sizes increasing
the levels of p. The large dose size and sensitivity to change may make this type
of treatment diﬃcult to implement in a clinical setting.
3.9 Discussion
Cytokines, MMPs and ﬁbronectin fragments are key mediators in destructive
OA mechanisms. Eﬀective disease modifying therapies are much needed for OA
[110, 28], and these pathways appear to oﬀer good targets. However, the lack of
success in clinical trials suggests that we may not fully understand the dynamic
interactions of these pathways. The aim of this modelling was to gain a better
understanding of the nature of these dynamics. We have grouped cytokines by
function, either pro-inﬂammatory or anti-inﬂammatory, in addition to MMPs and
Fn-fs. This allowed us to simplify the problem to four variables and study the
feedback loops in the system.
The bifurcation analysis revealed a range of diﬀerent behaviour types. In gen-
eral terms we can class the behaviour as monostable health, monostable disease,
bistable or tristable. These groups respond very diﬀerently to treatment. In the
cytokine-only model, Chapter 2, the regions of monostable health were relatively
large and we suggested that many individuals would, therefore, not be susceptible
to RA. However in this model, in all the parameter space we considered, monos-
table health only accounted for very small regions in comparison with the other
behaviours. This may imply that most healthy individuals actually fall into the
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bistable or tristable regions, and that given the necessary stimulus could be moved
to a disease state. This idea corresponds with the etiology of OA, given the large
percentage of aﬀected individuals including asymptomatic individuals.
Both oscillatory and ﬁxed disease states are present in the model. Some patients
report intermittent periods of pain in early OA. This pattern of behaviour in
RA has been linked to cyclic levels of cytokines, and the same may be true for
OA, although data is not yet available for OA. It may be possible, with disease
modifying drugs, to move a patient from an oscillatory disease state to a ﬁxed
disease state, such as in the tristable case illustrated in Figure 3.49 . In this model,
we do not examine which type of disease behaviour is most destructive long term,
but it may be possible to explore this with a spatial model of OA cartilage. It
has been proposed that OA is a not a condition that has a single cause, but a
group of many diseases with a common pathway of progression. The bifurcation
analysis in Section 3.4 is consistent with this idea. Single parameter variation in
all of the fourteen model parameters were considered for a reference parameter set
and in each case led to regions of monostable and bistable behaviour. This would
suggest that variations in any of these parameters outside of a normal range may
lead to abnormal cartilage behaviour, moving an individual to a bistable region
where they are more susceptible to OA or moving them from a bistable region to
a monostable disease region, likely to indicate established disease. Additionally,
analysis of the mechanical damage parameter showed that even small increases
in this parameter can lead to monostable disease, consistent with the view that
mechanical damage is the largest risk factor for OA.
The system shows a wide range of mathematically interesting behaviours, includ-
ing ﬁve steady states which appear to be closely tied to Bogdonov-Takens bifur-
cations, mushrooms and isolas, and regions of excitability. It is also possible that
there are additional behaviours that we have not found since we were unable to
fully explore the parameter space.
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The two parameter bifurcation analysis suggests that although the behaviour of
the system is complex, the overall behaviour as some parameters vary is relatively
simple. Increases in Pfp and Ppp and decreases in App and Afp lead to monostable
disease, whereas the changes in Mpp and γf are not so easy to classify. This may
mean that cytokine production levels may make the best molecular targets for
therapy approaches as they are most likely to have consistent results in diﬀerent
individuals.
We have shown in Section 3.4 that changes in many of the system parameters
over time can lead to raised levels of p which we believe to be indicative of OA.
Increasing evidence suggests that aging chondrocytes undergo telomere shortening,
which could lead to changes in production rates over time [81]. The pattern
of disease onset is variable in the model and this may correlate with signiﬁcant
variation in clinical presentation of OA. However, this is diﬃcult to prove without
a better disease measure for OA, such as a biomarker, and also without a clear link
between the disease measures used and the model variables. Similarly, whilst we
describe a reduced level of p as a return to health, it is more likely that this simply
reﬂects a reduction or halting of cartilage degradation, which may not result in an
improvement in pain or symptoms for the individual, since the structural damage
leading to pain persists. We have shown that increases in parameter values over
time can lead to OA onset and generally lead to monostable disease after a period
of time. To have the greatest chance of treating OA eﬀectively treatment during
the bistable phase would be preferable. For this it is likely that early diagnosis of
OA would be needed in conjunction with disease modifying treatments.
We have shown that the system is sensitive to mechanical damage. Increases in
this parameter can move the system from health to disease, either as a result of
moving to another steady state in the case of bistability or as a result of increasing
the value of p at a previously healthy steady state. These ﬁndings are consistent
with that fact that mechanical damage is a large risk factor for initiation and
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progression of OA. The absence of any reparative inﬂuences in this model however,
may make the eﬀect of mechanical damage more dominant than it is in reality.
We have considered four diﬀerent treatment strategies: anti cytokine therapy,
anti-inﬂammatory cytokines, MMP inhibitors and Fn-fs inhibitors. We found a
combined treatment strategy could be eﬀective at treating bistable, tristable and
monostable disease. Dose size and timing were important to treatment outcome
and it may be possible to optimise these using control theory. We found that the
only eﬀective monotherapy was to use anti-inﬂammatory cytokines, although this
treatment often required very high dose sizes and treatment outcome was highly
sensitive to dose timing and interval. These issues may make clinical treatment
with anti-inﬂammatory cytokines, such as IL-1Ra, unfeasible and may explain the
failure of IL-1Ra drugs trials [25], despite promising experimental results. For
the other three treatment options any one of these alone was ineﬀective, and
combined treatments were necessary (Section 3.8). We can see from the phase
diagram (Figure 3.4) why this is the case. The basin of attraction of the healthy
state is small and local to the state itself, for the reference parameter set. Any
move from the disease state in only one direction would remain in the basin of
attraction of the disease state. In all the parameter sets that we considered the
basin of attraction of the healthy state was small. If this is seen biologically, results
from our model suggest that combined treatments oﬀer a much better possibility of
success than single treatments, even where the single treatment showed no beneﬁt
alone (Figures 3.42 and 3.43). We saw that in the case of tristability we had an
option of treatment to move the system from a higher disease state to that of a
lower one. However it is unlikely that in the foreseeable future that we would be
able to identify individuals with such multiple disease states or personalise the
treatment plan to such a degree.
We explored the possibility that an increase in the Fn-fs clearance parameter,
γf , could have a positive eﬀect on cartilage health. An increase in γf (Figure
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3.12) could move the system from monostable disease to bistability. Whilst this
alone would not move an individual to health, since they would still be on the
disease branch, this change could be combined with disease modifying drugs which
might either improve treatment outcome or reduce the amount of drugs required.
Research has shown that cyclic loading can increase the movement of molecules
such as Fn-fs in the joint, which would result in an increased rate of clearance
from the joint, so it seems likely that some form of low impact cyclic loading could
increase this parameter. This form of therapy has already been established to have
positive eﬀect on OA patients [40, 38, 112] although the biophysical mechanisms
of the improvements are not well understood.
In this chapter we have explored the behaviour of cytokine interactions in the joint
and identiﬁed potential areas of future research into OA treatment strategies. Lim-
itations of the model include the lack of a link to clinical disease measures, which
include joint space narrowing and radiographic evidence of cartilage deteriora-
tion.. In future, as better measures of OA disease activity are developed, such
as OA biomarkers (easily measurable indicators of disease severity) we may be
able to draw more detailed conclusions about OA disease dynamics. We have not
explored spatial and mechanical aspects of the disease, which play a large role in
OA progression, and have been explored mathematically by others. We believe
that future work in this area needs to combine all these aspects of OA and joint
mechanics, as it is becoming increasingly clear from biological research that the
interactions between the physical and biochemical factors in OA are signiﬁcant.
In the next chapter we extend this model to a spatial version. This gives a new
results variable, cartilage degradation, and allows us to consider the eﬀects of cell
sparsity and local tissue changes.
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4.1 Introduction
In the previous chapter we considered an ODE model of the cytokine biochemistry
of cartilage. We found asymptotic solutions associated with health and disease,
and suggested possible treatment strategies based on these states. A major as-
sumption of our ODE model is that of spatial homogeneity. This assumption is
unlikely to hold in the cartilage, since the cartilage is a spatially structured tissue.
Cartilage tissue, as shown in Figure 4.1, contains chondrocytes ﬁxed in a collagen
and proteoglycan matrix. The chondrocytes are spaced irregularly through the
tissue with a higher density at the synovial interface. Chondrocytes are eﬀectively
immobile, trapped within a dense network of ﬁbres [95], meaning that cytokines,
MMPs and matrix components which are all secreted from the cell surface, rely
on diﬀusion and advection to disperse through the tissue, leading to further inho-
mogeneity. Additionally, as the ECM degrades it does so non-uniformly [71].
In this chapter, we will assess whether the ﬁndings from the ODE model still
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Figure 4.1: Diagram of cartilage tissue showing chondrocytes (represented by blue
dots) enclosed in a mesh of collagenous ECM.
hold in a more realistic spatial model. We will consider the importance of spa-
tial structure and diﬀusion to both the disease processes and possible treatment
strategies.
4.2 Model speciﬁcation
We model the biochemical network of cytokines, MMPs and ﬁbronectin fragments
in the cartilage and its eﬀect on the tissue as depicted in Figure 4.2.
We require the model we develop to be cell based in order to simulate randomly-
placed chondrocytes enclosed in an ECM, for this reason we choose not to use a
PDE-only model and instead develop a hybrid model, with continuous variables,
such as cytokine concentrations, represented by PDE's and the discrete elements
of this model, such as chondrocytes, represented by a cellular approach. The
Compucell3D modelling environment [122] is a hybrid system which combines PDE
and Cellular Potts models, making it ideal for combining cell and tissue dynamics
we require. Compucell3D uses an algorithm based on the Cellular Potts algorithm
(also known as the Glazier-Graner-Hogeweg (GGH) algorithm) to simulate cells on
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Figure 4.2: Schematic showing the tissue and cell signalling included in the model.
The cell dynamics that were present in the ODE modelling take place within
chondrocytes, with the exception of Fn-fs release, which takes place in the ECM.
All biochemicals are secreted and move freely by diﬀusion through the domain,
MMPs and anabolic cytokines act directly on the ECM.
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a lattice. This allows us to simulate irregularly placed chondrocytes which secrete
biochemical molecules. Compucell3D is an open source modelling environment
written in a combination of XML, Python and C++. Users can build simulations
using a combination of pre-deﬁned plugins, modules that calculate the eﬀective
energy in the model edited via XML scripts, and user-deﬁned steppables, that
perform cell based operations and are written in Python.
We model the system in two spatial dimensions for simplicity, but could extend
to a three dimensional model within the modelling framework later if necessary.
We consider three diﬀerent tissue types as well as synovial ﬂuid. These are ECM,
chondrocytes and bone. For simplicity, we assume bone is an inert tissue providing
a surface for the ECM to adhere to. We include ﬁve biochemical variables in the
model, pro-inﬂammatory, anti-inﬂammatory and anabolic cytokines, ﬁbronectin
fragments and MMPs. Anabolic cytokines are a class of cytokines that stimulate
the production of collagen to remodel the ECM. Since we include the ECM volume
in this model, and since pro-inﬂammatory cytokines have a background production
term, without the inclusion of anabolic cytokines we could not represent healthy
ECM remodelling. Instead the ECM would always degrade. Anabolic cytokines
are present to balance the background ECM degradation, simulating normal re-
modelling of the tissue. Initial conditions for the model consist of the spatial
conﬁguration of the tissue and initial concentrations of the biochemical variables.
We also impose boundary conditions. Figure 4.3 shows an example of the initial
conﬁguration of the tissue we have used in the simulations. The chondrocytes are
randomly spaced throughout the ECM, and make up 5% of the tissue.
4.2.1 Modelling approach
The GGH algorithm associates an eﬀective energy to the system conﬁguration,
and accepts changes to that conﬁguration with a probability that is an increasing
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Figure 4.3: Example initial spatial conﬁguration of tissue in model. ECM is
shown in orange, and sparsely populated with chondrocytes (blue). A layer of
bone (white) lines the bottom edge of the ECM and synovial ﬂuid ﬁlls the top of
the domain (black).
function of the associated eﬀective energy reduction. Cell behaviours such as
growth, cell-cell contact, mitosis and chemotactic responses are represented by
energy terms, which may represent real energies or be metaphoric. The eﬀective
energy (HGGH) of the cell is the sum of these terms. The eﬀective energy term
must include volume (or area in 2D models), surface area and boundary adhesion
terms. In addition, in our model we also include a focal point plasticity term,
giving,
HGGH = Hvol +Hsurf +Hadhesion +Hfocal. (4.2.1)
We shall discuss the calculation of these terms further below.
The system consists of a collection of lattice sites within a square grid. We divide
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the grid into a series of cells each of which is a smaller collection of the lattice
sites, each of which has a unique index (Figure 4.4). These cells, termed generalised
cells, are distinct from biological cells and may consist of a single biological cell, a
cluster of biological cells, or other tissue constituents, e.g. ECM. To diﬀerentiate
generalized cells from biological cells we will italicise. In our model, we use a cell
to represent a section of ECM, chondrocyte or a bone cell. Initially we set all
these cells to be of similar volume since we expect chondrocytes and bone cells to
be similar and the size of the ECM cells is arbitrary.
We simulate changes to the cells using a stochastic simulation mechanism through
a series of Monte Carlo Steps and index copy attempts. The index copy is the basic
building block. This has the eﬀect of moving cells, changing cell size or changing
their shape. We select a pixel at
−→
i (target pixel) and a neighbouring pixel
−→
i ′
(source pixel) randomly. If the two are in the same cell we do nothing. If they
are diﬀerent cell (i.e. we have selected a pixel on the cell border) we calculate the
change in eﬀective energy (∆HGGH) associated with copying selected pixel to the
target pixel and accept the copy attempt with the probability,
P (σ(
−→
i → −→i ′)) =
 exp(−∆HGGH/Tm) if ∆HGGH > 01 if ∆HGGH ≤ 0
 , (4.2.2)
where σ is the cell and Tm is the eﬀective cell motility (the amplitude of cell
membrane ﬂuctuations).
Each Monte Carlo step (MCS) consists of a number of index copy attempts equal
to the number of pixels in the simulation. Eﬀective energy is calculated at each
MCS. Monte Carlo steps move the simulation forward in time and between each
MCS we perform additional operations such as diﬀusion and secretion. These
aﬀect the levels of the chemical ﬁeld variables in the model but do not directly
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Figure 4.4: Schematic showing the lattice sites for three cells with two diﬀerent cell
types. The strength of the interactions between cells J depends on the diﬀerence
in eﬀective energy between the cells. Each pixel copy attempt will try and copy
the cell type from one pixel to another, and the success of this will depend on the
value of J .
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change the eﬀective energy of cells.
The main simulation process is shown in Figure 4.5, adapted from the Compu-
cell3D documentation.
Figure 4.5: Flowchart showing the simulation process for the cartilage model in
Compucell3D. Each simulation is a series of Monte Carlo steps (MCS) consisting
of many index copy attempts.
4.2.2 Physical properties of the model
Volume
The volume constraint along with the boundary adhesion constraint is a manda-
tory term in the GGH algorithm and these two terms combined give the basic
GGH eﬀective energy equations. In this model, since we are working in 2D the
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volume constraints are actually area constraints. We use the volume constraint
to simulate degradation of the collagen ﬁbres within the cartilage. The volume
constraint contribution to equation 4.2.1 is,
Hvol =
∑
σ
λvol(σ)(v(σ)− Vt(σ))2, (4.2.3)
where σ is the cell, λvol(σ) is the inverse compressibility of the cell, Vt is the target
area and v is the actual area. Area is measured in units of pixels2. Since site
copies are more likely to be accepted if they decrease their eﬀective energy this
form of volume constraint will tend to drive the cell volumes towards their target
volumes.
We set synovial ﬂuid as the default tissue type (described as medium in Compu-
cell3D) and hence it does not require a target volume as it simply ﬁlls in the space
left by other cells to stop empty space appearing. We ﬁx the volume and shape
of bone cells, so we only consider changes to ECM and chondrocyte volumes in
the model. ECM is degraded by MMPs and is synthesised by anabolic cytokines.
Hence, we change the target volume of the ECM cells dynamically as a function
of the MMP and anabolic cytokine concentrations according to the term,
∆Vt = ffp(nc − pc), (4.2.4)
where nc and pc are the concentrations of anabolic and pro-inﬂammatory cytokines
respectively and ffp is a non-negative parameter.
The target volume of the chondrocytes is generally ﬁxed. However if these cells
come in contact with synovial ﬂuid their target volume is reduced to zero so that
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the cell is degraded, and shrinks until it is removed when its actual volume reaches
zero, which may be a short time later. This constraint stops individual chondro-
cytes existing in synovial ﬂuid once the surrounding tissue has been degraded,
since this is not seen in vivo.
Adhesion
Cellular adhesion refers to the way in which cells stick to each other to form a
tissue. In this model the majority of the cells are ECM rather than true biological
cells. Therefore, the adhesion properties of the model can be considered to be a
proxy for the strength of the ECM. Compucell3D deﬁnes adhesion as,
Eadhesion =
∑
i,j
J(τσ(i), τσ(j))(1− δσ(i),σ(j)),
where i and j are neighbouring lattice sites, J is the contact energy, τ denotes
the cell type and σ denotes the cell ID. The ﬁrst term sums the adhesion energies
between diﬀerent sites whilst the second term ensures that pairs of neighbours
that belong to the same cell are discounted. The values of the contact energy
between diﬀerent cell types are model parameters and the values we have used
are listed in Table 4.1. The units are dimensionless with the default value of ten
indicating moderate adhesion and lower values indicating stronger adhesion since
lower eﬀective energies are favoured by the algorithm. We deﬁne neighbours in
the model as any cells which directly touch the cell.
Since the cells of the ECM tissue are representing a interconnected mesh, as well
as boundary adhesion we also include focal point plasticity in the model. This
Compucell3D plugin allows connections between the centers of mass of the cells.
We specify a maximum distance constraint between the centre of mass of a cell
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and the centre of mass of its neighbour and specify how many neighbours each cell
will have. The determination of which cells are neighbours is determined by Com-
pucell3D based on these parameters and may change as the cells move/degrade.
The energy contribution of the focal point plasticity term is given by,
E =
∑
i,j−cellneighbours
λij(Iij − Lij)2, (4.2.5)
where λ is a measure of the plasticity, speciﬁed as a model parameter; Iij is the
distance between the cells i and j; Lij is the target distance between cells i and
j and is another model parameter and the max distance, which is the point at
which a link breaks. We also specify the likelihood of a new link being made in
any particular pixel copy attempt. In this model we keep this likelihood low since
we are modelling mature cartilage whose ability to form new collagen crosslinks is
poor. The parameters we have used in the model are listed in Table 4.1.
Diﬀusion
We model diﬀusion of pro- and anti-inﬂammatory cytokines, MMPs and Fn-fs
through both the ECM and synovial ﬂuid. We have not found any experimental
work giving the diﬀusion coeﬃcients of these parameters in cartilage. However,
we can estimate the diﬀusion coeﬃcients of these proteins by considering their
size. Leddy and Guilak [76] provides diﬀusion coeﬃcients of various sizes of dex-
tran molecules in cartilage. The values given are compatible with the value we
calculate using the Einstein formula for diﬀusion. Hence we choose a diﬀusion co-
eﬃcient for all tissue types of 2 µm2s−1 which is compatible both with the dextran
experiments and the Einstein formula. However, we believe that the eﬀective dif-
fusion coeﬃcient for these proteins could be much lower than that of dextran since
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these cytokines, MMPs and ﬁbronectin fragments will all be actively binding and
unbinding to cell surface receptors on chondrocytes and possibly interacting with
collagen. For this reason we also consider a slower rate of diﬀusion, 0.002µm2s−1.
For the slower diﬀusion simulations we use non-steady state diﬀusion,
∂c
∂t
= D∇2c− kc+ secretion, (4.2.6)
where D is the diﬀusion constant and k is the decay constant. We solve this at
each MCS using the Forward Euler method. For faster diﬀusion this method is
unsuitable, since numerical instabilities necessitate very small time steps, making
simulations over longer timescales unfeasible. Hence, for faster diﬀusion we use
a steady state approximation. We discuss this diﬀusion approximation further in
Section 4.6. The secretion term for both types of diﬀusion is calculated separately
and discussed in section 4.2.3. We use periodic boundary conditions in the x-
direction and no ﬂux boundary conditions in the y-direction for the diﬀusion.
4.2.3 Biochemical properties
Secretion
Wemodel secretion of pro-inﬂammatory, anti-inﬂammatory and anabolic cytokines
and MMPs from chondrocyte cells. Additionally we model release of ﬁbronectin
fragments from ECM cells as their volume reduces. Pro-inﬂammatory, anti-
inﬂammatory and anabolic cytokines and MMPs are secreted according to the
state at the beginning of each Monte Carlo step and the level secreted is a func-
tion of the state of the cell secreting. Pro-inﬂammatory cytokines are secreted
according to the function,
149
Chapter 4: Spatial modelling of joint degradation in OA
psecreted =
(
pbp + ppp
p2c
p2ph + p
2
c
+ pfp
f 2c
p2fh + f
2
c
)
p2ah
p2ah + a
2
c
. (4.2.7)
where pc and fc are the concentrations of pro-inﬂammatory cytokine and ﬁ-
bronectin at the centre of the cell. The secretion term reﬂects up-regulation of
pro-inﬂammatory cytokines, by themselves and ﬁbronectin fragments, and the
down-regulation of pro-inﬂammatory cytokine production by anti-inﬂammatory
cytokines. Anti-inﬂammatory cytokines are secreted according to the term,
asecreted = app
p2c
a2ph + p
2
c
+ afp
f 2c
a2fh + f
2
c
+ anp
n2c
p2nh + n
2
c
. (4.2.8)
Here the level of anti-inﬂammatory cytokine secreted is up-regulated in the pres-
ence of pro-inﬂammatory cytokines, anabolic cytokines and ECM fragments.
MMPs are up-regulated by pro-inﬂammatory cytokines and down-regulated by
anabolic cytokines, according to the term,
msecreted =
(
mbp +mpp
p2c
m2ph + p
2
c
)
m2np
m2np +mnhn
2
. (4.2.9)
Anabolic cytokines are involved in the normal homeostasis of the ECM tissue,
hence have a background production rate. They are also upregulated in response
to ﬁbronectin fragments in the joint according to the term,
nsecreted =
(
nbp + nfp
f 2c
n2fh + f
2
c
)
. (4.2.10)
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All of the chemicals secreted by chondrocytes in this model are secreted on the
boundary of the cell, they then diﬀuse away from the cell according to the diﬀusion
PDE.
During each MCS when the cell volume is amended in response to MMP levels we
also make a corresponding secretion of Fn-fs. The amount of ﬁbronectin fragments
released is calculated as:
fsecreted =
 −ffp∆v if ∆v < 00 if ∆v ≥ 0 (4.2.11)
where ∆v is the change in target volume of the cell.
4.3 Model Parameters
Table 4.1: Summary of base parameter values in model. Dimensionless unless
otherwise stated.
Parameter Value
Temperature 20
Neighbour Order 2
λ Surface ECM 2
λ Surface Chondrocytes 2
Target Surface ECM 2 pixels
Target Surface Chondrocytes 25 pixels
Contact Adhesion Energy
Medium-Medium 10
Medium-ECM 10
Continued on next page
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Table 4.1  continued from previous page
Parameter Value
Medium-Chondrocyte 16
Medium-Bone 10
ECM-ECM 4
ECM-Chondrocyte 6
ECM-Bone 6
Chondrocyte-Chondrocyte 10
Chondrocyte-Bone 16
Bone-Bone 10
Focal Point Plasticity
λ ECM-ECM 10
Activation Energy ECM-ECM -100
Target Distance ECM-ECM 7 pixels
Max Distance ECM-ECM 10 pixels
Max no. of junction ECM-ECM 5
λ ECM-Chondrocyte 10
Activation Energy ECM-Chondrocyte -100
Target Distance ECM-Chondrocyte 7 pixels
Max Distance ECM-Chondrocyte 10 pixels
Max no. of junction ECM-Chondrocyte 5
λ ECM-Bone 10
Activation Energy ECM-Bone -100
Target Distance ECM-Bone 7 pixels
Max Distance ECM-Bone 10 pixels
Slow Diﬀusion Coeﬃcient 1.8 pixels2MCS−1 (0.002 µ2s−1)
Fast Diﬀusion Coeﬃcient 1800 pixels2MCS−1 (2.0 µ2s−1)
Continued on next page
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Table 4.1  continued from previous page
Parameter Value
Decay Coeﬃcient 0.17 MCS−1 (0.69 hr−1)
ECM λ area 2 pixels2
ECM target area 55 pixels2
Chondrocyte λ area 2 pixels2
Chondrocyte target area 55 pixels2
pbp 0.0017
ppp 1.7
pph 1
pfp 1.7
pfh 1
pah 1
app 1.7
aph 1
afp 1.7
afh 1
anp 1
anh 1
mbp 0.00017
mpp 1
mph 1
mnh 1
nbp 0.0001
nfp 0.001
nfh 1
ffp 0.17
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4.4 Transition from ODE to spatial model
4.4.1 Direct Comparison
To explore the relationship of this model to the ODE model we start by simplifying
the spatial model to minimise the diﬀerences between the two models. We replace
the synovial ﬂuid, ECM and bone tissue in the model with chondrocytes to create
a uniform domain, which also necessitates allowing ﬁbronectin to be released from
chondrocytes rather than ECM.We also change the parameters nbp and nfp to zero,
to remove anabolic cytokine production. We change the boundary conditions to
be periodic in both the x- and y-axis. We then run a series of simulations of the
model varying the parameter ppp each time. We use non-steady state diﬀusion.
At the start of the simulations all cytokines, MMP and ﬁbronectin fragment con-
centrations are zero. For each simulation we run the model for 10000 MCS and
simulate a trauma, a pulse of ps=10, at t = 1000. In each case the biochemical
variables reach a steady level by t = 1000 and then after the trauma either re-
covers to the original level or moves to a diﬀerent steady level or a oscillates. We
measure the maximum and minimum and average value of ps in the chondrocytes
over the ﬁnal 500 MCS in each simulation with and without a trauma and use
this to construct a plot which we compare with a bifurcation plot from the ODE
model, Figure 4.6.
Comparing the Cellular Potts model to the ODE model, we appear to have broadly
the same behaviour. We have a steady state at a low concentration of p for low
values of ppp, which we lose as we increase this parameter. At higher values of
ppp we have oscillatory behaviour. In the Cellular Potts model the amplitude and
average value of the oscillations is larger than for the ODE model. This is likely to
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Figure 4.6: Comparison of bifurcation plot from the cartilage ODE model with the
results from the spatial model with parameters approximating the ODE model.
The solid lines are the stable and unstable branches of the ODEmodel bifurcations,
The dashed black and red lines of the ODE limit cycle maximum, minimum and
average values. The black and red stars are the maximum,minimum and average
values from the spatial model at 10000 MCS.
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be due to the slight diﬀerences in the two models, principally the eﬀect of diﬀusion.
At even larger values of the ppp both models move to a stable steady state, at a
similar level of p.
4.4.2 Number of cells
A major diﬀerence between the spatial model and the ODE model is the spar-
sity of chondrocytes, since the ODE model assumes spatial homogeneity which we
can consider analogous to 100% chondrocytes in the spatial model. In cartilage
tissue only 5% of the volume is chondrocytes. We now gradually reduce the num-
ber of chondrocytes in the Cellular Potts model, whilst still secreting ﬁbronectin
fragments from the chondrocytes. In these simulations the ECM plays no part
in the cartilage dynamics, but instead acts as an inert connective tissue between
cells. This allows us to consider the eﬀect of reduced intercellular communication.
Figure 4.7 shows a set of bifurcation plots as the proportion of chondrocytes is
reduced from 100% to 10% and replaced by ECM.
As we reduce the number of chondrocytes in the tissue the bifurcation plot changes.
The Hopf point appears to remain at a similar value of ppp, but the amplitude of
the oscillations reduces, possibly due to the limit cycle colliding with the unstable
branch and the resulting homoclinic bifurcation moving up unstable branch of the
fold. As the number of cells reduces further oscillatory behaviour is lost altogether.
In addition, the disease branch rises, occurring at higher values of p as the number
of chondrocytes reduces.
Reducing the number of cells has two eﬀects on the model. Firstly the overall
amount of all the variables secreted is reduced, due to the reduction in the number
of cells. Secondly, communication between cells is reduced, due to being spaced
further apart, and chemicals having to diﬀuse through the ECM, which can lead
to cells behaving less uniformly. In the full model where tissue degradation further
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Figure 4.7: Bifurcation plots of p against ppp showing the stable steady states. We
reduce the proportion of chondrocytes, replacing them with ECM tissue. As the
number of cells reduces we lose the oscillatory behaviour.
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increases non-uniformity this eﬀect could be more important.
In these simulations we have released ﬁbronectin (f) from the chondrocytes. This
is unrealistic so we next look at secretion of ﬁbronectin from the ECM. We reduce
the number of chondrocytes again, this time with f released from the ECM, Fig
4.8. Hence, when we have 100% chondrocytes we have no Fn-fs released. When f
is released from the ECM we do not see any oscillatory states. As the number of
cells reduces the disease state ﬁrstly lowers then rises again as the chondrocytes
reduce to more realistic numbers. The range for which we have only a healthy
state or both a healthy and disease state increases as we reduce the number of
chondrocytes.
Overall, moving the system from 100% chondrocytes with f released from the cells
to 5% chondrocytes with f released from the cells is more comparable to cartilage
biology. This change introduces non-uniform behaviour in the tissue, which could
not be modelled with ODE methods. The non-uniformity is dependent upon the
diﬀusion rate, and is likely to reduce and disappear as we increase the rate of
diﬀusion, which we show in Section 4.6.
4.4.3 Tissue boundaries
In the simulations so far we have considered only cartilage tissue. However in
the joint the cartilage in anchored to bone and surrounded by synovial ﬂuid. We
now introduce these aspects back into the model. Figure 4.9c shows the initial
conﬁguration of the tissue with bone on the bottom boundary and synovial ﬂuid
on the top boundary. Since we now have diﬀerent tissues on the boundary a
periodic boundary condition is no longer appropriate for the y-axis so we instead
change this to no ﬂux. We leave the x-axis boundary periodic since we assume the
cartilage is wider than is it deep in line with normal cartilage histology in joint
such as the knee or hip.
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Figure 4.8: Bifurcation plots of p against ppp showing the stable steady states for
decreasing numbers of cells. Here, f is released from the ECM rather than from
the chondrocytes.
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(a) (b)
(c)
Figure 4.9: a) Bifurcation plot of spatial model with 5% chondrocytes in ECM
with no other tissue types. b) Bifurcation plot of the spatial model with 5%
chondrocytes in the ECM but realistic tissue boundaries of synovial ﬂuid on the
top boundary and bone on the bottom boundary. c) Initial spatial domain used
in (b).
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Figure 4.9a shows a bifurcation plot of p against ppp where we have 5% chon-
drocytes. Comparing this to Figure 4.9b, in the ﬁrst we have cartilage tissue
only as in previous simulations, whereas in the second we have bone and synovial
ﬂuid. There is little diﬀerence between these two plots, so adding the bone and
synovial ﬂuid makes little diﬀerence for this conﬁguration. When the percentage
of chondrocytes is higher however, the eﬀect of the change is greater. Since a
higher percentage of chondrocytes is not biologically realistic we do not explore
this further.
4.4.4 Tissue degradation and disease measures
The ﬁnal feature that we need to add back into the model that is not present in
the ODE model is the degradation of the cartilage. This is a signiﬁcant change
from the ODE model as it means that in disease we have a continually changing
environment. At this point we also put anabolic cytokines back into the model,
as even with low level of pro-inﬂammatory cytokines the background production
would lead to tissue degradation without a balance to give homeostasis. Figure
4.10 shows a time course of the levels of p as the tissue is degraded. As the tissue
is degraded the number of chondrocytes is reduced and cytokine feedback between
cells is made more diﬃcult by the tears that develop in the tissue, as this moves the
cells further apart. This, coupled with the stochastic changes in the model means
that to we can no longer consider the model in behaviour at a ﬁxed time point, but
instead need to consider the time course of the model. With these considerations
in mind we will now move on to considering how this model behaves and how we
deﬁne health and disease in the spatial model.
In the previous chapters we have used the concentration of pro-inﬂammatory cy-
tokine as the main measure of disease, loosely deﬁning health as very low concen-
trations of pro-inﬂammatory cytokine and disease as higher levels. This measure
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(a) (b)
Figure 4.10: Time course plot of the model over 3000 MCS, an instantaneous
increase in p is simulated at t = 500 to move the system to disease. a) The
concentration of p initially remains at a low concentration suggesting a healthy
state, but after the stimulus the level of p changes with time. b) The ECM volume
continually degrades once disease is initiated. This may be a better measure of
disease than pro-inﬂammatory cytokine concentration.
of disease has several limitations and with the spatial model we have the opportu-
nity to consider other measures of disease. Speciﬁcally, a measure of the amount
of tissue loss would seem intuitively to be a good disease measure. This measure
of disease is more in line with clinical disease measures that often include joint
space narrowing as seen on x-rays. In contrast, accurate measures of cytokine or
MMP levels are not practical in a clinical environment due to be the short half
life of these biochemicals and the diﬃculty of extracting samples from patients.
Since we know that tissue degradation is mediated by cytokines, we would expect
strong correlation between high levels of cytokines in disease and tissue degrada-
tion. Figure 4.10 shows time courses for a simulation of the model showing the
proportion of cartilage tissue remaining in addition to the pro-inﬂammatory cy-
tokine levels. We see here that the level of p is very variable and drops to zero once
all chondrocytes have died, which could be misinterpreted as a return to health.
However the ECM plot clearly shows that the ECM volume is much reduced, and
here the ECM volume is a better measure of disease stage and progression.
Overall in this section we have seen the eﬀect of moving from an ODE to a Cellular
Potts model. Whilst there are diﬀerences in model behaviour at certain parameter
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values, generally comparable behaviour types seem to exist, which may mean that
the treatment strategies seen in the ODE model are still applicable. In the next
section we will further examine the behaviour groups that we see in this spatial
model.
4.5 Classiﬁcation of behaviours in the spatial model
In the ODE modelling we were able to classify behaviour based on the nature and
stability of the steady states and limit cycles of the system. In the spatial model
the domain is continually changing as the matrix remodels. Hence it is no longer
possible to observe behaviour that is homogeneous either in time or space. For this
reason we look at how the system behaves over time in the presence and absence
of pro-inﬂammatory stimulus to classify diﬀerent parameter sets into behavioural
groups. This grouping is important as it determines the type of treatments that
would be possible and the likelihood of slowing disease progression. Using the
bifurcation analysis from the previous chapter to help identify diﬀerent behaviour
types we have found three behaviour groups: persistent health, inducible disease
and persistent disease.
Persistent health is analogous to monostable health in the ODE model. With no
stimulus we have low levels of all the variables, and if a stimulus is given we quickly
move back down to a healthy state with little change to the ECM tissue (see Figure
4.11a). One point to note with this state is that if a pro-inﬂammatory stimulus
is given it will damage the cartilage and degrade it slightly, and this damage is
unlikely to recover, due to low levels of anabolic cytokines. For a short stimulus this
is not a problem since the amount of damage is small relative to the healthy tissue
(Figure 4.11c). However, if we stimulate repeated pro-inﬂammatory stimuli over a
longer time period we see that the matrix can become signiﬁcantly degraded, to the
point where you may get loading problems in the joint (Figure 4.12). We expect
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that the same result could be observed with a mechanical stimuli. This may be
representative of a simple wear and tear process where the joint cartilage becomes
degraded but the cartilage is not osteoarthritic. In these cases, removal of the
pro-inﬂammatory stimulus is suﬃcient to halt the degradation process, however
in a severely damaged joint the abnormal loading as a result of degradation may
in itself act as an additional pro-inﬂammatory stimuli.
(a) (b)
(c)
Figure 4.11: Plots showing behaviour of the persistent health type. a) Average
concentration of p in the chondrocytes against time. A pro-inﬂammatory stimulus
of p = 10 is given at t = 500. This quickly dies down without noticeable long term
eﬀects. b) Concentration of p in four individual chondrocytes plotted against
time. These shows generally uniform cell behaviour c) Proportion of ECM tissue
remaining relative to the initial level plotted against time. Only minor changes
on the ECM tissue are seen. (ppp = 0)
As we increase the value of ppp we move out of the region of persistent health and
into a region of inducible disease. Here for low initial conditions of all variables
we have a state of heath as before. However, if a pro-inﬂammatory stimulus is
given the system will move to a disease state where the concentration of cytokines,
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Figure 4.12: Time course plot of the spatial model over 10000 MCS, with a series
of regular stimuli of p in all chondrocytes. Stimuli of 10 units of p are made at
intervals of 20 MCS between t = 500 and t = 6000. These cause degradation of
the ECM. However, once these secretions are halted at t = 6000 the degradation
ceases. The parameters are as speciﬁed in Table 4.1 except that ppp = 2.
MMPs and ﬁbronectin are all comparatively high, and the ECM is being degraded.
Figure 4.13a shows the average concentration of pro-inﬂammatory cytokine in the
chondrocytes over time as the simulation progresses. A pro-inﬂammatory stimulus
is given at t = 1000, at which point the level of p increases and then settles to
a disease level and the ECM tissue starts to be degraded (Figure 4.13c). As
the simulation progresses the number of chondrocytes is decreasing, hence the
increasing variation in the concentration of p, until at approximately t = 2500 the
level of p drops back down to zero as the last chondrocyte is degraded. Figure 4.13b
shows time courses for four individual chondrocytes from the same simulation.
This ﬁgure demonstrates that although broadly similar, the behaviour of each
chondrocyte is individual and inﬂuenced by the concentration of biochemicals in
its vicinity. Large spikes in the concentration of p are seen and the cells die at
diﬀerent times during the simulation.
Figure 4.14 shows spatial domain at four diﬀerent time points through the simula-
tion shown in Figure 4.13. We can see that as the tissue degrades the chondrocytes
cluster together as the tissue between the chondrocytes degrades quicker than the
rest of the tissue due to higher concentrations of cytokines. We also see that the
pro-inﬂammatory cytokine concentration is higher in the locality of chondrocytes,
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(a) (b)
(c)
Figure 4.13: Plots showing behaviour of the inducible disease type. a) Average
concentration of p in the chondrocytes against time. A pro-inﬂammatory stimulus
of ps = 10 is given at t = 500 which moves the model to a disease state. By
t = 2500 all the chondrocytes have been degraded. b) Concentration of p in
three individual chondrocytes plotted against time. c) Proportion of ECM tissue
remaining relative to the initial level plotted against time. (ppp = 15)
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we will later contrast this with the case when we have faster diﬀusion.
Figure 4.14: Plots showing behaviour of the inducible disease type at diﬀerent time
points. The ﬁrst column shows the cells degrading whilst the second column shows
the pro-inﬂammatory cytokine concentration through the domain at the same
time points. The images show that the diﬀusion of the pro-inﬂammatory cytokine
concentration in addition to the spatial conﬁguration of the domain determine
how the tissue degrades. (ppp = 15)
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Persistent disease is analogous to monostable disease in the ODE model, and
we ﬁnd this behaviour as we increase ppp to 20 with the reference parameter
set. Without any stimulus the system is in a disease state regardless of initial
conditions. Figure 4.15a shows the average concentration of pro-inﬂammatory
cytokine in the chondrocytes, and even though we start with initial conditions of
zero for all variables in the model, the level of pro-inﬂammatory cytokines rise.
The other variables rise in a similar fashion and the cartilage is degraded (Figure
4.15c). Interestingly, for some parameter ranges this does not occur uniformly
in every chondrocyte. The majority of chondrocytes move quickly to be disease
state (Chondrocytes 1 in Figure 4.15b) but some chondrocytes remain healthy
for a short time before moving to disease (Chondrocytes 2 and 3), whilst others
remain healthy throughout the simulation (Chondrocyte 4). This is likely to be
dependent on the local positioning of the chondrocyte, and is suggestive that the
structure of chondrocyte positioning through the tissue could be a factor in disease
progression. This type of behaviour is seen close to the threshold where we switch
between inducible and persistent disease.
Figure 4.16 shows the spatial domain during the simulation where ppp = 20 and
hence have non uniform cell behaviour. It is clear that cells that are in closest
vicinity to other cells are the ones which reach disease levels soonest. Then as pro-
inﬂammatory cytokine diﬀuses and as the ECM degrades the disease state spreads
to cells further away. We can also see that the ECM degradation itself causes fur-
ther clustering, presumably because the ECM tissue between two chondrocytes
is subject to higher concentrations of pro-inﬂammatory cytokines and hence de-
grades quickest. Biologically, chondrocyte clustering is seen in OA, although it
is theorised that this is due to cell division. It is possible that the movement
of chondrocytes via ECM degradation may also be contributing to this observed
phenomena.
At higher levels of ppp (ppp = 50), further away from this threshold, we get more
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(a) (b)
(c)
Figure 4.15: Plots showing behaviour of the persistent disease type. a) Average
concentration of p in the chondrocytes against time. No stimulus is given in
this simulation. By t = 3000 most of the chondrocytes have been degraded.
b) Concentration of p in four individual chondrocytes plotted against time. c)
Proportion of ECM tissue remaining relative to the initial level plotted against
time (ppp = 20).
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Figure 4.16: Plots showing behaviour of the persistent disease type at diﬀerent
time points. The ﬁrst column shows the cells degrading whilst the second col-
umn shows the pro-inﬂammatory cytokine concentration through the domain at
the same time points. The images show that cell clustering is occurring during
the simulation as tissue between cells receives the highest concentration of pro-
inﬂammatory cytokine. (ppp = 20)
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uniform cell behaviour, Figure 4.17b. As we might expect with a larger rate of
pro-inﬂammatory production we also degrade the ECM much quicker. Here, we
see that the additional disease measure of ECM tissue in the spatial model gives
us a better link to the disease that an individual may experience. For example,
where we see a drop to low cytokine levels in the ODE model, and assume health,
we may ﬁnd that the ECM is signiﬁcantly damaged.
(a) (b)
(c)
Figure 4.17: Plots showing behaviour of the persistent disease type for a high value
of ppp compared to Figure 4.15 a) Average concentration of p in the chondrocytes
against time. No stimulus is given in this simulation. By t = 1500 most of
the chondrocytes have been degraded. b) Concentration of p in four individual
chondrocytes plotted against time. The chondrocyte behaviour is more uniform
compared to persistent disease with lower ppp (Figure 4.15) i.e. the chondrocytes
all reach raised cytokine levels at the same time c) Proportion of ECM tissue
remaining relative to the initial level plotted against time(ppp = 50).
As Figures 4.14 and 4.16 show, the diﬀusion rate used in these simulations is such
that the eﬀective diﬀusion length is about 4-5 cell lengths. Since the diﬀusion
coeﬃcients for cytokines, MMPs and Fn-fs are poorly deﬁned in cartilage, in the
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next section we will consider how both slower and faster diﬀusion aﬀect the tissue
degradation.
4.6 Impact of diﬀusion rate variation
As discussed previously in this chapter the diﬀusion coeﬃcients of cytokines,
MMPs and ﬁbronectin fragments in cartilage are poorly deﬁned. The diﬀusion
rates we have used so far for the simulations are slow compared to some esti-
mates. We will now consider the eﬀect of faster diﬀusion rates on the system. We
will also consider how slower diﬀusion rates aﬀect the simulations.
Large diﬀusion rates, present some practical problems in Compucell3D, since the
diﬀusion solver uses the forward Euler method, which is unstable for large diﬀu-
sion coeﬃcients. To avoid this Compucell3D adjusts the diﬀusion time step, but
this slows the simulations considerably. Hence, in order to consider faster diﬀusion
without excessively long simulations we make the assumption that the concentra-
tion proﬁle quickly settles to a steady state in time, allowing us to use steady state
diﬀusion methods. A steady state diﬀusion solver is built in to Compucell3D and
is based on the Helmholz equation,
52c− kc = F, (4.6.1)
where c is the concentration, k is the decay and F is the source term. F can
be input in the model through either an initial concentration, or through cellular
secretion. However, the cellular secretion option is designed to take a constant,
to be secreted at each MCS. To dynamically control the secretion amount at each
MCS, such that the amount secreted is based on the concentration of the other
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variables in the model we calculate this in a steppable written in Python then
couple it to the diﬀusion through F . At each time step, on a pixel-by-pixel basis,
we take the current concentration of all the chemical ﬁelds at the pixel. We
then calculate the secretion amount based upon the equations in Section 4.2.3.
The amount to be secreted is then fed back into the diﬀusion plugin as a constant
concentration to be used at the next time step. This method solves the problem of
non-constant secretion in Compucell's steady state diﬀusion solver, however since
the secretion is not fully integrated into the diﬀusion solver, there is an uncoupling
eﬀect that leads to unexpected results for some parameter regimes. For this reason
we restrict the use of this solver to fast diﬀusion where the use of the non-steady
state diﬀusion solver is impractical. For the parameters speciﬁed in Table 4.1
with changes only to ppp we see sensible results in line with the non-steady state
diﬀusion method.
In Section 4.5 where we had slower diﬀusion we found persistent health, persistent
disease and inducible disease. We ﬁnd that when we increase the diﬀusion (using
the fast diﬀusion parameters from Table 4.1) that the regions of persistent health
and inducible disease increase. The range of ppp for which we see inducible dis-
ease increases signiﬁcantly with the transition to persistent disease occurring at
approximately ppp = 1000 rather than 15. This ﬁnding is signiﬁcant as it suggests
that increasing the diﬀusion rate could transform the behaviour of the disease
from incurable to potentially curable (i.e. does not require ongoing treatment to
maintain low tissue degradation). It should be noted, however, that at the disease
state the rate of degradation is higher than when we have slower diﬀusion. Fig-
ure 4.18 shows time course plots of pro-inﬂammatory cytokine concentration and
ECM area for a simulation when ppp = 20. If we compare this with Figure 4.15
we can see that not only is the degradation more complete but the degradation is
approximately four times faster. This could have implications for the development
of therapies based on altering diﬀusion rates.
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(a) (b)
Figure 4.18: Plots showing behaviour when ppp = 20 for a fast diﬀusion rate.
Compared to Figures 4.15 and 4.17 the rate of tissue degradation is much faster,
however, with a larger diﬀusion rate the behaviour is of the inducible disease type
and hence potentially curable.
4.7 Discussion
In this chapter we have considered whether the spatial structure of cartilage tissue
is of importance to the dynamics of the biochemical networks in OA. We have de-
veloped a spatial model in which we have two main tissue types, chondrocytes and
ECM, along with bone and synovial ﬂuid, within the Compucell3D modelling envi-
ronment. By modelling in Compucell3D, which uses the Cellular Potts algorithm
on a lattice, we have been able to use a complex and realistic spatial structure of
chondrocytes spaced randomly through the ECM tissue. The modelling has shown
that in the spatial model we lose the concepts of monostable health, monostable
disease and multi-stability, which we saw in the ODE modelling (Chapter 3). This
is due in part to the stochastic nature of the model, but mainly to the continually
changing spatial domain. We do however have analogous behaviour types of per-
sistent health, persistent disease and inducible disease. It is possible that inducible
disease behaviour includes scenarios where there is more than one disease state,
but we have not found this in the parameter regimes we have considered.
Persistent health, analogous to monostable health, maintains background levels of
all biochemical species even after a stimulus. However, in the presence of a con-
tinual or regular stimulus damage to the ECM will occur. Clinically, radiographic
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evidence (i.e. x-ray images) of OA is seen in almost all individuals over the age of
30, however not all of these go on to develop symptomatic and ongoing OA. It is
possible then that this type of behaviour could explain those cases where evidence
of OA is seen, i.e. wear and tear due to mechanical or biochemical stimuli over
time, but OA does not develop. Persistent disease does not require any stimulus
to enter a disease state, even when starting in the absence of any cytokines, MMPs
or Fn-fs. Interestingly, our simulations suggest that for some parameter ranges,
the disease state is not uniform through the tissue and some chondrocytes remain
healthy. This behaviour depends of the diﬀusion rate with faster diﬀusion leading
to more uniform behaviour. Since OA tends to develop with old age, it is likely
that persistent disease only exists biologically if the parameters of the model, e.g.
production rates, are able to change with either time or disease advancement.
Given the changes that have been observed in OA, e.g. chondrocyte division and
increased numbers of receptors, this is likely to be the case. However this would
need to be studied in more detail.
Inducible disease requires a stimulus to move from a healthy state to disease. In
our simulations we induced a pro-inﬂammatory stimulus in all the chondrocytes,
leading to uniform disease behaviour. If the stimulus was conﬁned to a speciﬁc
area, the behaviour of the model would be less uniform. Inducible disease is
analogous to the multi-stable behaviours seen in the ODE model and oﬀers the
possibility of treatment leading to remission since we could move the system back
to health, as we discussed in detail in Chapter 3, in relation to the ODE model.
With the spatial model we can also better consider how the method of treatment
is likely to aﬀect outcome, although a more accurate realisation of the synovial
ﬂuid may be required.
The most important ﬁnding of this modelling has been the importance of diﬀusion
coeﬃcients to disease initiation and progression. The structure of the cartilage tis-
sue means that diﬀusion is key to intracellular communication. In the previous
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chapter, we theorised that increased diﬀusion could increase clearance of Fn-fs,
slowing disease progression. Here we also see that decreased diﬀusion halts in-
tracellular communication, which also slows disease progression. The possibility
of changing diﬀusion coeﬃcients as a therapy for OA is not seen in the currently
available literature, and it may not be possible to signiﬁcantly change coeﬃcients
in vivo. However, it may be that changes to cyclic loading could oﬀer a way of
increasing the eﬀective diﬀusion by increasing advection in the tissue. This could
be investigated as a way of slowing disease progression.
This modelling has showed that a spatial model introduces important parameters
that can not be considered in the ODE model, and gives a better disease measure
that is more easily compared to clinical measures. There are many diﬀerent di-
rections which we would like to explore by extending this model in future. One
important direction which would need signiﬁcant expansion is the inclusion of the
mechanical aspects of the joint in the model. This would allow us to consider both
mechanical damage and whether cyclic loading of the tissue could aﬀect transport
of biochemicals through the tissue. We would also like to consider coupling the
model with a model of cytokine dynamics in the synovial ﬂuid, to be a better
realisation of the cytokine dynamics through the whole joint. We have not fully
considered the eﬀect of stochasticity in this model, and this is something we could
consider further in future.
Overall, the spatial model has demonstrated that whilst the ODE modelling is
useful in considering the behaviour of the cartilage in osteoarthritis there are
several advantages to using a spatial model. The additional complexity, while
making interpretation more diﬃcult, allows us to consider further possibilities for
therapies.
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Binding interactions in cytokine
mediated STAT signalling
5.1 Introduction
A group of proteins involved in signal transduction for some cytokine networks
is a family of transcription factors called Signal Transducers and Activators of
Transcription (Stat) [77]. Stat proteins are uniquely able to take signals directly
from the cytokine receptors on the cell membrane to the DNA within the nucleus.
An example of how this occurs is described below. There are seven diﬀerent Stats
identiﬁed; they share similar structure but properties can vary quite signiﬁcantly,
particularly in relation to binding aﬃnities [78].
In this chapter we are particularly interested in Stat1 binding both alone and
in the presence of Stat3 dimers. Stat1 is activated by Interferon-γ (IFN-γ) as
part of the immune response. It is found in a wide range of mammalian cells and
is responsible for the regulation of over 200 diﬀerent genes. Activation of IFN-γ
receptors leads to tyrosine phosphorylation of Stat1 which then dimerises with
another Stat1 molecule and translocates to the nucleus. Tyrosine phosphorylation
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is the binding of a phosphate group to the tyrosine residue of the Stat1 molecule,
this process is described more fully in Chapter 1. Once in the nucleus the Stat1
dimers are able to bind to speciﬁc sequences of DNA and if the sequence is a
IFN-γ activated (GAS) site, transcription will occur [78]. Once bound to DNA,
Stat1 binds cooperatively with other Stat1 dimers at adjacent sites allowing it
to remain on DNA. Experimental results suggest that this cooperativity is vital to
Stat1 gene response. As well as binding to GAS sites the Stat protein may bind
to non-GAS sites where there is partial conservation of Stat protein sequence.
In this case the binding aﬃnity is low and the Stat is more likely to disassociate
than when it is bound to a GAS site [93]. The distribution of GAS sites in DNA
is not known precisely and distinction between GAS and non GAS site is unclear.
Figure 5.1: Schematic showing how STAT1 dimers bind to both GAS and non-
GAS sites on the DNA then cooperatively form dimers to remain.
Stat3 is activated by Interleukin-6 (IL-6) and like Stat1 will dimerise and translo-
cate to the nucleus. Stat3 is able to bind to the same sites as Stat1 since their
conformations are very similar. However, Stat3 binding to GAS sites will not
activate gene transcription. Stat3 is found mainly in dimer form but can rarely
form polymers [77].
One of our aims in this chapter is to comment on the importance of GAS site
position and binding strength to DNA binding and gene response. Early research
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into Stat1 suggested that adjacent GAS sites were required to facilitate poly-
merisation and nuclear retention. More recent research has shown that single
GAS sites are more abundant than these double sites, implying that having an
adjacent GAS site is not a necessity for retention. We aim to show with modelling
whether single GAS sites are suﬃcient for nuclear retention. We will also analyse
how the two Stat proteins, Stat1 and Stat3, with diﬀerent properties, co-exist
whilst competing for binding at the same sites. We develop here two models of
Stat binding, a cooperative binding model, and a competitive binding model.
5.2 Experimental Work
The importance of cooperativity to Stat1 gene expression has been demonstrated
using a Stat1 mutant cell line, F77A [11]. In this mutant an amino acid residue,
alanine, in the Stat1 N-domain is swapped for Phe77. Since cooperative bind-
ing occurs in the N-domain this inhibits cooperative binding. Figure 5.2a shows
a competition electrophoretic mobility shift assay (EMSA) experiment for both
F77A (KI) and wildtype Stat1 (ST). The plots show that for wildtype Stat1,
Stat1 dimers are mostly bound as tetramers (GAFx2) suggesting cooperative
binding is taking place. For F77A, Stat1 is bound mainly as dimers showing
that cooperative binding is inhibited. Stat1 only remains in the nucleus when
bound to DNA. Fluorescence recovery after photobleaching (FRAP) experiments
measuring nuclear mobility can be used to measure Stat1-DNA binding. This
involves making Stat1 molecules ﬂuoresce by attaching a ﬂuorescent tag, then
using light to bleach an area of the nucleus. Fluorescence is then measured as
the tagged Stat1 molecules move back into the bleached area giving a measure
of the mobility of Stat1. Figure 5.2b shows FRAP recovery times for both wild-
type and F77A Stat1. The mutant recovers quicker from bleaching than wildtype
suggesting that it is more mobile and not bound at tightly to the DNA. This com-
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bined with the results from Figure 5.2a show that inhibiting Stat1 cooperativity
impedes its ability to eﬀectively bind to DNA.
Figure 5.2: a) Adapted from Fig 1 in [11]. Competition EMSA with tandem GAS
sites stimulated with IFN-γ for 60 mins. The wildtype is bound as tetramers to
the DNA probe whilst the mutant is bound predominantly as dimers. b) Adapted
from Fig 3.15 in [6]. FRAP recovery curves for the F77A mutant and wildtype
Stat. The mutant recovers more quickly from photobleaching suggesting it is not
bound as tightly to the DNA.
We are concerned in this modelling with Stat1-DNA binding to both single and
tandem GAS sites. In [11] the authors discuss their experimental work with the
F77A mutant, which has shown that cooperativity is beneﬁcial at both single and
tandem GAS sites. Figure 5.3 gives an example of two genes, one at a single GAS
site and one at a tandem GAS site. In both cases gene expression is lost when
cooperativity is inhibited. The authors found this with many of the genes they
looked at. Additionally, they found that of the genes known to be activated by
Stat1, 85% of these were single GAS sites rather than tandem GAS sites.
Finally, we considered how Stat3 interacts with Stat1 and aﬀects gene expres-
sion. Figure 5.24 shows the gene expression of Stat1 after activation by IFN-γ.
In these experiments cell lines were stimulated with low levels of IFN-γ to produce
low concentrations of Stat1. The cells fell into three categories Stat3 KO, where
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Figure 5.3: Example of Stat recruitment to a genes with (a) tandem GAS sites
and (b) a single GAS site. These gels show that wildtype Stat1 binds to the gene
cooperatively in both cases. Adapted from [11].
no Stat3 was activated, IFN-γ stimulation only, resulting in a very low concen-
tration of Stat3 or IFN-γ and IL-6 stimulation, resulting in a high concentration
of activated Stat3. The gene response was recorded in each case and found to be
the same. All the cells were then boosted with high levels of IFN-γ, increasing the
Stat1 concentration. Stat1 High refers to Stat1 after additional boosting with
IFN-γ. When Stat1 is boosted to higher concentrations in the presence of Stat3,
the gene expression is much reduced which we theorise is due to Stat3 competing
for binding space with Stat1 [U. Vinkemeier, personal communication, 2013]. We
will test this with modelling.
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Figure 5.4: The gene expression of Stat1 with either no Stat3 (black) a low
amount of Stat3 through cross stimulation (grey) or high Stat3 (white) after
activation with IFN-γ and boosted with further IFN-γ to achieve higher Stat1
activation [U. Vinkemeier, personal communication 2013]. When we have low
Stat1 the presence of Stat3 makes no diﬀerence to Stat1 binding. At higher
concentrations of Stat1 the presence of Stat3 aﬀects Stat1 binding.
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5.3 Cooperative Binding Model
5.3.1 Model Rationale
In this model we consider free Stat1 dimers binding to promoter regions of DNA
(Figure 5.5).
Figure 5.5: Diagram showing binding of Stat1 dimers to DNA in the cooperative
binding model. Activated Stat1 dimers can bind to both the non-GAS DNA
binding sites (1) and the GAS DNA binding sites (2). Adjacent bound Stat1
dimers can then polymerise (3). Stat1 dimers bind to the GAS and non-GAS
sites with diﬀerent aﬃnities.
We produce three variations of the model with two, three and four binding sites.
The two-site model replicates the typical in vitro situation where, generally, two
binding sites are analysed. This may either be a double GAS site or a single GAS
site adjacent to a non-GAS site. We also use a symmetric single GAS site and
symmetric double GAS site model where we have either a single or double GAS
site with a non-GAS site at either side (Figure 5.6). These models are closer to
the in vivo situation where the GAS sites exist on the DNA strand.
Once bound to DNA, Stat1 dimers may form polymers with Stat1 dimers on
adjacent sites leading to the formation of tetramers and longer polymers. We
allow dimers to unbind from DNA and from each other. Polymer units cannot
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Figure 5.6: Diagram showing some of the binding possibilities in the symmetric
single and double GAS site models. Activated STAT1 dimers can bind to either
the central GAS binding sites or the non-GAS biding sites. This situation is more
biologically feasible than the typical experimental two-site model.
unbind from DNA without ﬁrst breaking down into dimers. The GAS sites have
diﬀerent binding rates to the non-GAS sites. We have three pairs of reaction rates,
each containing an on and oﬀ rate. These are Stat-DNA binding rates at the
GAS site, Stat-DNA binding rates at the non-GAS site and polymerisation rates
(Figure 5.7). We neglect spatial dynamics, nuclear cycling and degradation in this
model.
We model the system using mass action kinetics. The reactions for the two site
model are,
DNA00 + S1
KonG−−−−⇀↽ −
Koff
G
DNA10
DNA00 + S1
KonNG−−−−−⇀↽ −
Koff
NG
DNA01
DNA01 + S1
KonG−−−−⇀↽ −
Koff
G
DNA11
DNA10 + S1
KonNG−−−−−⇀↽ −
Koff
NG
DNA11
DNA11
KonP−−−−⇀↽ −
Koff
P
DNA1-1,
where S1 is the concentration of Stat1 dimers and the DNA sites are denoted
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Figure 5.7: Diagram showing model parameters used in all the cooperative binding
models. KGon and K
NG
on are the binding rates for STAT-DNA binding at GAS and
non-GAS sites, respectively. Similarly, KGoff and K
NG
off are the unbinding rates at
the GAS and non-GAS sites. KPon and K
P
off are the binding and unbinding rates
for bound STAT polymerisation reactions.
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DNAXX , where each subscript represents one of the sites of the DNA segment.
The subscripts may take the value 0 or 1, representing an unbound site or a Stat1
bound site. For example, DNA01 is a length of DNA with a Stat1 dimer bound to
site 2, the non-GAS site. Cooperative binding results in dimer-dimer bonds and
these are denoted by a dash (-). Hence DNA1−1, denotes a length of DNA with a
Stat1 tetramer bound.
The symmetric single GAS site model has fourteen variables, and eighteen re-
versible reactions, composed of 12 Stat1-DNA binding reactions and 6 polymeri-
sation reactions as follows:
DNA000 + S1
KonNG1−−−−−⇀↽ − DNA100
DNA000 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA010
DNA000 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA001
DNA100 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA110
DNA100 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA101
DNA010 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA110
DNA010 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA011
DNA001 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA101
DNA001 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA011
DNA110 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA111
DNA101 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA111
DNA011 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA111
DNA110
KonP1−−−−⇀↽ −
Koff
P1
DNA1−10
DNA011
KonP1−−−−⇀↽ −
Koff
P1
DNA01−1
DNA111
KonP1−−−−⇀↽ −
Koff
P1
DNA11−1
DNA111
KonP1−−−−⇀↽ −
Koff
P1
DNA1−11
DNA11−1
KonP1−−−−⇀↽ −
Koff
P1
DNA1−1−1
DNA1−11
KonP1−−−−⇀↽ −
Koff
P1
DNA1−1−1.
The symmetric double GAS site model has 32 reversible Stat-DNA binding re-
actions and 25 polymerisation reaction, which are listed in Appendix B. We use
Copasi [62] to generate ODEs from these reactions and to simulate the three sys-
tems. Algebraic analysis of these models is not practical due to the number of
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Parameter or variable Initial Conditions
DNA00, DNA000 & DNA0000 0.1nM
S1 varies
Kon
G1 2x1010M−1s−1
Koff
G1 100s−1
Kon
NG1 2x1010M−1s−1
Koff
NG1 varies
Koff
P 100s−1
Kon
P 1000-60000s−1
Resulting dissociation constants
KGd 5x10−9M
KNGd varies
KPd (high) 0.0017-0.1
Table 5.1: Parameter variations and initial conditions in cooperative binding mod-
els
variables.
In the simulations to follow we vary KPon, K
NG
off and the initial Stat1 concen-
tration. The other parameters and initial conditions are ﬁxed (summarised in
Table 5.1). We start the simulations with only unbound DNA promoter frag-
ments, at a concentration of 0.1nM , and free STAT1 dimers, whose concentration
was varied in each simulation. The STAT-DNA binding rate used at the GAS
sites is 2x1010M−1s−1 and the unbinding rate is 100s−1. This gives the disso-
ciation constant a value of 5x10−9M, in line with experimental results [1]. The
STAT-DNA binding at the non-GAS sites retain the same on-rate as the GAS site,
2x1010M−1s−1. The polymerisation rate parameters are set to either high or low
cooperativity, with a 60-fold diﬀerence between the two groups in line with the
diﬀerence between the polymerisation rates of wild-type STAT1 and mutant with
a truncated N-domain [127]. The oﬀ-rate in both cases is 100s−1 and the on-rate
is 1000s−1 in the low cooperativity case and 60000s−1 in the high cooperativity
187
Chapter 5: Binding interactions in cytokine mediated STAT
signalling
case.
In order to make comparison with experimental results we use several results
measures. The main measure we use is fractional GAS site occupancy, which we
believe to be proportional to gene response. In the two site and single GAS site
model this is the proportion of the DNA with the GAS site occupied by Stat1.
Since the double GAS site model is symmetric, the fractional GAS site occupancy
at each GAS site is identical. Hence, we can measure the results at either site. We
also break this down by concentration of dimers and larger polymers, since some
experimental methods are able to diﬀerentiate them by molecular weight.
5.3.2 Model Simulations
We know from experimental work that Stat1 binds well to DNA and is bound
both as dimers and polymers [1]. When cooperative binding is inhibited, via
mutation of the N-domain of the protein, DNA binding is much reduced [6]. We
can replicate this mutant in the model by reducing the polymerisation on-rate.
Experimental work suggests a 60-fold diﬀerence between wildtype and mutant
binding rates [U Vinkemeier, personal communication 2013]. Figure 5.8 shows a
time course simulation for the two site model with high cooperativity and low
cooperativity, with a 60-fold diﬀerence in the polymerisation on rate. The Stat-
DNA binding rates are the same on both sites, representing a double GAS site.
Here we see that fractional GAS site occupancy is reduced from 1 to approximately
0.35 by the altered polymerisation rate. This is in line with experimental results
that showed a reduction in nuclear mobility of Stat1 in the mutant compared to
wildtype (see Figure 5.2b) [6].
For these simulations we assume a ﬁxed initial Stat1 concentration and a double
GAS site. It is likely that the Stat1 response, and therefore concentration, varies
both between cells and with diﬀerent stimuli. We also know that there are many
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Figure 5.8: Time course simulation of free Stat1 binding to DNA in double GAS
site (two site) cooperative model. When cooperativity is inhibited the fractional
occupancy of the GAS site is much reduced. We set KonP = 60000s−1 where
we have cooperativity and KonP = 1000s−1 to inhibit cooperativity. (KonG =
Kon
NG = 2x1010M−1s−1,KoffG = KoffNG = 100s−1,KoffP = 100s−1)
functional single GAS sites with a non-GAS site adjacent. A typical diﬀerence
between the binding rate of a GAS and non-GAS site is 50-fold [11] so we simulated
the model with this diﬀerence for a range of initial Stat1 concentrations. Figure
5.9 shows the single GAS site simulations compared to a double GAS site in
the two site model. We can see that a single GAS site, as might be expected,
will attain less GAS site occupancy than the double GAS site for a given Stat1
concentration. However, we can also see that for any particular level of GAS site
occupancy for the double GAS site, the same level can be achieved at the single
GAS site, with a higher Stat1 concentration.
The two site model artiﬁcially limits the length of polymers to tetramers or smaller
there is no biological reason or evidence that longer polymers do not form. For
this reason it is more useful to consider the single or double GAS sites as part of a
longer chain, and for this we use the single GAS site model in a three-site chain and
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Figure 5.9: Plot of fractional GAS site occupancy against initial free STAT1
concentration for both single and double gas sites in the two site model. The plot
shows that single GAS sites can attain the same occupancy as double GAS site but
requires a greater Stat1 concentration. We set KonP = 60000s−1 where we have
cooperativity and KonP = 1000s−1 to inhibit cooperativity. In the single GAS
site simulations KoffNG = 5000s−1; in the double GAS site simulation KoffNG =
100s−1. (KonG = KonNG = 2x1010M−1s−1, KoffG = 100s−1, KoffP = 100s−1)
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the double GAS site model in a four-site chain. Repeating the previous simulations
in these models we see that the same behaviour is observed (Figure 5.10). Here for
a GAS site occupancy of either 90% or 99% in the single site model we required
roughly a three-fold increase in the initial Stat1 concentration compared to the
double GAS site model, regardless of whether we have cooperativity (Figure 5.11a).
Figure 5.10: Plot of fractional GAS site occupancy against initial free STAT1
concentration for both the symmetric single and symmetric double gas site models.
The plot shows that single GAS sites can attain the same occupancy as double
GAS site but requires a greater Stat1 concentration. We set KonP = 60000s−1
where we have cooperativity and KonP = 1000s−1 to inhibit cooperativity. In the
single GAS site simulations KoffNG = 5000s−1; in the double GAS site simulation
Koff
NG = 100s−1. (KonG = KonNG = 2x1010M−1s−1, KoffG = 100s−1, KoffP =
100s−1)
Figure 5.11b, based on the data in Figure 5.10, also shows that the loss of cooper-
ativity would necessitate an 9-fold increase in Stat1 to reach the 90% occupancy
level. If a 99% occupancy level is required then the reduction in cooperativity
would require a 13-fold increase at the single gas site and a 22-fold increase at the
double GAS site.
In experimental models, boosting of Stat1 concentration by increasing the stim-
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(a) (b)
Figure 5.11: Plot of relative increasing in concentration required to compensate
for: (a) the presence of only a single GAS site rather than a double GAS site
with and without cooperativity at both 90% and 99% fractional GAS site oc-
cupancy; (b)the loss of cooperativity, at both 90% and 99% fractional GAS site
occupancy for both the symmetric single and symmetric double gas site models
We set KonP = 60000s−1 where we have cooperativity and KonP = 1000s−1 to
inhibit cooperativity. In the single GAS site simulations KoffNG = 5000s−1; in the
double GAS site simulation KoffNG = 100s−1. (KonG = KonNG = 2x1010M−1s−1,
Koff
G = 100s−1, KoffP = 100s−1)
ulus can achieve up to approximately a three-fold increase. If this is indicative of
the range of variation of Stat1 levels we may see in vivo, it implies two conclu-
sions. Firstly, that double GAS sites are not required for eﬀective gene response,
since single GAS sites can achieve the same levels of occupancy, within the range
of activated Stat1 concentrations we may achieve with boosting. Secondly, that
cooperativity is essential to gene response, since to achieve the required levels of
GAS site occupancy without cooperativity would require unrealistically high levels
of activated Stat1.
The ﬁnal source of natural variation that we consider is the strength of the non-
GAS site compared to the GAS site. The non-GAS site in vivo will vary in
the number of matching base pairs, and less matching base pairs leads to lower
aﬃnity. Hence, the aﬃnity of this site will vary for diﬀerent genes. The diﬀerence
in KNGoff between the GAS and non-GAS sites could be as much as 200-fold [U
Vinkemeier, personal communication 2013]. Figure 5.12 shows the fractional GAS
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site occupancy against initial Stat1 concentration for a range of diﬀerent non-
GAS site binding strengths relative to the GAS site binding strength in both the
single and double GAS site models. As the non-GAS site binding rate gets weaker
in the single GAS site model the fractional GAS site occupancy reduces quite
signiﬁcantly. In the double GAS site model, the reduction in binding strength of
the non-GAS sites has much less eﬀect; presumably the tetramerisation on the
GAS sites is suﬃcient to retain the GAS site occupancy. In the single site case,
the strength of the surrounding sites is much more important.
(a) (b)
Figure 5.12: Plot of fractional GAS site occupancy against initial free STAT1
concentration for diﬀering strengths of non-GAS site binding in the (a) single
symmetric and (b) double symmetric GAS site models. The plots shows that in
the single GAS site model GAS site occupancy reduces much more with increasing
diﬀerence between GAS and non-GAS binding strength than in the double GAS
site case. (KonP = 60000s−1, KoffP = 100s−1, KonG = KonNG = 2x1010M−1s−1,
Koff
G = 100s−1)
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5.4 Competitive Binding Model
5.4.1 Model Rationale
In the competitive binding model we extend the previous model to consider an
additional species of Stat protein, Stat3. Stat1 behaves exactly as in the simpler
model. Stat3, however, does not polymerise as readily. We therefore consider two
scenarios (i) no cooperative binding of Stat3 (also comparable to a Stat mutant
with cooperative binding inhibited) and (ii) a small amount of Stat3 cooperative
binding compared to Stat1. We have Stat3-DNA binding on- and oﬀ- rates for
both GAS and non-GAS sites and Stat3 polymerisation on- and oﬀ rates which
are minimal. Stat1 and Stat3 may bind to adjacent DNA sites, but cannot bind
with each other. We consider three diﬀerent lengths of DNA segment: two, three
and four (Figure 5.13). The reactions for each of these DNA lengths are listed in
Appendix B.
We refer to Stat1 homodimers as S1 and Stat3 homodimers as S3. The DNA
sites are denoted DNAXXX , where each subscript represents one of the sites of
the DNA segment. The subscripts may take the value 0, 1 or 3 representing
an unbound site, a Stat1 bound site or a Stat3 bound site respectively. For
example, DNA301, is a length of DNA with a Stat3 dimer bound to site 1 (from
left to right) and a Stat1 dimer bound to site 3. Cooperative binding results in
dimer-dimer bonds and these are denoted by a dash (-) hence DNA1-10, denotes a
length of DNA with a Stat1 tetramer bound.
We have little data on binding rates for Stat3. We set the concentration of DNA,
and the GAS and non-GAS on-rates to 1, and make all other concentrations and
rates relative to these on-rates.
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Figure 5.13: Diagram showing binding of Stat1 and Stat3 dimers to DNA in the
competitive binding model. Activated Stat1 and Stat3 dimers can bind to the
DNA binding sites and polymerise although Stat1 polymerises more readily than
Stat3. Three variants of the model are considered, with 2, 3 or 4 binding sites.
The GAS site position in each case is highlighted.
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5.4.2 Model Simulations
The experimental data suggest that at high concentrations of Stat1 the presence
of Stat3 dimers should reduce the amount of Stat1 that is bound to the GAS
site, whilst at low concentrations of Stat1 we should not see this eﬀect (Figure
5.24b). We believe this to be due to the Stat3 dimers competing with Stat1 at
high concentrations to bind to DNA, hence interrupting the cooperative binding
of Stat1. If this is the case we should be able to ﬁnd parameters that demonstrate
this behaviour.
No cooperative Stat3 binding
We ran several simulations for diﬀerent initial concentrations of Stat1 and Stat3
using the two site model. In each simulation the fractional occupancy of the GAS
site by Stat1 was recorded at steady state and plotted against Stat1 concentra-
tion (Figure 5.14).
We consider four diﬀerent initial concentrations of Stat3. The simulation with
a low Stat3 concentration represents a situation where only IFN-γ pathways are
stimulated leading to activation of Stat1 and a small amount of Stat3 activa-
tion (Stat3 is known to be weakly activated by IFN-γ). As Stat1 concentration
increases the occupation of the GAS site increases up to a limit close to one. Simu-
lations with a higher Stat3 concentration (Stat3 mid and high) represent a situ-
ation where both the IFN-γ and the IL-6 pathways are stimulated leading to both
Stat1 and Stat3 activation. In this situation, when the Stat1 concentration is
low, the response is close to that seen for Stat3 low. As the Stat1 concentration
increases the response seen deviates from the response at lower Stat3 concentra-
tions, and the fractional occupation of the GAS site is lower. When the Stat3
concentration is zero (Stat3 KO) the response curve is very similar to Stat3 low.
However at high Stat1 concentrations the response is slightly higher. When the
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Figure 5.14: Plot of fractional occupation of the DNA GAS site against the initial
concentration of free Stat1. The values are taken at steady state. The parameter
values are: KG1off = 0.01; K
NG1
off = 0.1; K
G3
off = 0.0001; K
NG3
off = 0.001; K
P1
off =
0.001; KG1on = K
NG1
on = K
G3
on = K
NG3
on = K
P1
on = 1; K
P3
on = K
P3
off = 0
cooperative binding of Stat1 is turned oﬀ (KP1on = 0) but all other parameters
kept the same the levels of GAS site occupation are similar to when cooperativity
is on (Figure 5.15 compared to Figure 5.14), suggesting that if polymers cannot
form, the GAS sites become occupied by Stat1 dimers. This is not the case in
vivo, since without polymerisation gene response is much reduced [6]. Hence it is
likely that the parameters we use here are not of similar magnitudes to those in
vivo.
In order for the model display behaviour as seen in vivo, the disassociation rate
of Stat1 binding to DNA needs to be increased further, and we do this by in-
creasing the parameters KG1off and K
NG1
off . It is conventionally assumed that Stat3
and Stat1 dissociation constants are relatively similar, since their structure is so
similar. However, if we make Stat3 oﬀ rates the same as Stat1 oﬀ rates then
at steady state Stat1 dominates, since it is able to polymerise and we do not
see the results observed experimentally (Figure 5.16). Hence, we keep the Stat3
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Figure 5.15: Plot of Fractional occupation of the DNA GAS site against the
initial concentration of free Stat1. The values are taken at steady state. The
parameter values are: KG1off = 0.01; K
NG1
off = 0.1; K
G3
off = 0.0001; K
NG3
off = 0.001;
KP1off = 0.001; K
G1
on = K
NG1
on = K
G3
on = K
NG3
on = 1; K
P1
on = K
P3
on = K
P3
off = 0
dissociation rate small.
Figure 5.17 shows that increasing the Stat1 dissociation rate and maintaining
the Stat3 rate lowers the GAS site occupation when there is no cooperativity
as required (Figure 5.17a). An undesirable eﬀect of this rate change is that the
diﬀerences between diﬀerent concentrations of Stat3 is greater even at low con-
centrations of Stat1 (Figure 5.17b).
We now look at increasing the number of DNA sites, and hence the maximum
length of Stat1 polymers. Using the same rate parameters as in the two-site model
and increasing the Stat1 and Stat3 concentrations proportionally to account for
the additional DNA binding sites, the results (Figure 5.18) can be compared with
Figure 5.17a and look quite similar.
However, with three sites we can consider higher concentrations of Stat3 (Figure
5.19), which will give a larger decrease in occupancy at higher Stat1 concentra-
tion. In the two site model, these larger concentrations resulted in large diﬀerences
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Figure 5.16: Plot of Fractional occupation of the DNA GAS site against the
initial concentration of free Stat1, with no cooperative binding and larger Stat-
DNA binding oﬀ rates compared to Figure 5.15. The values are taken at steady
state. The parameter values are: KG1off = 2; K
NG1
off = 20; K
G3
off = 2; K
NG3
off = 20;
KP1off = 0.001; K
G1
on = K
NG1
on = K
G3
on = K
NG3
on = K
P1
on = 1; K
P3
on = K
P3
off = 0
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(a)
(b)
Figure 5.17: Plot of Fractional occupation of the DNA GAS site against the initial
concentration of free Stat1, with and without cooperative binding. The values
are taken at steady state. a) KP1on = 1 b) K
P1
on = 0. (The other parameter values
are: KG1off = 2; K
NG1
off = 20; K
G3
off = 0.0001; K
NG3
off = 0.001; K
P1
off = 0.001;
KG1on = K
NG1
on = K
G3
on = K
NG3
on = 1; K
P3
on = K
P3
off = 0)
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Figure 5.18: Plot of Fractional occupation of the DNA GAS site against the
initial concentration of free Stat1 in the three site model. The values are taken
at steady state. The parameter values are: KG1off = 2; K
NG1
off = 20; K
G3
off = 0.0001;
KNG3off = 0.001; K
P1
off = 0.001; K
G1
on = K
NG1
on = K
G3
on = K
NG3
on = 1; K
P1
on = 1;
KP3on = K
P3
off = 0
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in occupancy at lower concentrations also. The diﬀerence in occupancy at lower
concentrations in the three site model is still greater than the experimental results
suggest (experimental results suggested the occupancy was unchanged), which
may point to there being some level of Stat3 polymerisation, as discussed in the
next section.
Figure 5.19: Plot of Fractional occupation of the DNA GAS site against the
initial concentration of free Stat1 in the three site model. The values are taken
at steady state. The parameter values are: KG1off = 2; K
NG1
off = 20; K
G3
off = 0.0001;
KNG3off = 0.001; K
P1
off = 0.001; K
G1
on = K
NG1
on = K
G3
on = K
NG3
on = 1; K
P1
on = 1;
KP3on = K
P3
off = 0
If we extend the model to four sites and again increase the Stat1 and Stat3
concentrations to account for the additional DNA binding site, the results (Figure
5.20) can be compared with Figure 5.18 and follow the same trend. With higher
concentrations of Stat3, Figure 5.21 can be compared with Figure 5.19 in the
three site model. These results show that the addition of another site increases
the diﬀerence in GAS site occupancy at higher Stat1 concentrations, but also
has a large eﬀect on the diﬀerence at lower concentrations. Additionally at higher
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Stat3 concentrations the shape of the curve as Stat1 is increased also starts to
become sigmoidal, as the Stat3 concentration relative to Stat1 concentration
increases.
Figure 5.20: Plot of fractional occupation of the DNA GAS site against the initial
concentration of free Stat1 in the four site model. The values are taken at steady
state. The parameter values are: KG1off = 2; K
NG1
off = 20; K
G3
off = 0.0001; K
NG3
off =
0.001; KP1off = 0.001; K
G1
on = K
NG1
on = K
G3
on = K
NG3
on = 1; K
P1
on = 1; K
P3
on = K
P3
off =
0
So far the results have shown that introduction of Stat3 dimers does aﬀect the
fractional occupancy of GAS sites by Stat1, due to reducing the amount of Stat1
cooperative binding. We have also shown that this has a much greater eﬀect
at higher Stat1 concentrations than at lower concentrations where there is less
competition for binding sites. However, the reduction in occupancy that we see at
lower Stat1 concentrations is still of greater magnitude than experimental results.
This may be due the assumption we have made that there is no cooperative binding
of Stat3. Cooperative binding of Stat3 would increase the time that Stat3
remains on DNA and so could potentially account for this discrepancy. In the
next section we assume a small amount of Stat3 cooperative binding.
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Figure 5.21: Plot of fractional occupation of the DNA GAS site against the initial
concentration of free Stat1 in the four site model. The values are taken at steady
state. The parameter values are: KG1off = 2; K
NG1
off = 20; K
G3
off = 0.0001; K
NG3
off =
0.001; KP1off = 0.001; K
G1
on = K
NG1
on = K
G3
on = K
NG3
on = 1; K
P1
on = 1; K
P3
on = K
P3
off =
0
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Minimal cooperative Stat3 binding
The simulations from the previous section were repeated with the addition of a
small amount of cooperative Stat3 binding. The results for the two site model
(Figure 5.22) show that this increases the fractional occupation of the GAS site by
Stat1 slightly, decreasing the eﬀect seen in Figure 5.17a. Whilst this may seem
counterintuitive, a close look at the diﬀerences in each variable provides the reason
for this result. With no cooperative binding of Stat3, the Stat3 molecules are
free to move on and oﬀ the DNA and spend a proportion of the time bound to
DNA with an adjacent Stat1 molecule which restricts polymerisation of Stat1.
With the addition of cooperative binding of Stat3, the free Stat3 molecules are
more likely to become tightly bound to the DNA in the form of Stat3 tetramers.
Hence there are less Stat1-Stat3 bound DNA sites, increasing the opportunities
for Stat1 cooperative binding since there are more unbound double DNA sites.
Importantly, at lower Stat1 concentrations, the curves of Fig 5.22 are pulled
closer together, and resemble more closely the response we see in the experimental
results. This is quite subtle in the two site model but more obvious as the number
of sites increases.
Adding cooperative binding of Stat3 into the three site model (Figure 5.23), we
see these properties are displayed here as well. The curves are pulled together at
low Stat1 concentrations and pulled up slightly at higher Stat1 concentrations
compared to the situation when we have no cooperative Stat3 binding. However,
since the reduction in fractional occupancy between low and high Stat3 is greater
in the three site model, this increase less pronounced.
If we compare the results from this model to the experimental results (Figure 5.24)
we now see that this model can explain the results gained from the experimental
work.
Continuing to the four site model (Figure 5.25), again we get the same eﬀect,
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Figure 5.22: Plot of fractional occupation of the DNA GAS site against the initial
concentration of free Stat1, with cooperative binding of both Stat1 and Stat3.
The values are taken at steady state. The parameter values are: KG1off = 2;
KNG1off = 20; K
G3
off = 0.0001; K
NG3
off = 0.001; K
P1
off = 0.001; K
P3
off = 0.01; K
G1
on =
KNG1on = K
G3
on = K
NG3
on = 1; K
P1
on = K
P3
on = 1
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Figure 5.23: Plot of fractional occupation of the DNA GAS site against the initial
concentration of free Stat1, with cooperative binding of both Stat1 and Stat3.
The values are taken at steady state. The parameter values are: KG1off = 2;
KNG1off = 20; K
G3
off = 0.0001; K
NG3
off = 0.001; K
P1
off = 0.001; K
P3
off = 0.01; K
G1
on =
KNG1on = K
G3
on = K
NG3
on = K
P1
on = K
P3
on = 1
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Figure 5.24: a)Plot of fractional occupation of the DNA GAS site against a low
and high concentration of Stat1 for three diﬀerent Stat3 concentration, with
cooperative binding of both Stat types. (Parameters as in Figure 5.23). b) Plot
of experimental results.
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however this time the diﬀerence achieved in moving from three to four sites is
minimal. This is likely to be due to the fact that the binding of polymers involving
a GAS site is more important than binding to a non-GAS site, and the four-site
model only allows additional non-GAS site bonds.
Figure 5.25: Plot of fractional occupation of the DNA GAS site against the initial
concentration of free Stat1, with cooperative binding of both Stat1 and Stat3.
The values are taken at steady state. The parameter values are: KG1off = 2;
KNG1off = 20; K
G3
off = 0.0001; K
NG3
off = 0.001; K
P1
off = 0.001; K
P3
off = 0.01; K
G1
on =
KNG1on = K
G3
on = K
NG3
on = K
P1
on = K
P3
on = 1
So far we have looked at a narrow range of parameters that display the behaviours
similar to those seen in vitro. We have found that the Stat-DNA binding of Stat3
must be much stronger than the Stat-DNA binding of Stat1. Another possible
explanation of the experimental results is that Stat1 will only initiate a gene
response if a tetramer is bound to the binding sites. We will consider this scenario
in the next section as we look at a wider parameter range.
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Parameter Exploration
Since Stat1 and Stat3 both actively stimulate transcription of genes, we expect
there must be conditions which allow Stat1 and Stat3 to both be bound on the
DNA. The binding rates may vary from site to site. We will look at how changes
in the parameters in the model aﬀect the binding of both these proteins. We
will ﬁrst at the two-site model in which only Stat1 is able to bind cooperatively.
We will initially set the GAS and non-GAS binding rates to be the same. In the
case of Stat1 we will now consider the gene response to be proportional to the
tetramer concentration. For Stat3 we will consider the gene response to be the
concentration of Stat3 bound to the ﬁrst DNA site regardless of what is bound
to the second site.
We set the DNA binding rate parameters to be the same and start with equal
concentrations of Stat1 and Stat3. Figure 5.26a shows that increasing the co-
operativity of Stat1 is beneﬁcial to the cooperative binder since it results in
a greater gene response across all DNA binding rates. For the non-cooperative
binder (Stat3), cooperativity of a competitor is detrimental to gene response,
Figure 5.26b.
There are two ways in which the concentration can be increased, either increasing
the total concentration whilst keeping the Stat1:Stat3 ratio the same or changing
the relative concentrations. Figure 5.27 shows the eﬀect of increasing the total
initial concentration of free STAT dimers. At low binding strengths, increasing
the concentration is marginally beneﬁcial to both Stat1 and Stat3, since there
is little competition for DNA sites. As the DNA binding strength increases the
higher concentrations are still beneﬁcial to the cooperative binder, but become
detrimental to the non-cooperative binder.
We now keep the total concentration the same and change the Stat1:Stat3 ratio,
Figure 5.28. As might be expected, Stat1 is at an advantage when its concentra-
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Figure 5.26: Plots of Stat1 and Stat3 gene response against the DNA binding
strength (DNA on rate / DNA oﬀ rate) for three increasing levels of Stat1
cooperativity. The cooperativity binding strengths (KP1on /K
P1
off ) are 1000 (Strong),
10 (Moderate) and 1 (Weak). The initial conditions are S1=3, S3=3, DNA00=1.
The values are taken at steady state.
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Figure 5.27: Plots of Stat1 and Stat3 gene response against the DNA binding
strength (DNA on rate / DNA oﬀ rate) for increasing initial concentrations of
Stat1 and Stat3. The cooperativity binding strength in all cases is 10. The
values are taken at steady state.
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Figure 5.28: Plots of Stat1 and Stat3 gene response against the DNA binding
strength (DNA on rate / DNA oﬀ rate) for diﬀerent proportions of Stat1 and
Stat3. The cooperativity binding strength in all cases is 10. The values are taken
at steady state.
tion is dominant and similarly for Stat3.
The two types of Stat proteins elicit the greatest gene response in diﬀerent en-
vironments. The cooperative Stat, works best in high concentrations, regardless
of the concentration of non-cooperative Stat. However, if the concentration of
the non-cooperative binder is low this increases the gene response further. The
non-cooperative Stat gene response is more dependent on the concentration of
the cooperative binder. The gene response is greatest where this is low. Where the
DNA binding strength is low this relationship is slightly changed since increasing
the concentration of both Stats is beneﬁcial to Stat3, however increasing Stat3
concentration whilst keeping Stat1 low results in a greater gene response.
So far we have considered only situations where the DNA binding strength of the
two Stat competitors is similar. Whilst we expect that generally the binding
strength will be of similar order, natural variation does exist, particularly on sub-
optimal sites where conservation of the genetic code is lower. We will now look
at situations where either Stat1 or Stat3 have higher binding rates. Trends in
the data show that the order of diﬀerence in the two binding rates is important in
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determining the gene response. When the Stat3-DNA binding strength is larger
than the Stat1 DNA binding strength the Stat1 gene response is much reduced
(Figure 5.29).
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Figure 5.29: Plot of Stat1 gene response against the DNA binding strengths
(DNA on rate / DNA oﬀ rate) of Stat1 and Stat3. The cooperativity binding
strength in all cases is 10 and the initial conditions are S1=3, S3=3, DNA00=1.
The values are taken at steady state.
Similarly, if the Stat1 DNA binding strength is larger than the Stat3 DNA
binding strength the Stat3 gene response is much reduced (Figure 5.30). This
agrees with the results from Section 5.4.2 which shows that when the binding rates
are diﬀerent Stat1 gene response is reduced in the presence of Stat3.
So far in this section we have kept the DNA binding rates the same on both sites
i.e. treating them as tandem GAS sites. As mentioned previously, aﬃnity varies
between sites and it is likely that the high aﬃnity GAS site is next to a site of
lower aﬃnity, since double GAS sites are rare. Figure 5.31 shows the eﬀect that
diﬀering site aﬃnity has on Stat1 gene response.
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Figure 5.30: Plot of Stat3 gene response against the DNA binding strengths
(DNA on rate / DNA oﬀ rate) of Stat1 and Stat3. The cooperativity binding
strength in all cases is 10 and the initial conditions are S1=3, S3=3, DNA00=1.
The values are taken at steady state.
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Figure 5.31: Plot of Stat1 gene response against the DNA binding strengths
(DNA on rate / DNA oﬀ rate) of GAS and non-GAS sites. Here the DNA binding
strength of Stat1 and Stat3 are equal. The cooperativity binding strength is 10
and the initial conditions are S1=3, S3=3, DNA00=1. The values are taken at
steady state.
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The gene response is greatest when the DNA binding strength to either site is
greater than the cooperativity strength. As the binding strength to either site
decreases the gene response goes down. In the case of Stat3 gene response (Fig-
ure 5.32), if the non GAS site binding strength is greater than the cooperativity
strength, then the gene response is at a maximum for strong GAS site binding
and decreases as the binding strength decreases.
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Figure 5.32: Plot of Stat3 gene response against the DNA binding strengths
(DNA on rate / DNA oﬀ rate) of GAS and non-GAS sites. Here the DNA binding
strength of Stat1 and Stat3 are equal. The cooperativity binding strength is 10
and the initial conditions are S1=3, S3=3, DNA00=1. The values are taken at
steady state.
However, unlike Stat1, when the non-GAS site binding strength is less than the
cooperativity binding strength, the gene response increases. Stat3 gene response
is less dependent on the non-GAS site than Stat1 so a low aﬃnity site is ad-
vantageous as it reduces Stat1's ability to compete as well as increasing the
concentration of free Stat3. This means that Stat1 is likely to be more eﬀective
where there are multiple high aﬃnity sites, whereas Stat3 appears to be better
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adapted to single high aﬃnity sites.
5.5 Discussion
In this chapter we have developed models of the binding of STAT transcription
factors to DNA. We have looked at Stat1 alone and in competition with Stat3.
With appropriate parameters this model can be generalised to any Stat protein.
We had four aims in this chapter. Firstly, we wanted to clarify the importance of
tandem GAS sites to Stat1 gene response. Secondly, we wanted to conﬁrm that
cooperativity increased DNA binding and suggest rates that allow this. Thirdly,
we wanted to show that Stat3 reduces the gene response of Stat1 by reducing
cooperative binding. Finally, we wanted to suggest conditions which favour each
of these species.
In Section 5.3 we showed that we could reproduce the results seen experimentally.
Namely, high fractional occupancy of the GAS site with cooperativity, and little
occupancy where cooperativity is blocked. We have shown that is it not necessary
to have double GAS sites for Stat-DNA binding. The amount of binding, even
to single GAS sites (those with poorly conserved neighbours), can be high given a
large enough Stat1 concentration. This ﬁnding supports recent research suggest-
ing that most of the Stat1 binding sites responsible for gene response are single
GAS sites. We also showed that in the absence of cooperativity, Stat1 cannot
eﬀectively bind to DNA.
In Section 5.4 we produced three models of competitive binding of Stat proteins,
each with a diﬀerent number of binding sites. If we consider the diﬀerence in
fractional occupancy of the GAS site by Stat1, between Stat3 at a high level and
Stat3 at low level, this diﬀerence increases as the number of DNA sites increases.
The change from three sites to four is less than that of two sites to three but
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this is expected since it does not involve additional GAS site binding. We would
expect this trend to continue up to a limit as the number of sites increases, since
as the length of the chain increases so does the probability of a bond in the chain
breaking resulting in two smaller polymers.
It has also emerged that with a small amount of Stat3 polymerisation the diﬀer-
ences in occupancy at lower Stat1 concentration is reduced. This eﬀect is most
signiﬁcant in the four site model, and is important in achieving results similar to
experimental results. This may suggest that Stat3 does form polymers on DNA
in vivo, albeit less frequently that Stat1. This also agrees with experimental work
that shows that Stat3 tetramers can form on GAS sites [6].
The models used here require Stat3 to have a smaller dissociation rate than
Stat1, and this is a restriction which has not been found experimentally. In
the simple models we have used here there appears not to be a way to achieve
competition between Stat1 and Stat3 where Stat1 is capable of cooperative
binding, without Stat3 having a smaller dissociation rate. This suggests that
either the dissociation rates in vivo are diﬀerent, as we have used here, or there
are more complex interactions involved than we have modelled here.
We propose here that although cooperativity may be necessary for Stat1 to bind
remain bound to DNA, double or tandem GAS sites are not required for this
cooperativity. However, under competitive conditions, such as the presence of
Stat3, tandem GAS sites are extremely beneﬁcial to Stat1. We believe that
Stat3 interferes with the cooperative binding of Stat1 when the concentration
of Stat1 creates competition for GAS sites. Although lack of cooperativity is
disadvantageous to Stat3, there are situations where it can bind well and co-exist
with Stat1. Namely, where we have only single high aﬃnity GAS sites, and where
Stat3 concentration greatly exceeds Stat1 concentration.
216
Chapter 6
Summary and Future Directions
Arthritic diseases aﬀect millions of individuals worldwide and cause signiﬁcant
pain, disability and loss of independence. As well as the large eﬀect this has on
the individual's quality of life it also places a large burden on health and social
services. Research into the pathobiology and treatment of these diseases is in the
relatively early stages and whilst disease modifying treatments are available in
some cases, most notably RA, there is not a full enough understanding of disease
dynamics to approach treatment systematically.
A range of cytokines have been observed to be raised in arthritic disease. Experi-
mental cell biology has shown that these cytokine pathways are important in the
mediation and progression of disease. However, the nature of the dynamics be-
tween cytokines, particularly in vivo, is still largely unclear. One of the reasons for
this is that the dynamics and the interactions of cytokines are diﬃcult to capture
experimentally, in part due to their short half-life. Therapies targeting cytokine
pathways in arthritic disease have been partially successful for RA, but for OA
have remained elusive. The purpose of this research has been to use mathemati-
cal modelling to clarify how diﬀerent cytokine groups interact in arthritic disease.
We have considered whether variations in cytokine production rate parameters
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could lead to arthritic disease and progression and whether the dynamics of the
cytokine interactions could identify treatment targets or strategies not previously
considered.
We initially looked at a two variable model of cytokine dynamics where we grouped
cytokines into pro- and anti-inﬂammatory groups (Chapter 2). We consider this to
be a feasible model for cytokine dynamics in the synovium and hence an appropri-
ate model for cytokine dynamics in RA. We found that the positive and negative
feedback mechanisms in this model lead to complex dynamics, with monostable,
bistable and oscillatory behaviours. We identiﬁed that where there is bistable
behaviour there is the possibility of inducing remission with an appropriate treat-
ment strategy. Eﬀective treatment was shown to depend not only on dose size but
also on dose timing and interval, and the optimum was not necessarily the high-
est dose over the shortest interval. We found that in some cases counter-intuitive
treatment strategies worked well, such as increasing dose interval or increasing the
concentration of pro-inﬂammatory cytokine. These types of treatment strategies
may not have been considered clinically, and oﬀer new opportunities for consider-
ation.
To make the model of the synovium applicable to the cartilage we extended it
to take into account two other major mediators of arthritic disease, MMPs and
ﬁbronectin fragments (Chapter 3). In this model we had two negative and two
positive feedback networks, giving rise to both monostable and multi-stable be-
haviour. In contrast to the two variable synovium model, we found that most
of the parameter space we explored contained disease states, which were either
monostable or bistable. This is in line with the higher prevalence of OA than RA.
We considered treatment targets for this extended model, and found that single
target therapies aimed at reducing pro-inﬂammatory cytokine or MMP concen-
trations were ineﬀective, a result also observed in clinical trials. Simulations of
therapies increasing anti-inﬂammatory cytokines were eﬀective but required large
218
Chapter 6: Summary and Future Directions
dose sizes. We found that combined target therapies were eﬀective both at induc-
ing remission in multi-stable cases, and slowing progression in monostable disease.
We suggested that increasing cytokine clearance rates, for example through exer-
cise, could be beneﬁcial as a complimentary therapy alongside other treatments.
To consider how the spatial structure of cartilage aﬀects the cytokine dynamics
that we had observed in the ODE models we developed a spatial model of carti-
lage in the Compucell3D modelling environment (Chapter 4). This allowed us to
model the diﬀusion of cytokines between chondrocytes and through the tissue, and
therefore investigate how chondrocyte spacing and diﬀusion rates aﬀects the dy-
namics. We found that with slow diﬀusion the cells were less able to communicate
(through cytokine signalling) and hence displayed less uniform behaviour. This
resulted in some chondrocytes secreting only low levels of cytokines (and therefore
considered healthy) whilst others secreted higher levels of cytokines (considered to
be a pathological response). When the diﬀusion rate was faster the behaviour of
the cells was more uniform. It is possible that this behaviour could be exploited to
optimise treatments, for example increasing diﬀusion or advection so that treat-
ments delivered to one area of cartilage would result in a tissue-wide response, or
decreasing diﬀusion so that disease type behaviour is isolated in small areas of the
tissue. This type of treatment strategy may be worthy of further modelling and
consideration.
Whilst we have mainly focused on cytokine dynamics in this work, the pathway
from signalling to cartilage degradation is much more complex with many down-
stream signalling factors. As with cytokines the dynamics of many of these factors
are not yet fully understood. We have looked at one example of these downstream
signalling factors, the Stat family of transcription factors (Chapter 5). In col-
laboration with experimentalists, we have considered a speciﬁc aspect of Stat
proteins, the binding of Stat dimers to DNA. We were able to show that cooper-
ativity between bound Stat1 dimers decreased the mobility of Stat1 even where
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when there was a single high aﬃnity site (GAS sites). We also showed that the
presence of Stat3 interfered with the ability of Stat1 to bind cooperatively at
high concentrations due to competition for binding sites. These ﬁndings helped to
support the ﬁndings of the experimental work. This work also demonstrated that
whilst we focus on cytokine dynamics in relation to OA initiation and progression,
there are many other aspects of cartilage remodelling and degradation that could
impact the condition.
Modelling of cytokines in terms of arthritic disease is a novel research area and
the models in this thesis have shown conceptually that such models can repli-
cate some of features of the behaviour seen in vivo and hence give insight into
treatment strategies. However, this work is at a very early stage and reﬁnement is
needed for these models. The simplest two-variable model oﬀers some insights into
treatment of RA, but to be able to translate this into clinical practice we would
need to be able to link the model parameters to measurable disease markers in
individuals. Although in this work we have considered this model in the context of
cytokine interactions in the synovium, cytokines are used throughout the body. It
is entirely possible that this model could be applied to a range of conditions where
cytokines play a role, with model extensions such as those used for OA applied
where necessary. Conditions such as asthma, eczema, diabetes and lupus are all
known to have some level of cytokine involvement.
The four-variable cartilage model concentrates on what we consider the four most
important variables in cartilage degradation. However there are other important
factors that could be considered such as nitric oxide and Prostaglandin E2, which
have been shown to play a role in cartilage breakdown [5]. The spatial model of
cartilage degradation should be expanded to consider the aﬀects of the mechan-
ical properties of the tissue. This needs to be considered at the tissue level, for
example, the diﬀering chondrocyte densities, material properties and proximity to
bone in diﬀerent cartilage zones may aﬀect how the tissue responds to treatment.
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Additionally, the mechanical properties of the tissue need, to be considered at
joint level, by including joint morphology and loading. Finite element modelling
would be an appropriate methodology to use to include these joint level extensions.
The current model could also be extended to include a more accurate representa-
tion of synovial ﬂuid and bone, which would enable the theoretical aspect of drug
placement to be considered.
This work has demonstrated that mathematical models of arthritis disease could
help to guide experimental research into treatment strategies and give a greater
understanding of the disease dynamics. Future research with collaboration with
both cell biologists and clinicians has the potential to make progress in our under-
standing of OA, leading to the development of disease modifying therapies, that
could transform the experiences of individuals with this debilitating condition.
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Appendix A
Hill Coeﬃcients in the Pro- and
anti-inﬂammatory cytokine model
So far we have taken all the Hill coeﬃcients (m1, m2 and m3) to be 2. In this
section we will justify this choice by examining the some other possibilities and
considering the eﬀect these would have on the model.
dp
dt
= −γpp+ 1
1 + am2
(
Pbp + Ppp
pm1
1 + pm1
)
(A.0.1)
da
dt
= −a+ App p
m3
Aph + pm3
(A.0.2)
The Hill coeﬃcients from the functions φ(p)ψ(p) and θ(a) also appear in the
nondimensionalised equations in the form of equations (A.0.1)-(A.0.2). There
are three main alternatives to the assumption we have made, ﬁrstly that all the
coeﬃcients are the same but are some value greater than 2, secondly that all the
coeﬃcients are 1 or ﬁnally that we have some combination of diﬀerent coeﬃcients
for the diﬀerent terms in the model.
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Hill Coeﬃcients m1,m2,m3 > 2
For coeﬃcients greater than two the qualitative shape of the Hill function does
not change, only its steepness. This means that for m1,m2,m3 > 2 the nullclines
of the system will cross in a similar manner, and we expect qualitatively similar
behaviour, with the stability of the steady states and the types of bifurcations
unchanged. The only change we would expect is alterations in the parameters
values at which the various bifurcations occur.
Hill Coeﬃcient m1 = m2 = m3 = 1
Since the shape of the Hill function when the coeﬃcient is 1 is diﬀerent from when
it is greater than 1, the behaviour of the model is also likely to change. In this
situation, the model equations become,
dp
dt
= −γpp+ 1
1 + a
(
Pbp + Ppp
p
1 + p
)
, (A.0.3)
da
dt
= −a+ App p
Aph + p
, (A.0.4)
which gives the nullclines,
a = N1(p) =
Appp
Aph + p
a = N2(p) =
p(Pbp + Ppp) + Pbp
γpp(1 + p)
− 1.
As in the original model, N1 is monotonically increasing. However, now N2 is
monotonically decreasing in p and hence there can be no more than a single steady
state.
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Mixed Hill Coeﬃcients
So far we have only considered situations where all three Hill coeﬃcients are ≥ 2
or equal to 1, but the coeﬃcients are independent and could have diﬀerent values.
Since values greater than 2 behave the same as a value of 2, we only need to
consider combinations of 1 and 2. Also, if we look at the nullcline N1 it is a
monotonically increasing function regardless of the value of m3, so, we need only
look at two situations: m1 = 2, m2 = m3 = 1 and m1 = 1, m2 = 2, m3 = 1.
In the ﬁrst case, when m1 = 2, m2 = m3 = 1, N2 becomes
a = N2(p) =
p2(Pbp + Ppp) + Pbp
γpp(1 + p2)
− 1.
This two real, positive turning points, meaning that we can have either one or
three steady states. This exhibits similar behaviour to the original model except
that the steady states tend to occur at larger values of both p and a.
In the second case, when m1 = 1, m2 = 2 and m3 = 1, N2 becomes,
a = N2(p) =
√
f(p)
where
f(p) =
p(Pbp + Ppp) + Pbp
γpp(1 + p)
− 1.
f(p) is monotonically decreasing, so that N2 must also be monotonically decreas-
ing in the positive quadrant, and can cross N1 only once giving, exactly one
steady state. This situation is similar to the case when all the coeﬃcients are 1
and exhibits similar behaviour. Essentially, m1 must be greater than 1 to give
bifurcations and bistability in the model, i.e. strong feedback in p is required.
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Stat signalling model reactions
B.0.1 Cooperative Four Site Model
DNA0000 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA0001
DNA0000 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA0010
DNA0001 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA0011
DNA0010 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA0011
DNA0000 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA0100
DNA0100 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA0101
DNA0001 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA0101
DNA0010 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA0110
DNA0100 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA0110
DNA0011 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA0111
DNA1001 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1011
DNA1010 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1011
DNA1000 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA1100
DNA0100 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1100
DNA0101 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1101
DNA1001 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA1101
DNA1100 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1101
DNA0110 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1110
DNA1010 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA1110
DNA1100 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1110
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DNA0101 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA0111
DNA0110 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA0111
DNA0000 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1000
DNA0001 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1001
DNA1000 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1001
DNA1000 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1010
DNA0010 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1010
DNA0011 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1011
DNA011−1
KonP1−−−−⇀↽ −
Koff
P1
DNA01−1−1
DNA1100
KonP1−−−−⇀↽ −
Koff
P1
DNA1−100
DNA1101
KonP1−−−−⇀↽ −
Koff
P1
DNA1−101
DNA1110
KonP1−−−−⇀↽ −
Koff
P1
DNA1−110
DNA0111
KonP1−−−−⇀↽ −
Koff
P1
DNA01−11
DNA1110
KonP1−−−−⇀↽ −
Koff
P1
DNA11−10
DNA1−110
KonP1−−−−⇀↽ −
Koff
P1
DNA1−1−10
DNA11−10
KonP1−−−−⇀↽ −
Koff
P1
DNA1−1−10
DNA1111
KonP1−−−−⇀↽ −
Koff
P1
DNA1−111
DNA1111
KonP1−−−−⇀↽ −
Koff
P1
DNA11−11
DNA0111 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1111
DNA1011 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA1111
DNA1101 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1111
DNA1110 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1111
DNA0011
KonP1−−−−⇀↽ −
Koff
P1
DNA001−1
DNA0110
KonP1−−−−⇀↽ −
Koff
P1
DNA01−10
DNA0111
KonP1−−−−⇀↽ −
Koff
P1
DNA011−1
DNA01−11
KonP1−−−−⇀↽ −
Koff
P1
DNA01−1−1
DNA1111
KonP1−−−−⇀↽ −
Koff
P1
DNA111−1
DNA1−111
KonP1−−−−⇀↽ −
Koff
P1
DNA1−11−1
DNA111−1
KonP1−−−−⇀↽ −
Koff
P1
DNA1−11−1
DNA1−111
KonP1−−−−⇀↽ −
Koff
P1
DNA1−1−11
DNA11−11
KonP1−−−−⇀↽ −
Koff
P1
DNA1−1−11
DNA11−11
KonP1−−−−⇀↽ −
Koff
P1
DNA11−1−1
DNA111−1
KonP1−−−−⇀↽ −
Koff
P1
DNA11−1−1
DNA1−1−11
KonP1−−−−⇀↽ −
Koff
P1
DNA1−1−1−1
DNA1−11−1
KonP1−−−−⇀↽ −
Koff
P1
DNA1−1−1−1
DNA11−1−1
KonP1−−−−⇀↽ −
Koff
P1
DNA1−1−1−1
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B.0.2 Competitive Three Site Model
DNA000 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA100
DNA000 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA010
DNA000 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA001
DNA100 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA110
DNA100 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA101
DNA010 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA110
DNA010 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA011
DNA001 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA101
DNA001 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA011
DNA110 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA111
DNA101 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA111
DNA011 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA111
DNA000 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA300
DNA000 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA030
DNA000 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA003
DNA300 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA330
DNA300 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA303
DNA003 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA303
DNA030 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA330
DNA030 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA033
DNA003 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA033
DNA330 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA333
DNA303 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA333
DNA033 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA333
DNA300 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA310
DNA100 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA130
DNA300 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA301
DNA100 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA103
DNA030 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA130
DNA010 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA310
DNA030 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA031
DNA010 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA013
DNA003 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA103
DNA001 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA301
DNA003 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA013
DNA130 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA131
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DNA001 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA031
DNA310 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA311
DNA310 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA313
DNA130 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA133
DNA301 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA311
DNA301 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA331
DNA113
KonP1−−−−⇀↽ −
Koff
P1
DNA1−13
DNA110
KonP1−−−−⇀↽ −
Koff
P1
DNA1−10
DNA011
KonP1−−−−⇀↽ −
Koff
P1
DNA01−1
DNA111
KonP1−−−−⇀↽ −
Koff
P1
DNA11−1
DNA11−1
KonP1−−−−⇀↽ −
Koff
P1
DNA1−1−1
DNA1−11
KonP1−−−−⇀↽ −
Koff
P1
DNA1−1−1
DNA311
KonP1−−−−⇀↽ −
Koff
P1
DNA31−1
DNA111
KonP1−−−−⇀↽ −
Koff
P1
DNA1−11
DNA103 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA133
DNA103 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA113
DNA031 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA331
DNA031 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA131
DNA013 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA313
DNA013 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA113
DNA330
KonP3−−−−⇀↽ −
Koff
P3
DNA3−30
DNA033
KonP3−−−−⇀↽ −
Koff
P3
DNA03−3
DNA333
KonP3−−−−⇀↽ −
Koff
P3
DNA33−3
DNA333
KonP3−−−−⇀↽ −
Koff
P3
DNA3−33
DNA33−3
KonP3−−−−⇀↽ −
Koff
P3
DNA3−3−3
DNA3−33
KonP3−−−−⇀↽ −
Koff
P3
DNA3−3−3
DNA133
KonP3−−−−⇀↽ −
Koff
P3
DNA13−3
DNA331
KonP3−−−−⇀↽ −
Koff
P3
DNA3−31
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B.0.3 Competitive Four Site Model
DNA0000 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA0001
DNA0000 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA0010
DNA0001 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA0011
DNA0010 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA0011
DNA0003 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA0013
DNA0030 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA0031
DNA0000 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA0100
DNA0100 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA0101
DNA0001 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA0101
DNA0003 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA0103
DNA0010 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA0110
DNA0100 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA0110
DNA0011 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA0111
DNA0101 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA0111
DNA0110 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA0111
DNA0013 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA0113
DNA0103 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA0113
DNA0030 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA0130
DNA0130 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA0131
DNA0031 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA0131
DNA0033 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA0133
DNA0300 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA0301
DNA0300 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA0310
DNA0310 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA0311
DNA0301 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA0311
DNA0303 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA0313
DNA0330 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA0331
DNA0000 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1000
DNA0001 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1001
DNA1000 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1001
DNA0003 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1003
DNA1000 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1010
DNA0010 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1010
DNA0011 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1011
DNA1001 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1011
DNA1010 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1011
DNA0013 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1013
DNA1003 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1013
DNA0031 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1031
DNA0030 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1030
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DNA1030 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1031
DNA0033 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1033
DNA1000 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA1100
DNA0100 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1100
DNA0101 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1101
DNA1001 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA1101
DNA1100 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1101
DNA0103 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1103
DNA1003 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA1103
DNA0110 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1110
DNA1010 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA1110
DNA1100 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1110
DNA0111 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1111
DNA1011 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA1111
DNA1101 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1111
DNA1110 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1111
DNA0113 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1113
DNA1013 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA1113
DNA0130 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1130
DNA1103 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1113
DNA1030 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA1130
DNA0131 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1131
DNA1031 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA1131
DNA1130 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1131
DNA0133 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1133
DNA1033 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA1133
DNA0300 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1300
DNA0301 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1301
DNA1300 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1301
DNA0303 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1303
DNA0310 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1310
DNA1300 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1310
DNA0311 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1311
DNA1301 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1311
DNA1310 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1311
DNA0313 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1313
DNA1303 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1313
DNA0331 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1331
DNA0333 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1333
DNA1330 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1331
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DNA3000 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA3001
DNA3000 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA3010
DNA3001 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA3011
DNA3010 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA3011
DNA3003 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA3013
DNA3030 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA3031
DNA3000 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA3100
DNA3001 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA3101
DNA3100 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA3101
DNA3003 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA3103
DNA3010 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA3110
DNA3100 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA3110
DNA3011 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA3111
DNA3101 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA3111
DNA3110 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA3111
DNA3013 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA3113
DNA3103 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA3113
DNA3030 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA3130
DNA3130 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA3131
DNA3031 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA3131
DNA3033 + S1
KonG1−−−−⇀↽ −
Koff
G1
DNA3133
DNA3300 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA3301
DNA3300 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA3310
DNA3301 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA3311
DNA3310 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA3311
DNA3303 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA3313
DNA3330 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA3331
DNA0330 + S1
KonNG1−−−−−⇀↽ −
Koff
NG1
DNA1330
DNA0000 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA0003
DNA0010 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA0013
DNA0000 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA0030
DNA0001 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA0031
DNA0030 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA0033
DNA0003 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA0033
DNA0100 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA0103
DNA0110 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA0113
DNA0100 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA0130
DNA0101 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA0131
DNA0103 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA0133
DNA0130 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA0133
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DNA0000 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA0300
DNA0001 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA0301
DNA0300 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA0303
DNA0003 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA0303
DNA0010 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA0310
DNA0011 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA0311
DNA0013 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA0313
DNA0310 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA0313
DNA0300 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA0330
DNA0030 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA0330
DNA0031 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA0331
DNA0301 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA0331
DNA0033 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA0333
DNA0303 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA0333
DNA0330 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA0333
DNA1000 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA1003
DNA1010 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA1013
DNA1000 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA1030
DNA1003 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA1033
DNA1001 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA1031
DNA1030 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA1033
DNA1100 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA1103
DNA1110 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA1113
DNA1100 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA1130
DNA1101 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA1131
DNA1103 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA1133
DNA1130 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA1133
DNA1000 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA1300
DNA1001 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA1301
DNA1003 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA1303
DNA1300 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA1303
DNA1010 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA1310
DNA1011 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA1311
DNA1013 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA1313
DNA1310 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA1313
DNA1030 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA1330
DNA1300 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA1330
DNA1031 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA1331
DNA1033 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA1333
DNA1301 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA1331
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DNA1303 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA1333
DNA1330 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA1333
DNA0000 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3000
DNA0001 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3001
DNA0003 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3003
DNA3000 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3003
DNA0010 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3010
DNA0011 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3011
DNA0013 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3013
DNA3010 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3013
DNA0030 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3030
DNA3000 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3030
DNA0031 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3031
DNA3001 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3031
DNA0033 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3033
DNA3003 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3033
DNA3030 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3033
DNA0100 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3100
DNA0103 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3103
DNA0101 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3101
DNA3100 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3103
DNA0110 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3110
DNA0111 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3111
DNA0113 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3113
DNA3110 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3113
DNA0130 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3130
DNA3100 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3130
DNA0131 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3131
DNA3101 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3131
DNA0133 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3133
DNA3103 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3133
DNA3130 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3133
DNA0300 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3300
DNA3000 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA3300
DNA0301 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3301
DNA3001 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA3301
DNA0303 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3303
DNA3003 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA3303
DNA0310 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3310
DNA3300 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3303
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DNA3010 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA3310
DNA0311 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3311
DNA3011 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA3311
DNA0313 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3313
DNA3013 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA3313
DNA3310 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3313
DNA0330 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3330
DNA3030 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA3330
DNA0011
KonP1−−−−⇀↽ −
Koff
P1
DNA001−1
DNA0110
KonP1−−−−⇀↽ −
Koff
P1
DNA01−10
DNA0111
KonP1−−−−⇀↽ −
Koff
P1
DNA011−1
DNA01−11
KonP1−−−−⇀↽ −
Koff
P1
DNA01−1−1
DNA011−1
KonP1−−−−⇀↽ −
Koff
P1
DNA01−1−1
DNA0113
KonP1−−−−⇀↽ −
Koff
P1
DNA01−13
DNA0311
KonP1−−−−⇀↽ −
Koff
P1
DNA031−1
DNA1100
KonP1−−−−⇀↽ −
Koff
P1
DNA1−100
DNA1101
KonP1−−−−⇀↽ −
Koff
P1
DNA1−101
DNA1103
KonP1−−−−⇀↽ −
Koff
P1
DNA1−103
DNA1110
KonP1−−−−⇀↽ −
Koff
P1
DNA1−110
DNA0111
KonP1−−−−⇀↽ −
Koff
P1
DNA01−11
DNA3300 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3330
DNA0331 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3331
DNA3031 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA3331
DNA3301 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3331
DNA3330 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3333
DNA3303 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3333
DNA3033 + S3
KonG3−−−−⇀↽ −
Koff
G3
DNA3333
DNA0333 + S3
KonNG3−−−−−⇀↽ −
Koff
NG3
DNA3333
DNA1110
KonP1−−−−⇀↽ −
Koff
P1
DNA11−10
DNA1−110
KonP1−−−−⇀↽ −
Koff
P1
DNA1−1−10
DNA11−10
KonP1−−−−⇀↽ −
Koff
P1
DNA1−1−10
DNA1111
KonP1−−−−⇀↽ −
Koff
P1
DNA1−111
DNA1111
KonP1−−−−⇀↽ −
Koff
P1
DNA11−11
DNA1111
KonP1−−−−⇀↽ −
Koff
P1
DNA111−1
DNA1−111
KonP1−−−−⇀↽ −
Koff
P1
DNA1−11−1
DNA111−1
KonP1−−−−⇀↽ −
Koff
P1
DNA1−11−1
DNA1−111
KonP1−−−−⇀↽ −
Koff
P1
DNA1−1−11
DNA11−11
KonP1−−−−⇀↽ −
Koff
P1
DNA1−1−11
DNA11−11
KonP1−−−−⇀↽ −
Koff
P1
DNA11−1−1
DNA111−1
KonP1−−−−⇀↽ −
Koff
P1
DNA11−1−1
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DNA1−1−11
KonP1−−−−⇀↽ −
Koff
P1
DNA1−1−1−1
DNA1−11−1
KonP1−−−−⇀↽ −
Koff
P1
DNA1−1−1−1
DNA11−1−1
KonP1−−−−⇀↽ −
Koff
P1
DNA1−1−1−1
DNA1113
KonP1−−−−⇀↽ −
Koff
P1
DNA1−113
DNA1113
KonP1−−−−⇀↽ −
Koff
P1
DNA11−13
DNA1−113
KonP1−−−−⇀↽ −
Koff
P1
DNA1−1−13
DNA11−13
KonP1−−−−⇀↽ −
Koff
P1
DNA1−1−13
DNA1130
KonP1−−−−⇀↽ −
Koff
P1
DNA1−130
DNA1131
KonP1−−−−⇀↽ −
Koff
P1
DNA1−131
DNA1133
KonP1−−−−⇀↽ −
Koff
P1
DNA1−133
DNA113−3
KonP1−−−−⇀↽ −
Koff
P1
DNA1−13−3
DNA3011
KonP1−−−−⇀↽ −
Koff
P1
DNA301−1
DNA3110
KonP1−−−−⇀↽ −
Koff
P1
DNA31−10
DNA3111
KonP1−−−−⇀↽ −
Koff
P1
DNA31−11
DNA3111
KonP1−−−−⇀↽ −
Koff
P1
DNA311−1
DNA31−11
KonP1−−−−⇀↽ −
Koff
P1
DNA31−1−1
DNA311−1
KonP1−−−−⇀↽ −
Koff
P1
DNA31−1−1
DNA3113
KonP1−−−−⇀↽ −
Koff
P1
DNA31−13
DNA3311
KonP1−−−−⇀↽ −
Koff
P1
DNA331−1
DNA3−311
KonP1−−−−⇀↽ −
Koff
P1
DNA3−31−1
DNA3313
KonP3−−−−⇀↽ −
Koff
P3
DNA3−313
DNA3330
KonP3−−−−⇀↽ −
Koff
P3
DNA3−330
DNA3330
KonP3−−−−⇀↽ −
Koff
P3
DNA33−30
DNA3−330
KonP3−−−−⇀↽ −
Koff
P3
DNA3−3−30
DNA33−30
KonP3−−−−⇀↽ −
Koff
P3
DNA3−3−30
DNA3333
KonP3−−−−⇀↽ −
Koff
P3
DNA3−333
DNA3333
KonP3−−−−⇀↽ −
Koff
P3
DNA33−33
DNA3333
KonP3−−−−⇀↽ −
Koff
P3
DNA333−3
DNA3−333
KonP3−−−−⇀↽ −
Koff
P3
DNA3−33−3
DNA333−3
KonP3−−−−⇀↽ −
Koff
P3
DNA3−33−3
DNA3−333
KonP3−−−−⇀↽ −
Koff
P3
DNA3−3−33
DNA33−33
KonP3−−−−⇀↽ −
Koff
P3
DNA3−3−33
DNA33−33
KonP3−−−−⇀↽ −
Koff
P3
DNA33−3−3
DNA333−3
KonP3−−−−⇀↽ −
Koff
P3
DNA33−3−3
DNA3−3−33
KonP3−−−−⇀↽ −
Koff
P3
DNA3−3−3−3
DNA3−33−3
KonP3−−−−⇀↽ −
Koff
P3
DNA3−3−3−3
DNA33−3−3
KonP3−−−−⇀↽ −
Koff
P3
DNA3−3−3−3
DNA1133
KonP3−−−−⇀↽ −
Koff
P3
DNA113−3
DNA1−133
KonP3−−−−⇀↽ −
Koff
P3
DNA1−13−3
DNA3311
KonP3−−−−⇀↽ −
Koff
P3
DNA3−311
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DNA331−1
KonP3−−−−⇀↽ −
Koff
P3
DNA3−31−1
DNA0033
KonP3−−−−⇀↽ −
Koff
P3
DNA003−3
DNA0133
KonP3−−−−⇀↽ −
Koff
P3
DNA013−3
DNA0330
KonP3−−−−⇀↽ −
Koff
P3
DNA03−30
DNA0331
KonP3−−−−⇀↽ −
Koff
P3
DNA03−31
DNA0333
KonP3−−−−⇀↽ −
Koff
P3
DNA03−33
DNA0333
KonP3−−−−⇀↽ −
Koff
P3
DNA033−3
DNA03−33
KonP3−−−−⇀↽ −
Koff
P3
DNA03−3−3
DNA033−3
KonP3−−−−⇀↽ −
Koff
P3
DNA03−3−3
DNA1033
KonP3−−−−⇀↽ −
Koff
P3
DNA103−3
DNA1330
KonP3−−−−⇀↽ −
Koff
P3
DNA13−30
DNA1331
KonP3−−−−⇀↽ −
Koff
P3
DNA13−31
DNA1333
KonP3−−−−⇀↽ −
Koff
P3
DNA13−33
DNA1333
KonP3−−−−⇀↽ −
Koff
P3
DNA133−3
DNA13−33
KonP3−−−−⇀↽ −
Koff
P3
DNA13−3−3
DNA133−3
KonP3−−−−⇀↽ −
Koff
P3
DNA13−3−3
DNA3300
KonP3−−−−⇀↽ −
Koff
P3
DNA3−300
DNA3301
KonP3−−−−⇀↽ −
Koff
P3
DNA3−301
DNA3303
KonP3−−−−⇀↽ −
Koff
P3
DNA3−303
DNA3310
KonP3−−−−⇀↽ −
Koff
P3
DNA3−310
DNA3331
KonP3−−−−⇀↽ −
Koff
P3
DNA3−331
DNA3331
KonP3−−−−⇀↽ −
Koff
P3
DNA33−31
DNA3−331
KonP3−−−−⇀↽ −
Koff
P3
DNA3−3−31
DNA33−31
KonP3−−−−⇀↽ −
Koff
P3
DNA3−3−31
DNA3133
KonP3−−−−⇀↽ −
Koff
P3
DNA313−3
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